The Role Of Spi-B And Pu.1 Transcription Factors In B Cell Development And In Suppression Of Leukemogenesis by Reyes Batista, Carolina
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
8-10-2018 10:30 AM 
The Role Of Spi-B And Pu.1 Transcription Factors In B Cell 
Development And In Suppression Of Leukemogenesis 
Carolina Reyes Batista 
The University of Western Ontario 
Supervisor 
DeKoter, Rodney P. 
The University of Western Ontario 
Graduate Program in Microbiology and Immunology 
A thesis submitted in partial fulfillment of the requirements for the degree in Doctor of 
Philosophy 
© Carolina Reyes Batista 2018 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
 Part of the Cancer Biology Commons, and the Immunity Commons 
Recommended Citation 
Reyes Batista, Carolina, "The Role Of Spi-B And Pu.1 Transcription Factors In B Cell Development And In 
Suppression Of Leukemogenesis" (2018). Electronic Thesis and Dissertation Repository. 5614. 
https://ir.lib.uwo.ca/etd/5614 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
i 
 
 
Abstract 
 
The E26 transformation-specific transcription factors (ETS) PU.1 and Spi-B are 
required for the earliest stages of B cell maturation within the bone marrow. PU.1 expression 
is first detected in hematopoietic stem and progenitor cells (HSPCs), whereas Spi-B levels 
begin to increase as early as the Pro-B cell stage. The expression levels of both factors are 
maintained as B cells progress in development, and the lack of PU.1 and Spi-B at early stages 
impairs B cell development and can lead to B cell leukemia. The mechanisms by which PU.1 
and Spi-B control B cell development progression and prevent leukemogenesis have not been 
completely elucidated. The work described in this thesis had two specific aims: 1) to determine 
the requirement and function of PU.1 and Spi-B transcription factors in developing B cells and 
2) to determine the requirement of these transcription factors in preventing leukemogenesis. It 
was hypothesized that PU.1 and Spi-B control events associated with the transition from high 
to low proliferative stages in B cell development and the absence of these factors favor a state 
of proliferative stress leading to leukemogenesis. To assess this central hypothesis, we used a 
mouse model in which Spi1 (encoding PU.1) was conditionally deleted in B cells by Cre 
recombinase under control of the Mb1 gene in Spib (encoding Spi-B) deficient mice. We found 
PU.1 and Spi-B were required in B cell development during the transition from Large to Small 
Pre-B cells. Our data showed that at this transition, PU.1 functioned as an accessibility factor 
for immunoglobulin light chain rearrangement, therefore enabling B cell maturation. In the 
absence of these factors, B cell development was blocked at the Large Pre-B cell, and resulted 
in the generation of B cell leukemia. We also determined that leukemogenesis in the absence 
of Spi-B and PU.1 factors was associated with driver mutations in the Janus Kinases genes 1 
and 3, conferring growth and survival advantages to these cells. We suggest that reactive 
oxygen species (ROS) generation is a possible mechanism by which genetic damage arises, 
consequently leading to B cell leukemia in the absence of Spi-B and PU.1. Collectively, this 
thesis contributes to the elucidation of molecular mechanisms by which the complementary 
transcription factors PU.1 and Spi-B coordinate B cell development and prevent 
leukemogenesis. 
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Chapter 1  
1 Introduction 
The immune system has evolved to protect organisms against pathogens that 
ultimately have the potential to cause infections. Antigen-specific responses have only 
become possible with the development of an intricate adaptive immune response, mostly 
mediated by clonally diverse T and B lymphocytes. B lymphocytes, also known as B 
cells, are distinguished by their ability to produce antigen-specific antibodies (Ab). This 
ability confers memory to the immune system, allowing for a rapid and robust response 
against previously exposed pathogens. Ab diversity is generated primarily during the 
early stages of B cell development and is only achieved after successful rearrangement of 
the immunoglobulin (Ig) genes. Effective generation of B cells requires an intricate 
network of transcription factors that coordinate the passage through several 
developmental stages. Disturbance of these stages can result in a failure to generate 
mature B cells and, ultimately to the generation of B cell malignancies. The following 
sections focus on the current understanding of B cell biology, including B cell subsets, B 
cell development and processes leading to Ab diversity. In the final sections, B cell-
related malignancies such as leukemia and lymphoma are also addressed. 
1.1 The Early Story of B Cells 
In vertebrates, B cells play a central role in immunity to counter infections, cancer 
and the development of auto-immune and inflammatory diseases. Despite their broad 
importance to the generation of immune responses, the “discovery” of B cells and the 
current understanding of B cell biology is a relatively recent focus of study. Abs, 
produced by B cells through the rearrangement of the Ig genes, have long been known to 
be important components of the humoral immune response. In 1965, the first 
demonstration that B cells had different developmental origins than T cells came through 
experiments in which the avian bursa of Fabricius was excised. These experiments 
demonstrated a reduction in the production of plasma cells and antibodies, a condition 
similar to that previously observed in X-linked agammaglobulinemia patients (M. D. 
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Cooper, Peterson, & Good, 1965).  A few years later, studies identified the bone marrow 
(BM) in mammals to be the equivalent to the bursa of Fabricius in birds (M. D. Cooper 
et al., 1966; Owen, Cooper, & Raff, 1974; Ryser & Vassalli, 1974). After these seminal 
discoveries, researchers focused on elucidating the genetic origins of Ab diversity. The 
process of somatic rearrangement, by which immunoglobulins genes rearranged to form 
an Ab of unique specificity, was subsequently elucidated by Hozumi & Tonegawa in 1976 
(Hozumi & Tonegawa, 1976). Later, recombination activating genes (RAG-1/2) were 
demonstrated to mediate somatic rearrangement within the Ig locus (Oettinger, Schatz, 
Gorka, & Baltimore, 1990; Schatz, Oettinger, & Baltimore, 1989). The sequential 
rearrangement of the Ig genes, in conjunction with the expression of distinct, stage-
dependent cell surface markers, used to gradually uncover the developmental stages and 
events governing B cell maturation (Hardy, 1991). Several transcription factors, including 
PU.1, E2A, EBF-1 and PAX5 were demonstrated to be required for B cell lineage 
commitment and developmental progression (Busslinger, 2004). These advances in 
understanding of B cell maturation processes have contributed to human health, including 
the development of vaccines, antibody based therapies and the understanding of genetic 
altered pathways in B cell developmental diseases such as B cell acute lymphoblastic 
leukemia (B-ALL). 
1.2 B Cells, B Cell Subsets and Functions 
B cells possess the unique capacity of rearranging Ig heavy (IgH) and light (IgL) 
chain genes to produce and secrete Abs of unique antigen-specificity. Soluble Abs can 
penetrate extracellular spaces and safeguard the organism against infections. The non-
secreted form of the Ab is expressed at the B cell surface as a membrane receptor known 
as the B cell receptor (BCR). Despite their role in mediating humoral immunity, B cells 
also contribute to cellular immune responses. B cells possess the ability to produce 
cytokines; can activate T cells through antigen presentation; and also execute regulatory 
functions which limit immune responses. In mammals, B cells originate from 
hematopoietic stem/progenitor cells (HSPC) which are initially generated in the neonatal 
fetal liver, and later in the BM after birth. Within the BM, immature B cells go through 
several stages to obtain a BCR specific for nonself-antigen. Nonself-reactive immature B 
cells exit the BM and complete their differentiation within the spleen, a stage which B 
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cells are known as transitional B cells. Transitional B cells express IgM+ and IgD+ at the 
cell surface, as well as high levels of the B cell activation factor receptor (BAFF-R), 
which confers cell survival (Vigolo et al., 2018). The first antigen exposure of naïve B 
cells occurs in the secondary lymphoid tissues. B cell activation leads to differentiation 
into memory or plasma B cells that produce soluble Abs (Shinnakasu & Kurosaki, 2017). 
Memory B cells develop in the germinal centers within secondary lymphoid organs and 
express Ig isotypes other than IgM (IgG, IgA, or IgE) and do not express IgD. Reactivated 
memory B cells can differentiate into plasma cells for a rapid response to an antigen. 
Terminally differentiated plasma cells originate in the germinal centers of lymph nodes 
or spleen, do not express Ig on the cell membrane and do not express the B cell marker 
CD19 (K. Wang, Wei, & Liu, 2012). While some plasma cells are able to persist for years, 
short-lived plasma cells remain in circulation for only days to weeks. The next section 
focuses on the early developmental processes that B cells undergo within the BM, before 
their egress to the spleen. 
1.3 Bone Marrow B Cell Development 
B cells originate from HSPC precursors within the BM after birth, as well as from 
HSPCs precursors derived from neonatal fetal liver. Committed lymphoid precursors 
(CLP) derived from HSPCs have the potential to generate either T or B cells (Ernst, 2009). 
CLPs, can derive two main B cell progenitor subsets, which derive to distinct B cell 
subsets: B-1 and B-2 B cells. While B-2 B cells, also known as conventional B cells, are 
present in the secondary lymphoid organs and are considered to be the mediators of 
adaptive immunity, B-1 B cells are part of the innate system and produce anti-microbial 
natural antibodies (Montecino-Rodriguez & Dorshkind, 2012). B-1 cells develop and 
mature within the BM and spleen however, Mature B-1 cells migrate to the serous cavities 
later in development. For the purpose of this thesis, the development of B-2 B cells is 
going to be emphasized. Five distinct developmental stages occur within the BM before 
B cells reach maturation in the peripheral lymphoid organs. These stages, are 
characterized phenotypically by the expression of cell surface molecules and by the status 
of Ig rearrangement. As shown in Fig. 1.1A - the Pre-Pro-B stage represents a 
heterogeneous population of cells which are not fully committed to the B cell fate. Stage 
2 or the Pro-B cell stage, represents the first commitment step towards the B lymphoid 
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lineage, although these cells still have the potential to develop towards the T cell lineage 
upon loss of the transcription factor Pax5 (Rolink, Nutt, Melchers, & Busslinger, 1999). 
At this stage, signaling through IL-7R is crucial for B cell proliferation and survival. The 
rearrangement of the variable (V), diversity (D), joining (J) and constant (C) segments of 
the IgH locus also occurs during this stage. Upon successful completion of IgH V(D)J 
recombination, the Pre-B cell receptor (Pre-BCR) composed by IgH and surrogate light 
chains is expressed at the cell surface. This event marks the transition to stage 3 or the 
Pre-B cell stage. The Pre-B cell stage can be divided in two major subsets: Large Pre-B 
cell and Small Pre-B cell stages. The Large Pre-B cells stage is characterized by rapid 
cycling cells which are responsive to IL-7R signals. This enables expansion of the 
population expressing a functional Pre-BCR (Clark, Mandal, Ochiai, & Singh, 2014). 
Later on, Large Pre-B cells migrate to low IL-7 niches in the bone marrow. With lowered 
IL-7, Large Pre-B cells differentiate into Small Pre-B cells and begin IgL chain 
rearrangement. Once IgL chain is rearranged, the BCR is expressed on the cell surface, 
marking the passage to stage 4 or the immature B cell stage. Immature B cells carrying a 
nonself-reactive BCR egress from BM and home to the spleen to complete final 
maturation as described above. Finally, mature naïve recirculating B cells can be found 
in the BM and are characterized by high levels of B220 expression (Hardy, 1991).  
1.3.1 “Hardy Scheme” of B Cell Development 
The developmental stages described above can be characterized by the expression 
of stage-specific cell surface markers. This enables the study of the specific stages of B 
cell development by immunostaining. The scheme described by Hardy, characterizes 
developing mouse B cells in six Fractions alphabetically labelled Fractions A, B, C, D, E 
and F (Hardy, 1991). Developing B cells within Fractions A, B and C express B220 and 
CD43 markers at the cell surface, while Fraction D, E and F lose CD43 expression (B220+ 
CD43-). CD43, also known as sialophorin, is a transmembrane cell surface protein which 
is expressed in B cells, T cells, monocytes, neutrophils and platelets. Deficient expression 
of CD43 is linked with X-chromosome-linked immunodeficiency disorder Wiskott-
Aldrich syndrome (Rosenstein et al., 1991). As CD43 expression is not restricted to B 
cells, other cell surface markers are used to further distinguish the later B cell 
development stages. Fractions A-C are further distinguished by differential expression of 
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BP-1 and CD24. Thus, Fraction A cells (Pre-pro B cells) are classified as 
B220+CD43+BP-1-CD24-; Fraction B (Pro-B cells), B220+ CD43+BP-1-CD24+ and 
Fraction C (Large Pre-B cells), B220+CD43+BP-1+CD24+. During the later stages of 
development, Fractions D-F are phenotypically distinguished by the lack of CD43 
expression and the differentiated expression of B220 and IgM. Therefore, Fraction D 
(Small Pre-B cells) are classified as B220+ (dull) CD43- IgM-; Fraction E (Immature B 
cells), B220+ (dull) CD43- IgM+ and Fraction F (Mature recirculating B cells), B220+ (bright) 
CD43- IgM+ (Fig. 1.1B). 
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Figure 1.1.  B Cell Development within BM and Maturation within Peripheral Lymphoid 
Tissue.  
 
(A) Stages of B cells development. Mature Naïve, Mature Activated, Short-Lived Plasma 
Cells, Memory B Cells and Plasma Cells reside the peripheral lymphoid tissue. (B) 
“Hardy Scheme” of B cell development. B cell developmental stages are distinguished 
by differential expression of cell surface markers and the status of Ig rearrangement. 
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1.3.2 The IL-7 Cytokine and IL-7 Receptor Signaling 
Interleukin 7 (IL-7) is critical for supporting the development and homeostasis of 
maturing T and B lymphocytes. IL-7 is produced by stromal cells within the bone marrow, 
as well as fetal liver  (Tokoyoda, Egawa, Sugiyama, Choi, & Nagasawa, 2004). CLP are 
the first progenitor cells within the BM to express the IL-7R, a heterodimeric receptor 
consisting of an IL-7 specific a chain and a common g chain (gc, encoded by Il2rg) shared 
by the cytokine receptors for IL-2, IL-4, IL-9, IL-15, and IL-21 (Kondo, Weissman, & 
Akashi, 1997). The earliest stages of B cell development seem to be dependent on IL-7R 
signaling since IgM- cells express high levels of this receptor at the cell surface (Sudo et 
al., 1993). Moreover, Pro-B cells migrate to IL-7 secreting sites within the BM (Tokoyoda 
et al., 2004). IL-7-/- and IL-7R-/- knockout mice have illustrated the importance of this 
cytokine for B and T cell development. While IL-7 knockout mice presented with 
decreased numbers of B and T cells in the blood and a blockade in B cell development at 
the Pro-B cell stage (von Freeden-Jeffry, 1995), IL-7R-/-  knockout mice presented with a 
strongly impaired phenotype and blockade in B cell development at the Pre-pro B cell 
stage (Peschon et al., 1994). Although IL-7R signaling is essential for murine early B cell 
development progression, the same requirement is not observed in human B cell 
progenitors. Defective IL-7R in humans is associated with severe combined 
immunodeficiency (SCID) characterized by a reduction in T cells, but not B cells or 
natural killer (NK) cells, illustrating that IL-7R signaling is not required for the 
development of B cells in humans (Puel, Ziegler, Buckley, & Leonard., 1998). 
IL-7R does not possess intrinsic kinase activity. Upon IL-7 binding, Janus Kinase 
1 and 3 (JAK1 and JAK3) which are constitutively associated with the IL-7Ra and IL-
2Rgc subunits, phosphorylate a tyrosine residue (Y449) in the IL-7Ra . Next, the Y449 
phosphorylated site recruits signal transducer and activator of transcription 5A (STAT5A) 
and STAT5B. Upon JAK-mediated phosphorylation of a conserved tyrosine at its C 
terminus, STAT5 becomes activated and translocates to the nucleus where it binds to 
DNA and activates transcription (Corfe & Paige, 2012). STAT5 leads to the activation of 
Ccnd3 gene, encoding cyclin D-type 3, which has been demonstrated to be required for 
pro and Pre-B cell proliferation. The D-type cyclins bind and activate cyclin-dependent 
kinases 4 and 6, which phosphorylate the retinoblastoma protein (RB) leading to  
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progression through the G1 phase of cell cycle (A. B. Cooper et al., 2006). IL-7R 
signaling through STAT5 also induces the expression of the antiapoptotic B cell 
lymphoma 2 (BCL-2) protein and induced myeloid leukemia cell differentiation protein 
(MCL-1) encoded by Bcl2 and Mcl1 genes, respectively (Malin et al., 2010). The 
phosphoinositide 3-kinase (PI3K)–AKT (PI3K-AKT) pathway is also activated upon IL-
7 stimulation (Corcoran et al., 1996). AKT phosphorylation by PI3K leads to degradation 
of the forkhead box protein O (FOXO), which in turn lowers the levels of Bcl-2-like 
protein 11, also known as BIM, a pro-apoptotic factor encoded by the Bcl2l11 gene (Clark 
et al., 2014). BIM mediates B cell apoptosis upon IL-7 withdrawal. In the absence of IL-
7, B cell development is partially rescued upon loss of BIM (Huntington et al., 2009). 
Altogether, IL-7R signaling activation has the capacity to stimulate proliferation and 
survival in early B cell progenitors in mice (Fig. 1.2A, left). 
1.3.3 Pre-BCR Checkpoint and Signaling 
Highly proliferative Pro-B cells responding to IL-7R signaling are unable to 
initiate the V(D)J rearrangement of IgH genes, since PI3K-AKT signaling induces 
FOXO1 degradation, and FOXO1 is required to induce the expression of recombination 
activating genes 1 and 2 (Rag1 and Rag2) (Amin & Schlissel, 2008). Because Ig 
rearrangement involves the action of RAG-1 and RAG-2, which have the ability to 
generate double-stranded breaks in the DNA, rearrangement during B cell development 
is restricted to non-proliferative stages. However, cells at the Pro-B cell stage can 
rearrange IgH chain genes as they migrate to sites in the BM with low IL-7, facilitating 
IgH rearrangement (Tokoyoda et al., 2004). IL-7R expression levels are proportional to 
the amount of phospho-STAT5 (Bertolino et al., 2005; Puel et al., 1998). In addition, Pro-
B cells represent a heterogeneous population expressing different levels of IL-7R at the 
cell surface (Bertolino et al., 2005; Puel et al., 1998). Collectively, these observations 
explain some of the processes whereby highly proliferative cells can escape IL-7R 
signaling, recombine IgH chain genes, and express the Pre-BCR at the cell surface. 
The basic unit of the Pre-BCR molecule is composed of two identical IgH chains 
and two invariant surrogate light chain proteins, l5 and VpreB (M. Zhang, Srivastava, & 
Lu, 2004). Signaling through the Pre-BCR and BCR is dependent on the interaction with 
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a Iga/Igb heterodimeric signaling complex (Fig 1.2A, right). Iga/Igb have intracellular 
segments containing immunoreceptor tyrosine-based activation motifs (ITAMs) that 
interact with downstream adaptor and effector molecules. Mice in which the 
Iga/Igb complex has been abrogated present a strong block at the Pro-B cell stage, 
characterized by the absence of B220+ CD43- cells in the BM, revealing the importance 
of Pre-BCR signaling in the transition from Pro-B to Pre-B cell stages (Kraus et al., 2001).  
Members of the Src family of tyrosine kinases (Src family) Blk, Lyn and Fyn, 
which are assembled within the Pre-BCR and BCR structures, become activated after 
receptor activation. Activated tyrosine kinases such as Syk, phosphorylate the adaptor 
protein B cell linker (BLNK) allowing it to bind to phospholipase C-gamma2 (PLC-g2) 
and the Bruton tyrosine kinase (Btk). Syk and Btk also phosphorylate a newly isolated 
adaptor protein named B cell adaptor molecule for PI3K (BCAP). Phosphorylation of 
both adaptor proteins, Blnk and BCAP leads to activation of two major signaling 
cascades: PLC-g2 and PI(3)K pathways (Kurosaki, 2011). Due the lack of an obvious Pre-
BCR ligand, it is understood that intrinsic activity of the Pre-BCR is sufficient to induce 
downstream signaling cascades required for B cell maturation (Lam, Kühn, & Rajewsky, 
1997; Monroe, 2006). Nonetheless, potential Pre-BCR ligands have been identified in the 
BM of humans and mice such as galectin-1 and heparan sulfate, respectively (Bradl, 
Wittmann, Milius, Vettermann, & Jack, 2003; Gauthier, Rossi, Roux, Termine, & Schiff, 
2002).  
The function of molecules downstream of the Pre-BCR has been studied through 
the generation of knockout mice ablated for of these effectors. Deletion of Blnk leads to 
an incomplete block at transition from Pro-B to Pre-B cell stage. The few mature B cells 
that are present in these mice are unresponsive to BCR crosslinking, suggesting further 
impairment in transduction events (S. Xu et al., 2000). In a similar fashion, mice carrying 
mutant Btk and CD40 demonstrated a reduced number of B cells in the spleen and lymph 
nodes and an absence of mature B cells expressing IgMlow/ IgDhigh compared to wild-type 
mice (Khan, 1997). Although mice demonstrated no major deficiencies in B cell 
development in the BM, Lyn seemed to be required for later stages of B cell maturation, 
since Lyn-deficient mice had reduced numbers of mature B cells in the GC (Lamagna, 
Hu, DeFranco, & Lowell, 2014). Because deletion of Src had only a moderate impact on 
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B cell development, it was assumed that these kinases had overlapping signaling 
functions. In fact, the triple deficiency of Blk, Fyn and Lyn leds to more severe 
impairments in B cell maturation, such as a reduction of Pro-B cells transiting to the Pre-
B cell stage. The number of peripheral B cells was also decreased in these mice (Saijo et 
al., 2003).  
Several studies have also demonstrated the crucial requirement of Btk and the 
adaptor protein Blnk, at the Pre-B cell stage transition stage. Double deletion of both Btk 
and Blnk in B cells results in a drastic reduction of Igk and Igl transcripts and a blockade 
at the Pre-B cell stage. These findings suggested that signaling through these proteins can  
not only contribute towards the termination of Pre-B cell expansion, but also facilitate Ig 
rearrangement (Kersseboom et al., 2003). It has also been observed that mice lacking Btk 
and Blnk develop Pre-B cell leukemias, suggesting the role of these proteins as tumour 
suppressors (Ta, De Haan, De Bruijn, Dingjan, & Hendriks, 2011). Altogether, these 
studies demonstrate that expression and signaling through the Pre-BCR is required for 
progression in B cell development and termination of proliferative events, consequently 
facilitating transition from Large to Small Pre-B cell stage. 
In recent years, the focus of attention has moved towards understanding the 
regulatory circuits mediated by IL-7R and Pre-BCR signaling. Lowering IL-7/IL-7R 
signaling is a requirement for IgL rearrangement, however the signaling through this 
pathway mediates proliferation and survival at the early stages of B cell development. 
This raised the question of how these cells survive upon IL-7 withdrawal. Experiments 
demonstrated that the phosphorylation of ERK correlated with Pre-BCR expression at the 
cell surface conferred the ability of these cells to proliferate in low IL-7 conditions, 
revealing involvement of the ERK/MAP kinase pathway for the selective expansion of 
Pre-BCR+ cells (Fleming & Paige, 2001).  
As previously observed, the deletion of Btk and Blnk leads to a failure of IgL 
recombination (Kersseboom et al., 2003), indicating that the Pre-BCR signaling is not 
limited to controlling survival, but also plays a role in coordinating differentiation events 
during B cell development. The PI(3)K pathway, activated in response to IL-7R 
stimulation, was also activated in response to Pre-BCR activation. In a similar fashion, 
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PI(3)K and PKB phosphorylate FOXO3A and FOXO1 factors leading them to 
degradation, consequently decreasing Rag1 and Rag2 expression. The presence of Blnk 
protein is crucial for attenuation of the PI(3)K pathway, consequently culminating in the 
stabilization of RAG and IgL recombination (Herzog et al., 2008; Ramadani et al., 2010). 
Once stabilized, FOXO1 is able to induce the expression of Blnk, Pax5 and Syk which 
will antagonize the activation of the PI(3)K–AKT pathway. This self-reinforcing 
network, favors induction of Rag genes and the attenuation of IL-7R signaling via 
PI(3)K–AKT (Ochiai et al., 2012).  
The transcription factors Spi-B and PU.1 are also involved in the Pro-B to Pre-B 
cell transition. Double-deletion of these factors blocked B cell development and leads to 
Pre-B cell leukemia (Christie et al., 2015). In fact, PU.1 and Spi-B are able to oppose IL-
7R dependent proliferation by regulating expression of the Btk and Blnk genes (Sokalski 
et al., 2011). Overall, the balance between IL-7R and Pre-BCR signaling, specifically the 
attenuation of IL-7R signals, is mandatory for Ig recombination, and consequently B cell 
maturation. 
Although attenuation of IL-7R signaling is required for B cell development 
progression, IL-7R silencing was not sufficient to induce IgL rearrangement in Pre-B 
cells. The generation of knockout Pre-B cells for IRF4 and IRF8 demonstrated the 
importance of IRF4 for IgL recombination. IRF4 seems to preferentially bind and induce 
Igk germline transcription, whereas attenuating IL-7 signals lead to a more potent 
activation of Rag expression. Upon IL-7R signaling attenuation increase in histone 
acetylation at the iEk enhancer was observed, indicating that a decrease in IL-7 signal is 
required for Igk recombination (Johnson et al., 2008).  
Investigating the mechanism by which IL-7R signaling attenuation facilitated Igk 
recombination, Mandal et al demonstrated that STAT5, activated by JAK1 and JAK3 
upon IL-7 stimulation, forms a tetrameric complex that binds to iEk and represses the Igk 
locus by recruiting the histone methyltransferase EZH2 (Mandal et al., 2011). Therefore, 
attenuation of IL-7 signaling relieved repression at the Igk locus, facilitating RAG1/2 
accessibility for Ig recombination. 
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In summary, signaling through the Pre-BCR plays several roles in the transition 
from proliferative stages in B cell development into resting stages where differentiation 
occurs. The functions executed by Pre-BCR signaling can be summarized in three main 
points: 1) Pre-BCR signaling confers survival to developing B cells under IL-7 reduced 
conditions; 2) Pre-BCR signaling through Blnk attenuates PI(3)K-AKT signals 
downstream of IL-7R enabling the stabilization of FOXO1 and FOXO3A factors - 
consequently leading to Rag expression;  3) attenuation of IL-7 signals is also crucial for 
IgL locus recombination, since tetrameric STAT5 recruits the histone methyltransferase 
EZH2, repressing chromatin and decreasing accessibility.  
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Figure 1.2. IL-7R and Pre-BCR Signaling. Interplay of these Signals Enables B Cell 
Development Progression. 
 
(A) IL-7R signaling (left) and BCR signaling (right) and its respective signaling 
pathways. (B) Antagonistic actions executed by IL-7 and BCR signaling during B cell 
development at the Large Pre-B cell to Small Pre-B cell transition. 
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1.3.4 Rearrangement of The Immunoglobulin (Ig) Genes 
V(D)J recombination is a sequential event that takes place at the Pro-B cell stage 
and later in development, at the Pre-B cell stage. V(D)J recombination was first described 
by Hozumi & Tonegawa in 1976, when they demonstrated that V and C gene segments, 
that exist at long distances within the genome get rearranged at the DNA level and then 
transcribed into a single mRNA molecule (Hozumi & Tonegawa, 1976). The mechanisms 
underlying this process were elucidated years later. The presence a cis-acting DNA 
sequence, consisting in a palindromic heptamer (CACAGTG) and an AT-rich nonamer 
separated by a spacer of either 12 or 23 bp flanking the variable (V) and constant (C) 
segments was noted. This cis-acting DNA sequence is known as the recombination signal 
sequences (RSSs), suggesting the concept that V(D)J recombinase is evolutionarily 
conserved (Schatz et al., 1989; Tonegawa, 1983). 
  The V(D)J recombinase was determined to be the product of two genes, 
recombination activating gene 1/2, (Rag1/Rag2) that work together to mediate Ig 
recombination. V(D)J recombination was induced in mouse NIH3T3 fibroblasts, through 
DNA transfer of a single lymphoid-specific locus, leading to the isolation and 
identification of recombination activating gene 1, or RAG-1 (Schatz & Baltimore, 1988; 
Schatz et al., 1989). The efficiency of V(D)J  recombination was increased ~1000 fold, 
when fibroblasts were also transfected with a gene adjacent to RAG-1, leading to the 
identification of RAG-2 (Oettinger et al., 1990).  
It has been recognized that V(D)J recombination occurs between two gene 
segments with flanking recombination signal sequences (RSSs) that differ in the spacer 
length (either by 12 or 23 bp) between the heptamer and nonamer. The process is initiated 
by RAG binding and nicking of a RSS within a single RSS complex. Next, the RAG 
proteins bind and nick the next RSS complex and catalyze a cleavage of both RSSs. These 
reactions yield a pair of blunt, 5’-phosphorylated signal ends, and a pair of coding ends 
that terminate in covalently sealed DNA hairpin structures. The coding ends are released 
and the RSSs are retained in a signal end complex (SEC). Coding ends are rejoined and 
DNA is repaired through the classical nonhomologous end joining (NHEJ) DNA repair 
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pathway (Bassing, Swat, & Alt, 2002). This pathway involves proteins including Ku70, 
Ku80, XRCC4, DNA Ligase IV and XLF that function in DNA repair, processing and 
reorganization (Schatz & Swanson, 2011).  
More recently, two major observations identified RAG as a potential danger to 
the mouse genome: 1) RAG has the ability to bind to thousands off-target regions within 
the genome and (Teng et al., 2015); and 2) RAG-mediated rearrangements are a common 
feature of human leukemias harboring the ETV6-RUNX1 translocation (Papaemmanuil 
et al., 2014). These independent observations brought forward the question whether B 
cell leukemogenesis could be derived from RAG off-target actions. Despite the ability of 
RAG to bind in several regions in the genome, substrates for RAG cleavage are 
preferentially depleted at sites of RAG binding, therefore protecting the genome against 
off-target RAG cleavage (Teng et al., 2015).  
1.3.5 The Mouse Immunoglobulin Heavy Chain Locus 
As discussed in the sections above, IgH rearrangement occurs at the Pro-B cell 
stage and culminates with the expression of two identical IgH chains in association with 
SLC chains. Further in B cell development, SLC are replaced by two identical light chains 
at the immature B cell stage. The IgH locus has a complex genomic organization, 
consisting in repeated sets of genes presenting high homology and of different types, 
variable (V), diversity (D) and junction (J). These genes rearrange in a unique way 
through the action of RAG-1 and RAG-2 to generate a highly variable repertoire of 
expressed BCR or secreted antibodies able to bind to a vast repertoire of epitopes. The 
mouse IgH chain locus is located on chromosome 12 (chr12:113,258,768 - 116,009,954) 
and spans ~2,800 kb according GENCODE Version M16 (Ensembl 91). This locus is 
constituted of 8-9 IgH constant genes, 4 IgH joining genes, 17-20 IgH diversity genes and 
152 IgH variable genes (Lefranc, 2004). Sequential rearrangement of this locus occurs in 
an ordered fashion in which DJ genes are rearranged first, following the subsequent 
rearrangement between V genes to the DJ segment (Alt et al., 1984).  
IgH enhancers have been described within the IgH locus and seem to play crucial 
roles in V(D)J recombination as well as in class switch recombination. The IgH intronic 
enhancer also known as IgH µ enhancer, was the first mammalian enhancer to be 
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characterized (Banerji, Olson, & Schaffner, 1983; Gillies, Morrison, Oi, & Tonegawa, 
1983). As previous studies have demonstrated, germline deletion of the IgH intronic 
enhancer impairs VH to DJH rearrangement at the IgH locus and decrease µ0 germline 
transcription, indicating an important role of this enhancer in chromatin accessibility for 
VDJ rearrangement. Interestingly,  deletion of the IgH intronic enhancer does not affect 
somatic hypermutation of their IgH variable region genes (Perlot, Alt, Bassing, Suh, & 
Pinaud, 2005). These findings suggested the existence of other regulatory regions within 
the IgH locus. The second enhancer, the IgH 3’ enhancer, was discovered years later and 
it is located in the 3’ of the C region of IgH locus (Pettersson, Cook, Brüggemann, 
Williams, & Neuberger, 1990). Lately, experiments performed by various investigators 
using DNase I hypersensitivity assays reveled a complex regulatory region (RR) located 
downstream of Cα that is predicted to serve as a major regulator of the IgH locus. This 
region contains an ~28 kb region comprising four enhancers and a ~12 kb region 
containing CTCF and Pax5 binding sites (Birshtein, 2014). Several studies have shown 
that this region is a major regulator of somatic hypermutation and class switch 
recombination within the IgH locus (Le Noir et al., 2017).  
1.3.6 The Mouse Immunoglobulin Light (Kappa and Lambda) Loci 
At the Small Pre-B cell stage, developing B cells begin rearrangement of the IgL 
chain locus. Similar to the IgH chain locus, the mouse IgL chain locus is highly complex. 
The IgL chain locus is composed of two different loci: an immunoglobulin kappa chain 
that is preferentially rearranged first during B cell development, and an immunoglobulin 
lambda chain locus, which also undertakes rearrangement in case of unsuccessful kappa 
chain rearrangement. A crucial difference between IgH and IgL loci is the lack of D 
segments on the IgL locus, hence rearrangement within this locus occurs only between V 
to J gene segments. The immunoglobulin kappa locus (Igk) in mouse is located on 
chromosome 6 (chr6:67,555,636 - 70,726,754) covering about 3,200 kb in size. Igk is 
constituted of 174 V gene segments, 5 J genes segments and a unique constant gene 
segment resulting in 189 genes in total (Lefranc, 2004). Unlikely Igk locus, the mouse 
immunoglobulin lambda chain (Igl),  has simpler features and organization. This locus 
is located on chromosome 16 (chr16:19,026,858 – 19,260,844), and only contains 3 V 
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gene segments, 5 J gene segments and 4 C gene segments, totalizing 12 gene segments 
(Lefranc, 2004). 
Genomic elements, such as enhancers, insulators and promoters, are known to act 
in a cis-regulatory manner mediating accessibility of this locus for Ig rearrangement. In 
the Igk locus, two important enhancers have been described: an intronic enhancer (iEk), 
located between Jk-Ck segments; the second enhancer is located ~9 kb downstream of 
Ck,  and its known as 3’Ek enhancer (Meyer & Neuberger, 1989; Queen & Baltimore, 
1983). Single deletion of this enhancer, impairs but does not abolish Vk-Jk rearrangement 
(Gorman et al., 1996; Y. Xu, Davidson, Alt, & Baltimore, 1996). Strikingly, double 
deletion of both enhancers results in the lack of Igk rearrangement, demonstrating the 
crucial function of these enhancers mediating Vk-Jk rearrangement (Inlay, Alt, Baltimore, 
& Xu, 2002). Following in the same fashion, the Igl locus also contains two enhancer 
elements which were characterized by mapping the relative sensitivity to 
deoxyribonuclease I (DNase I) digestion across the Igl locus. Two strong enhancers El2-
4 and second a genomic region El3-1 have been characterized to date (Hagman, Rudin, 
Haasch, Chaplin, & Storb, 1990).  
1.4 Transcriptional Control of B Cell Development 
Strict regulation of transcriptional activity is required to coordinate processes such 
as proliferation or the recombination of Ig genes. This task is achieved by the regulated 
action of transcription factors acting in a specific manner during B cell development. The 
action of these transcription factors can be presented in different developmental stages 
starting with B cell lineage specification and commitment until differentiation and 
recombination of Ig genes (Fuxa & Skok, 2007). The generation of lymphoid progenitors 
and B lymphocytes is dependent on signaling pathways mediated by IL-7R, c-Kit and 
Flt3. The ablation of signaling through any of these receptors results in impaired 
generation of B cell progenitors in the BM (Voßhenrich, Cumano, Müller, Di Santo, & 
Vieira, 2003; Waskow et al., 2008; Waskow, Paul, Haller, Gassmann, & Rodewald, 
2002). The transcription factors E2A (a helix- loop-helix protein) and EBF (early B cell 
factor) are important B cell lineage choice determinants, coordinating the expression of 
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B cell specific genes (Gyory et al., 2012; Shimamoto et al., 1995).  However, without the 
presence of the paired domain protein Pax5, B cells cannot fully commit to the B cell 
lineage. The targeted deletion of Pax5 in mice allowed mature B cells from peripheral 
lymphoid organs to dedifferentiate in vivo back to early uncommitted progenitors in the 
bone marrow, and rescued T lymphopoiesis in the thymus of T-cell-deficient mice 
(Cobaleda, Jochum, & Busslinger, 2007). Pax5 activates genes encoding proteins 
downstream of Pre-BCR and BCR signaling including Cd19, Cd21 and genes encoding 
transcription factor such as c-myb and Ebf-1 (Cobaleda, Schebesta, Delogu, & Busslinger, 
2007). Pax5 in conjunction with E2a and Ebf-1 factors are also known to facilitate IgH 
rearrangement (Fuxa, 2004). The transcription factors Ikaros and PU.1 are required for 
the activation of the B cell lineage program and cell fate determination. PU.1 
concentration is also known to determine the fate decision between myeloid or lymphoid 
progenitors (DeKoter, 2000). 
1.5 E26 Transformation Specific (ETS) Transcription Factors 
The E26 Transformation Specific (ETS) transcription factors are master 
regulators of developmental processes. Proteins belonging to this family have a conserved 
DNA binding domain, known as the ETS-domain. The founding member of this family 
Ets-1, was discovered as one of the two eukaryotic DNA sequences transduced by the 
avian retrovirus E26. Genes sequences from Ets-1 and Myb are fused with the viral gag 
gene forming the E26 oncogene. Therefore, the name of this family is derived from the 
name of the avian erythroblastosis virus, E26, carrying the v-ets (“E twenty-six”) 
oncogene (Nunn, Seeburg, Moscovici, & Duesberg, 1983). To date, nearly 30 members 
of this family have been identified and implicated in physiological and pathological 
processes. Largely, members of the ETS transcription factors family contain the ETS-
domain which is able to recognize purine-rich core (GGAA/T) DNA sequences (Karim 
et al., 1990). However, this family is sub-classified according to sequence similarities and 
the presence of other conserved domains (Sharrocks, 2001). The Spi sub-family is 
comprised of PU.1, Spi-B and Spi-C, which have broad actions in B myeloid and 
lymphoid differentiation as well as in B cell functions. Spi-C is the least understood 
amongst the members of this family, but studies indicate Spi-C as a negative regulator of 
the murine B cell lineage and regulating the follicular B cell differentiation (DeKoter et 
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al., 2010; S. K. H. Li, Solomon, Fulkerson, & DeKoter, 2015). In this thesis, we focused 
our attention on members of the Spi sub-family of ETS transcription factors PU.1 and 
Spi-B. Spi-B and PU.1 have high amino acid homology within the DNA binding and N-
terminal activation domains rich in acidic amino acids (ACID). PU.1 contains a Gln-rich 
(Q) region necessary for transactivation. The proline, glutamic acid, serine, and threonine 
(PEST) sequence contained within PU.1 and Spi-B is known to interact with interferon 
regulatory factor (IRF) family transcription factors, and is suggested to be involved with 
protein degradation (Fig. 1.3)  (Brass, Zhu, & Singh, 1999; Rogers, Wells, & Rechsteiner, 
1986). 
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Figure 1. 3 Transcription Factors PU.1 and Spi-B. 
(A) DNA-binding sequence consensus for PU.1 and Spi-B. This example was generated 
from genome-wide PU.1-binding sites in B cells. (B) Domains of mouse PU.1 and Spi-B 
protein. Indicated are acidic, glutamine-rich (Gln), proline/glutamic acid/serine/threonine 
(PEST), and DNA-binding (E26 transformation-specific, ETS) domains. 
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1.5.1 Transcription Factor PU.11 
1.5.1.1 Historical Background 
PU.1 is a DNA-binding nuclear protein (transcription factor) that is a member of 
the E26 transformation-specific (ETS) family. PU.1 was named because it can interact 
with a “PU box,” a stretch of purines in the SV40 viral enhancer, that was identified as 
being functionally active in lymphoid cells (Petterson & Schaffner, 1987). SPI1 was 
independently identified as the protein product of a gene dysregulated in murine 
erythroleukemia, as a consequence of proviral integration of the spleen focus-forming 
virus (SFFV) (Moreau-Gachelin, Tavitian, & Tambourin, 1988). This gene/protein was 
named SPI1 for “spleen focus-forming virus proviral integration site 1.” PU.1 and SPI1 
were subsequently recognized to be the same protein (Goebl, 1990; Paul, Schuetze, 
Kozak, Kozak, & Kabat, 1991). PU.1 is encoded by Spi1 on mouse chromosome 2 and 
by SPI1 on human chromosome 11 (Van Cong et al., 1990). The presence of functional 
PU boxes led to the identification of PU.1 as a transcription factor that could interact with 
the immunoglobulin (Ig) kappa 3’enhancer (Pongubala & Atchison, 1991; Pongubala et 
al., 1992), the Ig heavy chain intronic enhancer (Nelsen et al., 1993), and the CD11b 
promoter (Hickstein, Baker, Gollahon, & Back, 1992). PU.1 was thereafter described to 
interact with a number of lymphoid- and myeloid-specific promoters and enhancers 
(Turkistany & DeKoter, 2011). 
1.5.1.2 PU.1 Structure and Function 
  Mouse PU.1 protein has 272 amino acids and has high sequence identity to human 
PU.1 (Klemsz, McKercher, Celada, Van Beveren, & Maki, 1990; Ray et al., 1992). PU.1 
is a member of the ETS family that includes 28 members in humans  (Hollenhorst, 
McIntosh, & Graves, 2011). The ETS family is defined by high amino acid sequence 
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homology within a helix-loop-helix DNA-binding domain located in the C-terminal 
region of the protein (Fig. 1.3)  (Kodandapani et al., 1996). PU.1 is most highly related 
to Spi-B and Spi-C among the ETS family (Hollenhorst et al., 2011). Dissection of PU.1 
activity using in vitro reporter assays identified an N-terminal acidic domain of 100 amino 
acids, a centrally located proline/glutamic acid/serine/threonine (PEST) domain, and a 
112-amino acid ETS domain (Fig. 1.3) (Klemsz & Maki, 1996; Klemsz et al., 1990). The 
N-terminal 100 amino acids of PU.1 represent an activation domain that has been reported 
to recruit transcriptional cofactors including retinoblastoma (Rb), TFIID (Hagemeier, 
Bannister, Cook, & Kouzarides, 1993), and CREB-binding protein (CBP) (Yamamoto, 
Kihara-Negishi, Yamada, Hashimoto, & Oikawa, 1999). Thus, PU.1 functions as a 
transcriptional activator by recruitment of transcriptional co-activators and RNA 
polymerase II components. PU.1 interacts as a monomer with an AGAA or 
GGAA purine-rich core motif (Fig 1.3). However, PU.1 can also bind DNA cooperatively 
with interferon regulatory factor (IRF4) or IRF8 transcription factors to recognize an 
ETS-IRF composite element (EICE) that has the consensus sequence 
GGAAgtGAAA  (Brass et al., 1999; Escalante et al., 2002). Cooperative binding of DNA 
with IRF4/ IRF8 requires interaction with serine 148 located in the PEST domain of PU.1 
(Eisenbeis, Singh, & Storb, 1995). Another well-studied interaction is between PU.1 and 
the regulator of erythroid cell fate GATA-1 (Nerlov, Querfurth, Kulessa, & Graf, 2000; 
Rekhtman, Radparvar, Evans, & Skoultchi, 1999; P. Zhang et al., 2000). PU.1 protein 
interacts with GATA-1 protein to impair the enforcement of erythroid cell fate by GATA-
1, whereas GATA-1 interaction with PU.1 protein impairs enforcement of myeloid cell 
fate by PU.1 (Hoppe et al., 2016; Stopka, Amanatullah, Papetti, & Skoultchi, 2005). 
Studies utilizing chromatin immunoprecipitation coupled with next-generation 
sequencing (ChIP-seq) permitted genome-wide analysis of PU.1 interaction in four 
hematopoietic lineages: erythroid (Wontakal et al., 2011), B lymphocyte (Heinz et al., 
2010; Schwickert et al., 2014; Solomon, Li, Piskorz, Xu, & DeKoter, 2015), T 
lymphocyte (J. A. Zhang, Mortazavi, Williams, Wold, & Rothenberg, 2012), and 
macrophage (Ghisletti et al., 2010; Heinz et al., 2010). These studies revealed that PU.1 
interacts with transcription start sites, within gene bodies, and within intergenic regions. 
PU.1- binding locations highly correlate with locations of predicted enhancers (Ghisletti 
et al., 2010; Whyte et al., 2013). PU.1-binding locations highly correlate with locations 
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of activating histone modifications, including in T cells and erythroid cells where PU.1 
functions as an antagonist of differentiation (Ghisletti et al., 2010; J. A. Zhang et al., 
2012) (Ghisletti et al., 2010; Wontakal et al., 2011; J. A. Zhang et al., 2012). In 
macrophages, PU.1 binding is associated with nearly all enhancers marked by the 
activating histone mark H3K4me1 (Ghisletti et al., 2010; Lara-Astiaso et al., 2014). PU.1 
interaction with target sites in the genome may be an important first step for nucleosome 
remodeling, facilitating binding of other transcription factors and cofactors (Ghisletti & 
Natoli, 2013). In summary, PU.1 interaction with the consensus motif GGAA or AGAA at 
transcription start sites and enhancers is associated with recruitment of transcriptional 
cofactors and induction of activating histone modifications. 
1.5.1.3 PU.1 Expression and Regulation 
 PU.1 is expressed in adipocytes (F. Wang & Tong, 2008) and in hematopoietic 
cells (Hromas et al., 1993) (Fig. 1.4). PU.1 is expressed at high levels in macrophages 
and at lower levels in B cells, and these differences are critically required to promote 
either macrophage or B cell development in culture (DeKoter, 2000). To determine PU.1 
levels during development, several laboratories generated reporter alleles for Spi1 using 
cDNA encoding green fluorescent protein or yellow fluorescent protein “ knocked in”  to 
the Spi1 locus (Back, Allman, Chan, & Kastner, 2005; Hoppe et al., 2016; Nutt, Metcalf, 
D’Amico, Polli, & Wu, 2005). These studies revealed that PU.1 is expressed at high levels 
in hematopoietic stem cells and throughout the development of all myeloid lineages (Fig. 
1.4). PU.1 expression is sharply downregulated during differentiation into 
megakaryocyte-erythroid progenitors and during differentiation into T cells. PU.1 
expression is reduced upon differentiation of lymphoid progenitors into B cell 
progenitors. PU.1 continues to be expressed throughout all stages of B cells, although at 
lower levels than macrophages, neutrophils, and dendritic cells, and is downregulated 
upon differentiation into plasma cells (Back et al., 2005; Nutt et al., 2005) (Fig. 1.4). PU.1 
expression is regulated by both transcriptional and posttranscriptional mechanisms. 
Spi1 transcription is regulated by interaction of the promoter region with an upstream 
regulatory element located at 14 kb relative to the transcription start site (Leddin et al., 
2011; Rosenbauer et al., 2004). Mutation of the 14 kb URE sequence led to reduced 
Spi1 transcription in myeloid and B cells and increased PU.1 expression in T cells 
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(Rosenbauer et al., 2006). The half-life of PU.1 protein allows for accumulation during 
increased cell cycle length (Kueh, Champhekar, Nutt, Elowitz, & Rothenberg, 2013). 
Finally, PU.1 expression is modulated by microRNA-155 in the B cell lineage. Mutation 
of the gene-encoding miR-155, or mutation of the miR-155 target site in the 30 UTR of 
the Spi1 gene, caused PU.1 expression to be upregulated in B cells (D. Lu et al., 2014; 
Vigorito et al., 2007). In summary, PU.1 levels are regulated by transcription, by protein 
stability, and by microRNAs.  
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Figure 1. 4. PU.1 Levels Throughout Hematopoiesis. 
 
Relative PU.1 levels are represented by intensity of the orange color within the diamond. 
Cellular stages of hematopoiesis are indicated progressing from left to right. HSC 
hematopoietic stem cell, MPP multipotent progenitor, MEP megakaryocyte-erythrocyte 
progenitor, CMP common myeloid progenitor, LMPP lymphoid-primed multipotent 
progenitor, GMP granulocyte-macrophage progenitor, MDP monocyte-dendritic cell 
progenitor, CLP common lymphocyte progenitor, MkP megakaryocyte progenitor, EP 
erythrocyte progenitor, CDP conventional dendritic cell progenitor, DCs dendritic cells, 
Pro-B progenitor B cell, B-1 and B-2 major B cell subsets, ALP all lymphocyte 
progenitor, ETP early thymic progenitor, pro-NK natural killer cell progenitor, NK 
natural killer cell, pro-T progenitor T cell, CD4+ and CD8+ major T cell subsets 
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1.5.1.4 Biological Function of PU.1 
  The biological function of PU.1 has been studied using genetically modified 
mouse models. Descriptions of mice homozygous for germline null alleles of Spi1 were 
published by Harinder Singh laboratory in 1994 (Scott, Simon, Anastasi, & Singh, 1994) 
and Richard Maki’ s laboratory in 1996 (McKercher et al., 1996). The DeKoter laboratory 
described mice homozygous for a hypomorphic allele of Spi1 in 2007 (DeKoter, Kamath, 
& Houston, 2007). These studies showed that PU.1 was required to generate all white 
blood cell lineages including B cells, T cells, granulocytes, and macrophages. Erythroid 
and megakaryocyte development was largely normal in these mice. In order to determine 
at what stage PU.1 was required for development, conditional knockout alleles of 
Spi1 were described by three groups in 2005 (Iwasaki et al., 2005; Polli et al., 2005; Ye, 
Ermakova, & Graf, 2005). These studies revealed that PU.1 was required to generate 
myeloid and lymphoid progenitors. Spi1 deletion at any stage resulted in blocked myeloid 
development (K. L. Anderson et al., 2000; Chopin et al., 2013; Iwasaki et al., 2005). After 
commitment to the B cell lineage, PU.1 was not absolutely required for B cell 
development, because PU.1 function was complemented by the related transcription 
factor Spi-B. In the absence of both PU.1 and Spi-B, B cell development was arrested at 
an early stage (Sokalski et al., 2011). PU.1 concentration plays key roles in regulation of 
immune function. Upregulation of PU.1 expression in B cells, caused by mutation of the 
gene-encoding miR-155 or by mutation of the miR-155 target site in the 3’UTR of the 
Spi1 gene, led to defects in B - T cell interaction, impaired antibody-forming responses, 
and impaired plasma cell differentiation (D. Lu et al., 2014; Vigorito et al., 2007).  
In the T cell lineage, PU.1 expression was downregulated at the beta-selection 
checkpoint during T cell development in the thymus (M. K. Anderson, Hernandez-Hoyos, 
Diamond, & Rothenberg, 1999). However, PU.1 is upregulated in a peripheral T cell 
population expressing interleukin-9 (IL-9). This population, known as T helper 9 (Th9) 
cells, requires PU.1 for proper development and function (Chang et al., 2010). This group 
showed that T helper cells are exquisitely sensitive to PU.1 concentration, as even low 
levels of expression have major functional consequences for T helper cell development 
(Awe et al., 2015).  
PU.1 concentration plays an important role in regulating self-renewal of 
hematopoietic stem cells (HSCs). Deletion of Spi1 in HSCs promotes premature cell cycle 
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progression and consequently stem cell exhaustion (Staber et al., 2013; Will et al., 2015). 
In contrast, increased expression of PU.1 in HSCs, induced by macrophage colony-
stimulating factor (M-CSF) signaling, opposed self-renewal and increased the frequency 
of “choice” toward the myeloid cell fate (Mossadegh-Keller et al., 2013). Therefore, HSC 
self-renewal is sensitive to PU.1 concentration. In general, high PU.1 levels promoted 
increased differentiation and reduced self-renewal, while reduced PU.1 levels lead to 
reduced differentiation and increased self-renewal. Taken together, these studies showed 
that PU.1 levels are biologically important for development, differentiation, and self-
renewal of hematopoietic lineages. 
1.5.1.5 Role of PU.1 in Disease 
  PU.1 has been associated with leukemia since its discovery. In 1988, researchers 
first identified Spi1 as a gene recurrently disrupted in murine erythroleukemia by proviral 
insertion of murine spleen focus-forming virus (SFFV) (Goebl, 1990; Moreau-Gachelin 
et al., 1988). SFFV proviral integration resulted in overexpression of PU.1; and 
overexpression of PU.1 was sufficient to induce erythroleukemia in mice (Moreau-
Gachelin et al., 1996). In contrast, reduced levels of PU.1 in mice can cause B cell acute 
lymphoblastic leukemia (B-ALL) and acute myeloid leukemia (AML). Mice that 
developed AML as a consequence of gamma-irradiation had recurrent deletions or point 
mutations of a 2Mbp region of chromosome 2 that included Spi1 (Cook et al., 2004). Mice 
expressing 20% of normal levels of PU.1, as a consequence of deletion of an upstream 
regulatory element (URE) located at 14 kb relative to the transcription start site, 
developed myeloid leukemia at high incidence (Rosenbauer et al., 2006, 2004). 
Interestingly, these mice also developed T cell lymphoma associated with increased levels 
of PU.1 expression in the thymus (Rosenbauer et al., 2006). Reduced PU.1 levels led to 
a preleukemic condition by increasing rates of proliferation and reducing differentiation 
of hematopoietic stem cells and myeloid progenitor cells  (Staber et al., 2013; Will et al., 
2015; Ziliotto et al., 2014). Even a modest 35% reduction in PU.1 expression strongly 
cooperated with Msh2 homozygous mutation to promote abnormal proliferation of 
myeloid cells leading to leukemia (Will et al; 2015). Restoration of PU.1 levels in AML 
cells restored the monocyte-macrophage differentiation program and opposed continued 
proliferation (Sive et al., 2016). In the B cell lineage, mutation of Spi1 led to B-ALL, but 
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with low incidence and with long latency (S. H. M. Pang et al., 2016). However, mice 
with deletions of genes encoding both PU.1 and Spi-B had impaired B cell development 
and developed B cell acute lymphoblastic leukemia at 100% incidence by 21 weeks of 
age (Sokalski et al., 2011). Thus, PU.1 and Spi-B function as complementary tumor 
suppressors in the B cell lineage.  
In summary, PU.1 is a tumor suppressor in the B cell and myeloid lineages but may 
function as an oncogene in the erythroid and T cell lineages. These opposing findings 
illustrate the importance of maintaining appropriate PU.1 levels throughout 
hematopoietic development. Mutation of human SPI1 was not associated with 
erythroleukemia or T cell leukemia, but was associated with human acute myeloid 
leukemia (AML). PU.1 expression is repressed by the protein product of the RUNX1-
ETO translocation, one of the most frequent chromosomal abnormalities in AML 
(Vangala et al., 2003). Reduced PU.1 levels are associated with MLL mutations in mixed 
lineage leukemia (Lavallée et al., 2015). In one cohort of patients, inactivating mutations 
of SPI1 were associated with AML (Mueller, 2003). These studies suggest that altered 
levels of PU.1 protein in human cells contribute to leukemogenesis. PU.1 marks 
superenhancers in B cells are associated with a wide variety of diseases (Whyte et al., 
2013). Alzheimer’ s disease was recently shown to be associated with upregulation of 
immune response genes that are targeted by PU.1 (Gjoneska et al., 2015). These studies 
indicate that perturbations in PU.1 levels are associated with cancer, B cell dysfunction, 
and inflammation.   
 PU.1 is an ETS transcription factor that is highly expressed in hematopoietic cell 
types, with expression highest in myeloid cells, lower in lymphocytes, and lowest in red 
blood cells and megakaryocytes. PU.1 interacts with “PU boxes” in the genome to activate 
transcription of target genes. Deletion of the gene encoding PU.1 results in multiple 
hematopoietic defects including loss of development of myeloid cells and lymphoid cells. 
Reduced PU.1 expression leads to impaired differentiation and increased proliferation of 
HSCs, myeloid progenitor cells, and progenitor B cells. Even modestly reduced or 
increased PU.1 expression can lead to leukemia and impaired immune function. Rapid 
advances in next-generation sequencing will allow a better understanding of the 
mechanisms by which deregulated levels of PU.1 lead to diseases such as leukemia. The 
global identification of PU.1 target genes in myeloid and B cell progenitors, as well as 
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the determination of genomic alterations found in leukemic cells, will enhance knowledge 
of the molecular mechanisms of human leukemia. 
1.5.2 Transcription Factor Spi-B 
1.5.2.1 Historical Background & Structure and Function 
The transcription factor Spi-B is the second member of the Spi subfamily of ETS 
transcription factors. The Spi-B gene is located on chromosome 19 in humans and to 
chromosome 7 in mice, and in humans it encodes a protein of 262 amino acids. This factor 
was identified by screening a Burkitt lymphoma cDNA library with a human cDNA probe 
corresponding to the DNA-binding region of the Spi-1 protein (Ray et al., 1992). Spi-B 
has a DNA-binding domain at the C-terminus and an acidic N-terminal domain which 
corresponds to the transactivation domain in PU.1. The human Spi-B protein shares 43% 
amino acid sequence identity and 67% DNA-binding domain sequence identity with 
human PU.1 (Fig 1.3) (Ray et al., 1992). Murine Spi-B and PU.1 share 70% sequence 
homology in their DNA-binding domain (Chen et al., 1995). In addition, PU.1 and Spi-B 
also bind to identical DNA- binding sequences and transactivate the same target genes in 
vitro (Ray-Gallet, Mao, Tavitian, & Moreau-Gachelin, 1995; Su, 1996). Spi-B 
transcription factor is less studied compared to the transcription factor PU.1.  
1.5.2.2 Biological Function and Gene Regulation of Spi-B 
Spi-B expression was first thought to be exclusive to B and T lymphocytes (Su, 
1996), but recent studies have demonstrated that Spi-B is expressed in intestinal microfold 
cells as well as plasmacytoid dendritic cells (pDCs) (Kanaya et al., 2012; Schotte, 2003). 
Although its expression decreases in mature T cells, Spi-B expression increases as B cells 
mature, suggesting a critical role for Spi-B in differentiated B cells (Su, 1996). Consistent 
with its lineage-specific expression, Spi-B mRNAs are restricted to the lymphoid organs 
of developing mouse embryos and adult mice (Su, 1996). Unlike PU.1 knockout mice, 
germline Spi-B knockout are viable and possess mature B and T cells, despite the fact 
that Spib-/- B cells have defects in functional and humoral responses (Su et al., 1997), 
suggesting the involvement of Spi-B is in BCR-mediated responses. It is thought that the 
less severe phenotype observed in Spi-B knockout mice is a consequence of Spi-B degree 
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of complementary with PU.1, as both transcription factors recognize the same binding 
sites (Ray et al., 1992) and can activate the same reporter gene constructs in vitro (Ray et 
al., 1992; Su, 1996). In order to test that these transcription factors have complementary 
functions, mice heterozygous for Spi1 were crossed to Spib-/- to generate Spi1+/- Spib-/- 
mice (Garrett-Sinha et al., 1999), since complete PU.1 deletion resulted in embryonic 
lethality (Scott et al., 1994). The double deletion of these factors, increased the severity 
of the deficiencies observed in Spi-B knockout mice, such as the basal levels of apoptotic 
cells, reduced BCR signaling, and impaired IgM and LPS-mediated B cell proliferation. 
Therefore, Spi-B was required in mature B cells specifically for BCR transduction in a 
complementary manner. 
 To test whether-B and PU.1 complementarity during B cell development, a bone 
marrow specific mouse strain deleting Spi-B and PU.1 in Pre-B cells was generated by 
crossing Spi-B germline knockout mice with mice in which PU.1 is conditionally deleted 
in the bone marrow (Cd19+/Cre Spi1lox/lox) (Sokalski et al., 2011). While mice lacking one 
of these factors resulted in only mild impairments in B cell development, mice lacking 
both factors have a severe blockade in B cell development, reaffirming that these factors 
function in a complementary manner (Sokalski et al., 2011). With the advance of next 
generation sequencing methods, the existence of differential PU.1 and Spi-B binding sites 
was investigated by chromatin immunoprecipitation followed by next generation 
sequencing (ChIP-seq) in murine WEHI-279 lymphoma cells (Solomon et al., 2015). 
PU.1 occupied 4528 regions and Spi-B occupied 3360 regions, with a high number of 
overlapping regions occupied by both factors. Spi-B and PU.1 binding sites were 
frequently located immediately upstream of genes associated with immune response and 
activation of B cells. Motif-finding revealed that both transcription factors were 
predominantly located at ETS motifs (5’ GGAA 3’), however, other unique motifs were 
identified when examining regions associated with only one of the two factors. Motifs 
associated with unique PU.1 binding included POU2F2, while unique motifs in Spi-B 
regions contained a combined ETS-IRF motif (Solomon et al., 2015). In summary, 
although Spi-B seems to have unique functions in BCR activation in mature B cells, most 
of Spi-B function in B cell development seems to be complemented by PU.1 acting as a 
safeguard guarantying the generation of mature B cells exiting the BM. 
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1.6 B Cell Related Malignancies 
Blood cancers originating from B lymphocytes are classified as B cell related 
malignancies, also known as B cell neoplasms. B cell neoplasms originate from either B 
cell precursors or from mature B cell subtypes. According to the World Health 
Organization (WHO), B cell neoplasms can be classified in two major subtypes according 
developmental stage of the cells involved: Precursor lymphoid B cell neoplasms and 
mature B cell neoplasms. The classification of Leukemia versus Lymphoma is also used 
to classify B cell neoplasms, classifying disease according to the level of BM or blood 
involvement in the neoplasm. As an example, B cell acute lymphoblastic leukemia (B-
ALL) is characterized as a neoplasm originating from of precursor lymphoid cells which 
are committed to the B cell lineage. Since B-ALL is composed of Small to medium-sized 
blast cells involving bone marrow and blood, this disease is further classified as leukemia. 
The term lymphoma is used when the process is confined to a mass lesion with minimal 
evidence of blood or marrow involvement. Therefore, precursor B cell neoplasms or 
mature B cell neoplasms can be classified as either leukemia or lymphoma according with 
the degree of marrow or blood involvement (Terwilliger & Abdul-Hay, 2017). 
Acute Lymphoblastic Leukemia (ALL), including both subtypes originating from 
T or B lymphocytes, primarily affects children <6 years, and corresponds to 75% of all 
cancers diagnosed in children. Despite cure rates exceeding 90% in children, it remains 
an important cause of morbidity and mortality in children and adults (Iacobucci & 
Mullighan, 2017). The estimated annual incidence worldwide is 1- 475 cases per 100,000 
population, with 6,000 new cases per year in the USA. The majority of the cases (80-
85%) are diagnosed as B-ALL subtype affecting males whereas lymphoblastic 
malignancies of precursor T-cell type more often present as lymphoma, with mediastinal 
masses. Male predominance is seen in lymphoblastic malignancies of both B cell and T 
cell lineages (Canadian Cancer Society, 2018). Moreover, according to Canadian Cancer 
Statistics, 3% of diagnosed cases of cancer in 2017 were leukemia, including subtypes 
originated from lymphoid and myeloid cells (6,200 in 206,200). The Canadian Cancer 
Statistics (2017) also showed that leukemia affects youth with an average age of incidence 
of 15.5 years (Canadian Cancer Society, 2018). For the purposes of this thesis, we focused 
our attention on B-ALL. To date, B-ALL is subcategorized in B cell lymphoblastic 
 
36 
leukemia/lymphoma not otherwise specified (NOS) and B cell lymphoblastic 
leukemia/lymphoma with recurrent genetic abnormalities. 
1.6.1 B Cell Lymphoblastic Leukemia/Lymphoma Not Otherwise 
Specified 
Despite the fact that 75% of B-ALL harbor recurrent chromosomal alterations, a 
Small percentage of B-ALL cases are associated with single-nucleotide polymorphisms 
(SNVs) and DNA copy number alterations. Many genes containing structural alterations 
are involved in lymphocyte development including PAX5, IKZF1, EBF1 and LMO2, 
cell-cycle regulation and tumor suppression (CDKN2A/B, PTEN and RB1), lymphoid 
signaling (BTLA, CD200, TOX and NR3C1), and transcriptional regulation and 
coactivation (TBL1XR1, ETV6, and ERG) (Iacobucci & Mullighan, 2017). Children with 
Down syndrome and other congenital diseases also have been reported to have increased 
susceptibility to B-ALL (Antonarakis, 2017). These observations illustrate that even 
Small non-recurrent mutations in genes harboring important regulatory functions in B 
lymphocytes have the potential to lead to leukemogenesis.  
1.6.2 B Cell Lymphoblastic Leukemia/Lymphoma with Recurrent 
Genetic Abnormalities 
Recurrent genetic alterations in B-ALL include aneuploidy and chromosomal 
rearrangements that result in oncogene deregulation or expression of chimeric fusion 
genes. Nine subtypes of B-ALL classified according a recurrent genetic abnormality.      
1) B cell lymphoblastic leukemia/lymphoma with hypodiploidy, is a high-risk 
leukemia that may be sub classified by degree of aneuploidy into near haploid 
(NH-ALL, 24-31 chromosomes) and low hypodiploid (LH-ALL, 32-44 
chromosomes) cases. Genomic analysis previously has shown that NH-ALL 
has a high frequency of deletions and mutations that activate Ras signaling 
(Holmfeldt et al., 2013). LH-ALL have high frequency of inactivating 
alterations of the IKAROS genes IKZF2 (HELIOS) and IKZF3 (AIOLOS) 
(Nachman et al., 2007). Therapeutically targeting the Ras pathway may 
represent an important novel treatment outcome in this high-risk leukemia. 
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2) B cell lymphoblastic leukemia/lymphoma with hyperdiploidy, is a type of 
leukemia/lymphoma in which the neoplasm is committed to the B cell lineage 
lymphoblast. These blasts contain >50 chromosomes (usually <66) and do not 
present other structural alterations. B cell lymphoblastic leukemia/lymphoma 
with hyperdiploidy is very common in children (about 25% of all B-ALL 
cases) but also is frequent in adults (7%-8%) (Paulsson & Johansson, 2009). 
3) B-lymphoblastic leukemia/lymphoma associated with t(9;22) (q34.1;q11.2) is 
a neoplasm of lymphoblasts committed to the B cell lineage in which the blasts 
present a translocation between BCR on chromosome 22 and the ABL1 
oncogene on chromosome 9. This subtype of B-ALL accounts for 5% of all 
pediatric B-ALL and 40% of adult ALL (Boer & den Boer, 2017).  
4) B cell lymphoblastic leukemia/lymphoma with t(v;11q23) [MLL rearranged], 
is a rare leukemia more common in children than in adults. It is similar to ALL 
and acute myeloid leukemia with KMT2A rearrangements. 
5) B cell lymphoblastic leukemia/lymphoma with t(12;21) (p13;q22)[ETV6-
RUNX1] translocation, is a neoplasm of committed B cell lymphoblast 
precursors. The lymphoblasts show a translocation between ETV6 (also called 
TEL) on chromosome 12 and RUNX1 (also called AML1) on chromosome 
21. This leukemia is common in children, accounting for about 25% of cases 
of B-ALL in that age group, but very rare in adults (Zuna et al., 2011). 
6) B cell lymphoblastic leukemia/lymphoma with t(1;19) (q23;p13.3)[TCF3-
PBX1], harbors translocations is TCF3-PBX1 B-ALL. This leukemia presents 
a translocation between TCF3 (also known as E2A) on chromosome 19 and 
PBX1 (Alonso, 2013). It is a neoplasm of B-lymphoblasts and is relatively 
common in children (6%) and less common in adults. 
7) B-lymphoblastic leukemia/lymphoma (B-ALL/LBL) with t(5;14) 
(q31.1;q32.1), is a leukemia subtype defined by the presence of lymphoblasts 
committed to the B cell lineage in which the blasts harbor a translocation 
between IL3 and IGH gene, resulting in variable eosinophilia. This is a rare 
disease, accounting for < 1% of cases of ALL reported in children and adults.  
8) B cell lymphoblastic leukemia/lymphoma with intrachromosomal 
amplification of chromosome 21 (iAMP21), corresponds to 2% of B-ALL. 
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Patients presenting intrachromosomal amplification of chromosome 21 
(iAMP21)., is defined by gain of at least 3 copies of the region of chromosome 
21 containing RUNX1. The amplification is often large and complex and 
accompanied by deletion of the subtelomeric regions of chromosome 21. It is 
associated with poor outcome but the mechanisms of leukemogenesis are 
unclear. iAMP21has increased risk of relapse (Mueller, 2006). 
9) B cell lymphoblastic leukemia/lymphoma with translocations involving 
tyrosine kinase cytokine receptors (‘BCR-ABL1–like ALL’): The Ph-like 
ALL has a gene expression profile similar with BCR-ABL1-positive ALL but 
lack the rearrangement BCR-ABL1. Among the common genomic features of 
BCR-ABL1–like ALL are alterations of B-lymphoid transcription factor 
genes (particularly IKZF1 deletions) and genetic alterations deregulating 
cytokine receptor and tyrosine kinase signaling. 50% of the cases include 
rearrangements and mutations of CRLF2, 12% rearrangements of ABL-class 
tyrosine kinase genes, 7% JAK2, 11% mutations activating JAK-STAT 
signaling and 6% Ras signaling (Jain et al., 2017). 
1.6.3 Mouse Models for The Study of B Cell Related Malignancies  
Due to the existence of many leukemia subtypes, the development of murine 
models to study leukemia have been critical for the development of novel targeted 
therapy. Although, the development of mouse models seems to be in critical demand, 
currently only a few mouse models have been characterized and used for clinical 
translation (Jacoby, Chien, & Fry, 2014) . To date, the experimental systems used to study 
ALL are syngeneic models and xenografts, which have limitations since they cannot 
mimic the host microenvironment required for leukemia development (Kohnken, Porcu, 
& Mishra, 2017). Therefore, the development of spontaneous leukemia mouse model 
featuring aspects of human disease has become important for the understanding of disease 
biology as well for the development and testing of new target therapies for B cell 
neoplasms. 
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1.7 Central Hypothesis 
The central hypothesis of this thesis is that Spi-B and PU.1 transcription factors 
have redundant functions during B cell development, controlling events associated with 
transition from high to low proliferative stages in B cell development, and that the absence 
of these factors would favor a state of proliferative stress leading to leukemogenesis. 
1.8 Thesis Overview 
This thesis characterizes the role of the ETS transcription factors Spi-B and PU.1 
in normal B cell development as well as into the mechanisms by which the absence of 
these factors leads to leukemogenesis. Specifically, we elucidated the requirement of 
these factors during B cell development and the mechanism by which Spi-B and PU.1 
facilitate light chain rearrangement. Secondly, we determined that Spi-B and PU.1 
absence is the ‘first hit’ for leukemogenesis, but that secondary driver mutations in genes 
that confer survival and proliferative advantages is required for leukemia progression. 
Finally, we provide preliminary insight into the potential mechanisms by which Pro-B 
cells acquire a large number of mutations due to the lack of Spi-B and PU.1. 
Both studies described in Chapter 2 and Chapter 3, were performed using a 
conditional deletion mouse model, Mb1-CreΔPB, in which the Spib and Spi1 (encoding 
Spi-B and PU.1) genes are deleted during early B cell development. This mouse model 
facilitated the study of the role of these factors during the development of B cells, as well 
as in leukemogenesis. 
1.8.1.1 Chapter 2: PU.1 Regulates Ig Light Chain Transcription and 
Rearrangement in Pre-B Cells During B Cell Development 
In Chapter 2, we demonstrated a crucial requirement for Spi-B and PU.1 
transcription factors during B cell development at the transition from Large Pre-B cells 
(Fraction D) to Small Pre-B cells (Fraction E). At this transition, developing B cells 
rearrange immunoglobulin light chain genes expressed in the B cell receptor. The absence 
of Spi-B and PU.1 in vivo blocked the progression of developing B cells in the bone 
marrow at the Large Pre-B to Small Pre-B cells stage. PU.1 ChIP-seq combined with 
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RNA-seq in Pro-B cells in which PU.1 expression was restored by a doxycycline 
inducible-system, demonstrated that PU.1 binds to the variable genes within the 
immunoglobulin kappa locus and alters mRNA transcription. Forced PU.1 expression in 
this cell line leads to the rearrangement of the immunoglobulin light chain in conditions 
with low IL-7. Finally, we demonstrated that the level of transcription from the 
immunoglobulin kappa chain locus is reduced ex vivo in Small Pre-B cells derived from 
mice lacking Spi-B and PU.1, suggesting a role of these factors in the accessibility of this 
locus. 
1.8.1.2 Chapter 3: Deletion of Genes Encoding PU.1 And Spi-B Leads 
to B Cell Acute Lymphoblastic Leukemia Associated with Driver 
Mutations in Janus Kinases 
In Chapter 3, we focused our attention on understanding the mechanisms by which 
the absence of Spi-B and PU.1 in developing B cells results in B cell acute lymphoblastic 
leukemia (B-ALL) with a latency period of 18 weeks. We performed RNA and whole-
exome sequencing (WES) analyses in leukemias from mice lacking Spi-B and PU.1 in 
developing B cells aiming to identify secondary driver mutations of leukemogenesis. We 
found a large number of single-nucleotide variants (SNVs) present in the leukemias – the 
majority of which resulted in amino acid changes and in the gain of early stop-codons. 
Integration of RNA-seq and WES revealed the potential for IKZF3, JAK1 and JAK3 
mutations to act as secondary drivers of leukemogenesis, since these genes are often 
mutated and highly expressed in mouse leukemias. Further analyses showed that 
mutations found within the Jak3 gene resulted in amino acid substitutions located in the 
pseudo-kinase (R653H, V670A) and in the kinase (T844M) domains. Finally, we 
observed that these mutations confer survival and growth advantage to wild-type Pro-B 
cells. We conclude that absence of Spi-B and PU.1 leads to leukemogenesis in association 
with secondary driver mutations in JAK3. 
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1.8.1.3 Chapter 4: Genetic Signatures of Leukemias Derived From PU.1 
and Spi-B Knockout Mice Reveals Potential Etiology of The 
Disease 
In Chapter 4, we further investigated the etiology of leukemogenesis in the 
absence of Spi-B and PU.1. Mutational signature analysis revealed an enrichment of C•G 
> A•T genomic transversions in leukemias generated as a consequence of the lack of Spi-
B and PU.1. This type of signature has been recently observed in a Small proportion of 
leukemias and is proposed to be caused as a result of guanine damage that is repaired by 
a transcription-coupled nucleotide-excision repair pathway. A common type of guanine 
damage is the 8-oxoguanine (8-oxoG) lesion, that is often caused by oxidative stress. We 
examined the expression of DNA glycosylases, which are known to correct this type of 
lesion, in RNA-seq data performed in six different leukemias extracted from Mb1-DPB 
mice. We observed a modest increase in expression of Mutyh and Neil1 genes in mouse 
leukemias, which suggests the possible involvement of nucleotide-excision repair 
pathway in the repair of 8-oxoG lesions. Furthermore, our data also suggested that this 
damage is caused by oxidative stress since gene expression encoding glutathione 
peroxidase 1, Gpx1 and glutathione reductase Gsr were reduced in the RNA-seq data 
from Mb1-DPB leukemias. These preliminary data suggest that leukemia cells in the 
absence of Spi-B and PU.1 have impaired antioxidant mechanisms. These interesting 
findings led us to hypothesize that overload of ROS leads to 8-oxoG damage resulting in 
C•G > A•T mutational signature observed in leukemias in the absence of Spi-B and PU.1. 
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Chapter 2  
2 PU.1 Regulates Ig Light Chain Transcription and 
Rearrangement in Pre-B Cells During B Cell 
Development2 
B cell development and Ig rearrangement are governed by cell type and 
developmental stage–specific transcription factors. PU.1 and Spi-B are E26-
transformation–specific transcription factors that are critical for B cell differentiation. To 
determine whether PU.1 and Spi-B are required for B cell development in the bone 
marrow, Spi1 (encoding PU.1) was conditionally deleted in B cells by Cre recombinase 
under control of the Mb1 gene in Spib (encoding Spi-B)–deficient mice. Combined 
deletion of Spi1 and Spib resulted in a lack of mature B cells in the spleen and a block in 
B cell development in the bone marrow at the Small Pre-B cell stage. To determine target 
genes of PU.1 that could explain this block, we applied a gain-of-function approach using 
a PU.1/Spi-B–deficient Pro-B cell line in which PU.1 can be induced by doxycycline. 
PU.1-induced genes were identified by integration of chromatin immunoprecipitation–
sequencing and RNA-sequencing data. We found that PU.1 interacted with multiple sites 
in the Igκ locus, including Vκ promoters and regions located downstream of Vκ second 
exons. Induction of PU.1 induced Igκ transcription and rearrangement. Upregulation 
of Igκ transcription was impaired in Small Pre-B cells from PU.1/Spi-B–deficient bone 
marrow. These studies reveal an important role for PU.1 in the regulation of Igκ 
transcription and rearrangement and a requirement for PU.1 and Spi-B in B cell 
development. 
  
                                                
2
 Text and figures within this section have been adapted from the previously published manuscript: 
Batista, C. R., Li, S. K. H., Xu, L. S., Solomon, L. A., & DeKoter, R. P. (2017). PU.1 Regulates Ig Light 
Chain Transcription and Rearrangement in Pre-B Cells during B Cell Development. The Journal of 
Immunology, 198(4), 1565–1574. http://doi.org/10.4049/jimmunol.1601709 
CopyrightÓ The American Association of Immunologists, Inc. (AAI). 
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2.1 Introduction 
B cell development involves ordered rearrangement of Ig loci encoding H and L 
chain proteins that assemble into Abs capable of recognizing specific Ags. Stages of B 
cell development can be resolved using cell surface marker expression, as well as Ig gene 
rearrangement (Hardy, 1991; L. Lu, Smithson, Kincade, & Osmond, 1998; Osmond, 
Rolink, & Melchers, 1998). Progenitor B (Pro-B; also known as Pre-BI) cells are 
generated from lymphoid progenitors and initiate D-J segment rearrangement of Igh H 
chain alleles. Rearrangement of Igh alleles is completed by V-DJ rearrangement to encode 
H chains that can pair with surrogate L chain proteins and be deposited on the cell surface 
as a Pre-BCR. Pre-BCR signaling promotes proliferation of Large Pre-B cells (also 
known as Pre-BII cells). Cessation of proliferation induces re-expression of the RAG 
proteins RAG1 and RAG2, whose interaction is wide spread throughout the Ig loci at 
recombination signal sequences (RSSs) (Teng et al., 2015). Finally, successful pairing of 
Ig kappa or lambda chain proteins with IgH proteins results in expression of a BCR in 
immature B cells (Corfe & Paige, 2009).  Immature B cells emigrate from the bone 
marrow (BM) to the spleen to complete their maturation (Allman et al., 2001).  
The mouse Igk locus contains 101 functional Vk genes, 60 Vk pseudogenes, 4 
functional Jk genes, 1 J pseudogene, and 1 Ck gene. The Igk locus comprises > 3 MB of 
genomic sequence (de Almeida, Hendriks, & Stadhouders, 2015). Recombination occurs 
in a developmental stage–specific order that is thought to be regulated at the level of 
chromatin accessibility to RAG proteins (Aoki-Ota, Torkamani, Ota, Schork, & 
Nemazee, 2012; Yancopoulos & Alt, 1985). Accessibility is likely controlled at the level 
of transcription, as supported by two lines of evidence. First, deletions of enhancers 
within the Igk locus impair transcription and Ig recombination (Inlay et al., 2002; 
Sleckman, Gorman, & Alt, 1996). Second, deletion of genes encoding histone modifying 
enzymes or transcription factors reduce transcription and Ig recombination (de Almeida 
et al., 2015). Thus, Ig locus accessibility is regulated by transcription factor recruitment 
of the transcriptional machinery to regulatory regions within the Igk locus.  
B cell development is coordinated by the expression of a number of cell type– and 
developmental stage–specific transcription factors, including E2A, EBF, Pax5, Ikaros, 
 
44 
PU.1, and Spi-B (Swee Heng Milon Pang, Carotta, & Nutt, 2014). PU.1 (encoded by 
Spi1) and Spi-B (encoded by Spib) are highly related transcription factors of the E26 
transformation–specific (ETS) family (Solomon et al., 2015). Several lines of evidence 
suggest that PU.1 might play an important role in the control of Igk transcription. Igk V 
region promoters, as well as the intronic and 39 enhancers in the Igk locus, contain 
predicted binding sites for PU.1 (Brekke & Garrard, 2004; Pongubala & Atchison, 1991; 
Schwarzenbach, Newell, & Matthias, 1995). Chromatin immunoprecipitation–
sequencing (ChIP-seq) analysis in Pro-B cells reveals that PU.1 binding is widespread 
throughout the Igk locus (de Almeida et al., 2015; Schwickert et al., 2014). However, 
there has not been a clear demonstration of a role for PU.1 in Ig transcription, 
accessibility, or rearrangement in vivo. The ability of Spi-B to complement PU.1 function 
may have impeded a clear demonstration of PU.1 as a regulator of Igk gene transcription 
(Solomon et al., 2015; L. S. Xu et al., 2012). We previously generated mice that delete 
Spi1 encoding PU.1 under control of CD19-Cre on Spib-/- background of IgM (L. S. Xu 
et al., 2012). These mice had impaired development of follicular B cells and perturbation 
of BM B cell development, demonstrating a complementary role for PU.1 and Spi-B in 
B cell development and function (Christie et al., 2015; Sokalski et al., 2011). However, 
CD19-Cre does not delete alleles efficiently in BM (Hobeika et al., 2006), precluding an 
examination of PU.1 and Spi-B function in early B cell development.  
We hypothesized that deletion of Spi1 and Spib during early B cell development 
would reveal a role for PU.1 and/ or Spi-B in the transcription and rearrangement of Ig 
genes. To test our hypothesis, Mb1+/CreSpi1lox/loxSpib-/-(Mb1-CreDPB) mice were 
generated by crossing Spi1lox/loxSpib-/- mice to Mb1+/Cre mice. Mb1-Cre deletes alleles 
with high efficiency in BM (Hobeika et al., 2006), resulting in a Spib-deficient mouse 
that is expected to have high frequency of Spi1 deletion during early B cell development. 
Analysis of adult mice showed that deletion of Spi1 and Spib in Mb1-CreDPB mice 
resulted in the absence of IgM+ B cells in the spleen. In BM, there was a specific block 
in B cell development at the Small Pre-B cell to immature B cell transition that is marked 
by successful rearrangement of Ig L chain genes. To determine target genes of PU.1 that 
could explain this block, we applied a gain-of-function approach using a PU.1/Spi-B–
deficient Pro-B cell line in which PU.1 can be induced by doxycycline. PU.1-regulated 
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genes were identified by integration of ChIP-seq and RNA-sequencing (RNA-seq) data. 
PU.1 interacted with 23,647 sites located near transcription start sites (TSSs) of genes 
involved in immune system development. Interestingly, we observed PU.1 interaction 
with multiple sites in Vk gene promoters, as well as sites downstream of Vk second exons 
located near RSSs. Induction of PU.1 resulted in increased transcription of Igk V genes 
and Igk rearrangement. Finally, we found that upregulation of Igk transcription was 
impaired in PU.1 and Spi-B–deficient BM Pre-B cells. These studies reveal an important 
role for PU.1 in Igk transcription and rearrangement and a requirement for PU.1 and Spi-
B in B cell development. 
2.2 Results 
2.2.1 Deletion of Genes Encoding PU.1 and Spi-B Impairs B Cell 
Development at the Pre-B to Immature B Cell Transition 
It was shown that mice lacking PU.1 or Spi-B in the B cell lineage have relatively 
normal B cell development and mild impairment of B cell function (S. H. M. Pang et al., 
2016; Polli et al., 2005; Ye et al., 2005). However, mice lacking PU.1 and Spi-B in the B 
cell lineage (Cd19+/Cre Spi1lox/lox Spib-/- mice) have reduced numbers of B cells, suggesting 
that these factors are important during development (Christie et al., 2015; Sokalski et al., 
2011). We sought to determine whether efficient deletion of PU.1 and Spi-B in the early 
stages of B cell development in BM would result in a block at a specific stage. Mice that 
delete Spi1 under control of the Cd79a (Mb-1) gene, which deletes alleles efficiently in 
BM (Hobeika et al., 2006), were bred to Spib-/- mice to generate Mb1-CreDPB mice 
(lacking PU.1 and Spi-B), Mb1-CreDP mice (lacking PU.1), and DB mice (lacking Spi-
B). To assess B cell development, the frequency of mature B cells in the spleen of 6–10 
weeks old mice was determined. Mb1-CreDPB mice had few B220+ IgM+ B cells in the 
spleen compared with WT or DB mice (Fig. 2.1). Therefore, PU.1 and Spi-B are required 
to generate splenic B cells.  
  
 
46 
Figure 2. 1. Absence of PU.1 and Spi-B During B Cell Development Severely Impairs 
B Cell Maturation.  
(A) Flow cytometric analysis of B220 and IgM cell surface expression of spleen cells 
prepared from WT (left panel), DB (center panel), and Mb1-CreDPB (right panel) mice. 
(B) Percentage of B220+ IgM+ cells in WT, DB, and Mb1-CreDPB mice (n = 7). Data 
are mean ± SEM. ***p < 0.001. 
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To determine the stage at which the block of B cell development was occurring, 
the frequencies of developing B cells in BM of 6–10-wk-old Mb1-CreDPB mice were 
measured using flow cytometry according to the cell surface marker scheme described by 
Hardy et al. (Hardy, Carmack, Shinton, Kemp, & Hayakawa, 1991). There were no 
significant differences in the frequencies of B220+ cells among the groups (Fig. 2.2 A, 
B). However, immature BM B cells (B220+CD43+) were increased in frequency and 
mature BM B cells (B220+ CD43-) were decreased in frequency in Mb1-CreDPB mouse 
BM compared with Mb1-CreDP, DB, and WT mouse BM (Fig. 2.2 C–E). As a proportion 
of total B220+ cells, there were reduced frequencies of cells at the pre–pro B cell stage, 
or Fraction A, in Mb1-CreDPB, Mb1-CreDP, and DB mice compared with WT mice (Fig. 
2.2 F, G).  
There were increased frequencies of Fraction B (Pro-B/Pre-BI) cells and Fraction 
C (Pre-B, Large Pre-B/ Pre-BII) cells in Mb1-CreDPB mouse BM compared with controls 
(Fig. 2.2 F, G). Mb1-CreDPB mice had double the frequency of Fraction C BM cells 
compared with controls (Fig. 2.2 F, G). None of the groups analyzed showed significant 
differences in the frequencies of Fraction D (Small Pre-B) cells. However, Fraction E 
(immature B cells) and Fraction F (mature recirculating B cells) were nearly absent in 
Mb1-CreDPB BM. Strikingly, there were no B cells expressing high levels of surface Ig 
in 6–10-wk-old Mb1-CreDPB mice (Fig. 2.2F, G). These results demonstrate a critical 
requirement for PU.1 and Spi-B in the transition from Small Pre- B cells to immature B 
cells. 
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Figure 2. 2. Deletion of PU.1 And Spi-B Blocks B Cell Development in the BM at the 
Pre-B Cell Transition.  
(A) Representative graph showing the percentage of B220+ cells in WT, Mb1-CreDP, DB, 
and Mb1-CreDPB mice. (B) Percentage of B220+ cells in BM of WT, Mb1-CreDP, DB, 
and Mb1-CreDPB mice. (C) Representative flow cytometric analysis showing the 
percentage of B220+ CD43+ and B220+ CD43+ cells in WT (left panel) and Mb1-CreDPB 
(right panel) mice. (D) Percentage of B220+ CD43+ cells in BM of WT, Mb1-CreDP, DB, 
and Mb1-CreDPB mice. (E) Percentage of B220+ CD43+ cells in BM of WT, Mb1-CreDP, 
DB, and Mb1-CreDPB mice. (F) Representative flow cytometric analysis according to the 
Hardy scheme representing the frequency of developing B cells in Fractions A–C in WT, 
Mb1-CreDP, DB, and Mb1-CreDPB mice (gated on B220+ CD43+ population) (upper 
panels). Flow cytometric analysis according to the Hardy scheme representing the 
frequency of developing B cells in Fractions D–F in WT, Mb1-CreDP, DB, and Mb1-
CreDPB mice (gated on B220+ CD432 population) (lower panels). (G) Percentage of 
B220+ cells in BM of WT, Mb1-CreDP, DB, and Mb1-CreDPB mice in Fractions (A–F). 
WT, n = 10; Mb1-CreDP, n =8; DB, n = 9; and Mb1-CreDPB, n = 12. Data are mean ± 
SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 
.  
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2.2.2 Analysis of PU.1 Target Genes in the Pro-B Cell Line i660BM 
To identify target genes of PU.1 that could explain the developmental block in 
Mb1-CreDPB mouse BM, we applied a gain-of-function approach using a PU.1-inducible 
Pro-B cell line (Fig. 2.3 A). The 660BM cell line is fully deleted for Spi1 and Spib, has a 
nonproductive rearrangement of the Igh locus, and is germline for Igk locus 
rearrangement. This cell line was implemented through the BM isolation from a germline 
knockout for Spib mouse (660), which Spi1 gene was deleted by Cre recombinase under 
control of the Cd19 gene. After BM isolation, 660BM cells were kept in IL-7-conditioned 
media and have shown the ability to proliferate indefinitely in the presence of IL-7 
(Christie et al., 2015). 660BM cell line was infected with a two-vector inducible system 
in which PU.1 is inducible using 70 ng/ml doxycycline (Christie et al., 2015), originating 
the i660BM cell line. To define sites of PU.1 interaction, anti-PU.1 ChIP was performed 
on chromatin prepared from i660BM cells induced with (+DOX) or without (-DOX) 70 
ng/ml doxycycline for 24 h. Illumina sequencing was performed on two biological 
replicates of PU.1-induced chromatin, as well as input chromatin. An average of 70 
million 100-bp single-end reads were obtained. Reads were aligned to the mouse genome 
(mm10), and data were analyzed using the Galaxy suite of software tools. PU.1 was found 
to be associated with 49,385 unique genomic regions. The top interaction motif recovered 
for all PU.1-associated regions was the ETS motif containing the core A/5’-GGAA-3’ 
sequence (Fig. 2.3 B). PU.1 was found to associate primarily with distal intergenic regions 
and gene bodies, similar to what was reported previously for PU.1 in splenic B cells (Fig. 
2.3 C) (Heinz et al., 2010). Seventeen percent of PU.1-interaction sites were at annotated 
gene promoters, and 23,647 peaks were located within 15 kb of annotated TSSs (Fig. 2.3 
C, D). 
Next, RNA-seq analysis was performed on three biological replicates of RNA 
prepared from i660BM cells induced or not with 70 ng/ml doxycycline for 48 h. An 
average of 60 million 100-bp paired-end reads were obtained per sample. RNA-seq reads 
were aligned to the mouse genome (mm10) using TopHat, and differential gene 
expression was determined using Cufflinks suite. Genes presenting a log2-fold change in 
expression > 0.5 were considered in our analysis. Using these criteria, transcript levels of 
811 genes were significantly increased upon PU.1 induction, and transcript levels of 531 
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genes were significantly decreased upon PU.1 induction (Supplemental Table II is 
available on the online version of this manuscript). To identify PU.1-regulated genes, the 
genomic region that interacts with PU.1 was associated with differentially expressed 
transcripts. A total of 793 of 811 upregulated genes and 521 of 531 downregulated genes 
were associated with PU.1 binding sites located within 15 kb of the TSS, suggesting that 
these genes were regulated directly by PU.1 (Fig. 2.3 E). As shown in Fig. 3F, 670 PU.1-
associated genes were upregulated and 465 PU.1-associated genes were downregulated 
with fold changes in expression, log2 (1.5). However, 141 genes were upregulated log2 
(1.5)-fold, of which 12 were upregulated log2 (5)-fold. Sixty-six genes were 
downregulated log2 (1.5)-fold, of which five were downregulated log2 (3)-fold (Fig. 2.3 
F). In summary, 793 upregulated gene transcripts and 521 downregulated gene transcripts 
were associated with PU.1 peaks and, therefore, were considered direct targets of PU.1 
regulation. 
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Figure 2. 3. Identification of PU.1-Regulated Genes in i660BM Pro-B cells.  
(A) Flow chart illustrating the strategy used to identify PU.1- regulated genes. RNA-seq 
of i660BM cells in the presence (+DOX) or absence (-DOX) of doxycycline was 
integrated with PU.1 ChIP- seq data sets to determine PU.1-regulated genes. 
Differentially expressed genes in the RNA-seq were categorized by the presence or 
absence of PU.1 binding within 15 kb of the TSS. (B) Motif enrichment analysis of PU.1 
ChIP-seq data shows the ETS binding motif as the primary motif of PU.1 binding. (C) 
Pie chart representing the enrichment of PU.1 binding across genomic regions based on 
PU.1 ChIP-seq analysis. (D) Clustering of PU.1 ChIP-seq data demonstrates PU.1- 
enriched regions at the TSS of mouse RefSeq genes. (E) Defining PU.1-regulated genes. 
Venn diagrams illustrate the number of TSS-associated PU.1 peaks associated with 
upregulated (left panel; green circle) and downregulated (right panel; red circle) genes 
from the RNA-seq experiment. (F) Distribution of PU.1-regulated genes according to 
RNA-seq fold change (log2). 
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2.2.3 Gene Ontology Analysis of PU.1 Targets 
Upregulated and downregulated genes associated with PU.1 binding in i660BM 
cells were explored further using gene ontology analysis. Protein-classification analysis 
showed that 11% of PU.1- upregulated or -downregulated genes encoded proteins related 
to nucleic acid binding, whereas 7% of upregulated or downregulated genes encoded 
transcription factors (Fig. 2.4 A). PU.1-regulated genes encoded cell signaling molecules, 
cell receptors, and cellular transporters, among others, illustrating a broad role for PU.1 
in regulating diverse cellular processes (Fig. 2.4 A, B). Gene ontology analysis using 
DAVID showed that upregulated genes were classified into biological processes 
including immune response, cell activation, and lymphocyte activation (Fig. 2.4 C). 
Downregulated genes were classified into biological pathways including 
nucleosome assembly, chromatin assembly, and nucleosome organization (Fig. 2.4 C). 
These genes included a number of genes previously shown to be directly regulated by 
PU.1, such as Blnk (38), Il7r (39), and E2f1 (40) (Fig. 2.4 B). Interestingly, Rag1/Rag2 
was the fifth most upregulated gene and was associated with an upstream peak in PU.1 
interaction (Fig. 2.4 D). Id2, an inhibitor of E2A transcription factor activity, was a 
downregulated gene that was associated with a peak in PU.1 interaction (Fig. 2.4 E). RT-
qPCR analysis confirmed upregulation of Rag1, Rag2, and Spi1 transcript levels, as well 
as downregulation of Id2 mRNA transcript levels (Fig. 2.4 F). These results suggest that 
PU.1 directly regulates genes involved in BCR signaling, as well as Ig recombination 
and/or accessibility. 
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Figure 2. 4. Characterization of PU.1-Regulated Genes.  
 (A) Gene ontology data analysis showing the PANTHER protein classification of PU.1-
regulated genes (left panel, upregulated; right panel, downregulated). (B) Examples of 
PU.1-upregulated (↑) and downregulated (↓) genes according to the protein classification 
ontology analysis. Numbers indicate log2 fold change. (C) Gene ontology analysis by 
DAVID identifying the biological processes related to PU.1-regulated genes (left panel, 
upregulated; right panel, downregulated). (D) UCSC genome browser tracks of PU.1 
ChIP and RNA-seq experiments showing Rag2 and Rag1 genes. (E) UCSC genome 
browser tracks of PU.1 ChIP and RNA-seq experiments showing Id2 gene. (F) 
Confirmation of changes in gene expression. RT-qPCR analysis for the indicated genes 
was performed on four biological replicates of RNA prepared from uninduced (-DOX) or 
70 ng/ml doxycycline-induced (+DOX) i660BM cells cultured in 2.5% IL-7–conditioned 
medium. *p < 0.05, ***p < 0.001, ****p < 0.0001. 
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2.2.4 Regulation of Igk Transcription and Recombination by PU.1 
Upregulation of Rag mRNA transcripts and downregulation of Id2 mRNA 
transcripts suggested that PU.1 may be involved in the regulation of Igk rearrangement 
during B cell development. Igk V-J rearrangement is preceded by increased transcription 
of V region genes, as well as of sterile transcripts initiating in regulatory regions (Schlissel 
& Stanhope-Baker, 1997; Yancopoulos & Alt, 1985). Analysis of ChIP-seq data 
identified 179 peaks in PU.1 interaction within the 3-Mb Igk locus, of which 60 were 
located in GENCODE-annotated Igk genes (Fig. 2.5 A). Analysis of RNA-seq data 
revealed widespread changes in Igk V region mRNA transcript levels upon PU.1 
induction (Fig. 2.5 B). For 166 annotated Igk genes, 69 were unchanged, 42 were 
downregulated, and 55 were upregulated in the RNA-seq analysis (Fig. 2.5 B, 
Supplemental Table III available in the online version of this manuscript). Thirty peaks 
in PU.1 interaction were associated with upregulated Igk V transcripts, and 10 peaks in 
PU.1 interaction were associated with downregulated Igk V transcripts (Fig. 2.5 A). Igk 
V genes that were upregulated upon PU.1 induction included Igkv1-135, Igkv10-96, 
Igkv4-57, Igkv6-13, and Igkv4-73 (Fig. 2.5 B). Interestingly, there were two distinct 
patterns of PU.1 interaction with Ig V genes. PU.1 interacted with the promoters of 11 V 
genes, with a region downstream of the second exon of 26 V genes, and with both the 
promoter and a region downstream of the second exon of 14 genes (Fig. 2.5 C, 
Supplemental Table IV, online version of this manuscript). For the Igkv4 family, PU.1 
interacted with 11 sites downstream of the second exon and only one site in a promoter. 
For the IgkV6 family, PU.1 interacted with both the promoter and a site downstream of 
the second exon for six members (Fig. 2.5 C, D). A total of 32 of 40 PU.1 sites 
downstream of V region second exons were located an average of 91 bp from the RSS 
heptamer sequence 5’-CACAGTG-3’. MEME analysis of the 32 genomic regions 
associated with PU.1 binding sites located downstream of V region second exons revealed 
a 12-bp RSS as the most frequently discovered motif (Fig. 2.5 E). Taken together, these 
results indicate that PU.1 interacts with a number of sites downstream of Igk V region 
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second exons that are located close to RSSs. This suggests that PU.1 might be involved 
in the regulation of chromatin accessibility near RSSs.  
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Figure 2. 5. PU.1 Binds to the Igk Locus and Induces Transcription of Variable Genes.  
(A) Venn diagrams showing the number of PU.1 peaks located on upregulated and 
downregulated Igk V genes. (B) Heat map showing the differential expression of Igk V 
genes with (+DOX) or without (-DOX) doxycycline using the mouse genome annotation 
available on GENCODE. (C) Distribution of PU.1 peaks within the Igk V locus. (D) 
Distribution of PU.1 peaks separated by Igk V family. (E) MEME motif analysis of 
sequences containing PU.1 peaks downstream of Igk V gene second exons show RSS as 
a top enriched motif.  
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2.2.5 PU.1 Induction Induces Igk V-J Rearrangement 
Because PU.1 interacts with Igk V region genes, induces Igk V region 
transcription, and induces Rag transcription, we hypothesized that PU.1 induction in 
i660BM cells coupled with reduced IL-7 concentration might be sufficient to induce Igk 
V-J rearrangement in i660BM cells. To confirm this, Igk V-J rearrangement was 
measured using DNA prepared from i660BM cells in which PU.1 was induced with 
doxycycline in the presence of a high or low concentration of IL-7. DNA prepared from 
WT spleen cells was used as a control. Low IL-7 concentration or PU.1 induction resulted 
in low levels of Igk V-J rearrangement in i660BM cells. Igk V-J rearrangement was 
robustly detected in i660BM cells in which PU.1 was induced with a low concentration 
of IL-7 (Fig. 2.6 D, left side). In the parent 660BM cells that did not express PU.1, reduced 
IL-7 concentration was not sufficient to induce Igk V-J rearrangement (Fig. 6D, right 
side). We conclude that induction of PU.1 expression, coupled with reduced IL-7 
concentration, is sufficient to induce Igk V-J rearrangement in a cultured Pro-B cell line.  
Quantitative PCR analysis confirmed that each of these Igk V genes was inducible 
by PU.1, and reduced IL-7 concentration resulted in increased induction of transcription 
by PU.1 (Fig. 2.6 A). Each of these Igk V genes was associated with at least one peak in 
PU.1 interaction (Fig. 2.6 B). PU.1 also was shown to interact with the 2-4 and 3-1 
enhancers in the Igl locus (Eisenbeis, Singh, & Storb, 1993). Interestingly, induction of 
PU.1 increased Igl1 mRNA transcript levels (Fig. 2.6 C). These results suggest that PU.1 
directly regulates Igk and Igl V region transcription in i660BM cells.  
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Figure 2.6. Induction of PU.1 in i660BM Pro-B cells Induces Transcription and 
Rearrangement of the Igk Locus.  
(A) RT-qPCR for detection of Igkv1-135, Igkv10-96, Igkv4-57, Igkv6-13, and Igkv4-73 
transcripts with (+DOX) or without (-DOX) doxycycline in conditions of high and low 
IL-7 (5% and 2.5%, respectively). UCSC genome tracks (left panels) show the PU.1 
binding peak from PU.1 ChIP-seq data and the transcription tracks from the RNA-seq 
experiment in conditions without (-DOX) and with (+DOX) doxycycline. (B) UCSC 
genome browser tracks of PU.1 ChIP sequencing and RNA-sequencing. Tracks show 
PU.1 binding to Igkv1-135, Igkv10-96, Igkv4-57, Igkv6-13, and Igkv4-73 and increased 
expression (C) PU.1 induces Igl germline transcription. RT-qPCR analysis of the Igl1 
mRNA transcript was performed on four biological replicates of RNA prepared from 
uninduced (-DOX) or 70 ng/ml doxycycline-induced (+DOX) i660BM cells cultured in 
2.5% IL-7 conditioned medium. D) PCR for detection of Igk-chain rearrangement (Igvk-
IgJk5) in i660BM and 660BM cells without doxycycline (-DOX) and with doxycycline 
(+DOX) induction and various levels of IL-7. 
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2.2.6 Reduced Igk Transcription in BM Pre-B Cells from Mb1-CreDPB 
Mice 
Igk V gene transcription is upregulated during theLarge Pre-B (Fraction C) to 
Small Pre-B (Fraction D) transition (Painter, Davis, Hardy, Mathis, & Benoist, 2011). 
BM B cell development was blocked at the Small Pre-B cell stage in the absence of PU.1 
and Spi-B (Fig. 1). Because induction of PU.1 resulted in increased Igk V region 
transcript levels and Igk V-J recombination, we hypothesized that Mb1-CreDPB Pre-B 
cells might have a reduced ability to activate Igk V-J transcription. To test this, Fraction 
C and Fraction D Pre-B cells were enriched from the BM of Mb1-CreDPB mice, or DB 
mice as controls, using cell sorting; the gating strategy is shown in Fig. 2.2 F. Fraction E 
cells were not enriched, because this Fraction was absented in Mb1-CreDPB mice (Fig. 
2.2 G).  
Quantitative PCR was used to determine changes in transcript levels of Igk V 
genes with which PU.1 interacted. We found that, in BM cells from DB mice, Igk V gene 
transcription was upregulated during the Fraction C to Fraction D transition for Igkv1-
135, Igkv12-98, Igkv12-44, Igkv3-5, and the sterile transcript Glk-1 (Fig. 2.7 A–F). In 
contrast, transcript levels for Btk and the control gene b-actin did not change (Fig. 2.7 G, 
H). In BM cells enriched from Mb1-CreDPB mice, mRNA transcript levels for Igkv1-
135, Igkv12-98, Igkv12-44, Igkv3-5, and Glk-1 failed to increase during the Fraction C 
to Fraction D transition (Fig. 2.7 B–F). Transcript levels for Spi1 and its target gene (Btk) 
decreased, consistent with deletion of Spi1 at this transition, whereas the control gene b-
actin did not change from Fraction C to Fraction D (Fig. 2.7 G–I). These data demonstrate 
that PU.1 and Spi-B are important for inducing transcription of certain Igk V genes during 
B cell development in the BM and suggest that the absence of PU.1 and Spi-B might lead 
to reduced Igk V region accessibility and V-J recombination. 
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Figure 2.7. Absence of PU.1 and Spi-B in Vivo Results in Reduced Levels of Igk 
Transcripts in Small Pre-B Cells.  
 
(A) Schematic diagram of the mouse Igk locus showing the variable (V) region, the 
joining and constant regions (C-V regions), and the gene segments assessed in this study 
by RT-qPCR. Variable gene segments are highlighted, and the Glk-1 (ko) transcript is 
also indicated. (B–E) RT-qPCR showing the fold induction of the Igkv1-135, Igkv12-98, 
Igkv12-44, and Igkv3-5 genes in developing B cells from Fraction C (Large Pre-B cells) 
and Fraction D (Small Pre-B cells) of DB and Mb1-CreDPB mouse BM. (F) RT-qPCR 
showing the fold induction of the Glk-1 mRNA transcript in developing B cells from 
Fraction C (Large Pre-B cells) and Fraction D (Small Pre-B cells) of DB and Mb1-
CreDPB mouse BM. (G–I) RT-qPCR showing the fold induction of b-actin, Btk, and Spi1 
mRNA transcripts in developing B cells from Fraction C (Large Pre-B cells) and Fraction 
D (Small Pre-B cells) of DB and Mb1-CreDPB mouse BM. *p < 0.05, **p < 0.01, ***p 
< 0.001, ****p < 0.0001. 
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2.3 Discussion 
In this study, we showed that B cell development is blocked in mice that delete 
the Spi1 gene encoding PU.1 under control of the Mb1 locus, which are also germline 
knockout for Spib (Mb1-CreDPB mice). Adult Mb1-CreDPB mice did not have splenic B 
cells, and few surface IgM+ B cells were present in BM, suggesting a block in B cell 
development starting at the Pre-B cell stage. Identifying target genes of PU.1 and/or Spi-
B might explain this block in B cell development; therefore, a Spi1/Spib-deleted IL-7–
dependent Pro-B cell line was used in which PU.1 expression can be induced using 
doxycycline (i660BM cells). RNA-seq and anti-PU.1 ChIP-seq experiments were 
performed to determine the genome-wide target genes of PU.1 in this model. These 
experiments confirmed a number of previously identified PU.1 target genes involved in 
the Pro-B to Pre-B cell developmental transition. Unexpectedly, the Rag locus was also 
found to be a direct target of PU.1 induction. Closer examination revealed that PU.1 
interacted with 179 sites within the Igk locus, of which 60 sites were located within V 
genes, including at V gene promoters and near RSSs. An increase in PU.1 expression, 
combined with reduced IL-7 concentration, induced Igk rearrangement. Finally, we found 
that Igk V region mRNA transcript levels were not increased at the Pro-B to Pre-B cell 
transition in Mb1-CreDPB mice. These results show that PU.1 directly regulates Igk locus 
transcription and suggest that PU.1 is an important regulator of Igk locus accessibility 
during B cell development. 
Comparison of BM B cell development in Mb1-CreDPB mice with that in control 
mice revealed a relative increase in the frequency of Pre-BII/Large Pre-B cells (Fraction 
C), no difference in the frequency of Small Pre-B cells (Fraction D), and a near absence 
of immature sIgM+ B cells (Fraction E). These results are most consistent with a block in 
B cell development at the stage when Ig L chain recombination is taking place in Small 
Pre-B cells. Previous analysis of CD19-CreDPB mice, which did not delete alleles 
efficiently in BM, showed a relative increase in immature B cell frequencies in BM but a 
decrease in mature recirculating B cells (Fraction F) and in the frequency of splenic 
follicular B cells. The differences between these two models suggest that PU.1 and Spi-
B play important roles in B cell development at late, as well as early, stages. 
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B cell–specific deletion of the gene encoding PU.1 in mice (Polli et al., 2005; Ye, 
Ermakova, & Graf, 2005) or deletion of the gene encoding Spi-B in mice (Su et al., 1997) 
resulted in relatively mild defects in B cell development. Similarly, deletion of the Irf4 or 
Irf8 gene resulted in mild B cell developmental defects  (Holtschke et al., 1996; 
Mittrucker, 1997). Combined deletion of Spi1 and Irf8 resulted in mild impairment of B 
cell development, whereas combined deletion of Spi1 and Irf4 resulted in impaired B cell 
development at the Pre-B cell stage (S. H. M. Pang et al., 2016). Strikingly, combined 
deletion of Irf4 and Irf8 resulted in a block in B cell development at the Pre-B cell stage 
(R. Lu, Medina, Lancki, & Singh, 2003). In this study, we showed that combined deletion 
of Spi1 and Spib results in a block in B cell development at the Pre-B cell stage. 
Collectively, these studies reveal a critically important PU.1/Spi-B/IRF4/IRF8 regulatory 
axis for Pre-B cell development. PU.1 and Spi-B interact interchangeably with IRF4 or 
IRF8 to regulate genes containing ETS-IRF composite elements (EICEs) (Singh, 
Glasmacher, Chang, & Vander Lugt, 2013). Recently, it was shown that ∼50% of PU.1 
binding sites in Pro-B cells are at EICEs, suggesting that this regulatory element may 
control a large number of genes in developing B cells (S. H. M. Pang et al., 2016). These 
studies collectively suggest that genes important for early B cell development require 
activation through EICEs to promote their expression. More work is necessary to identify 
key EICE-regulated target genes. 
PU.1 was implicated in the regulation of Ig transcription in numerous studies. In 
1991, PU.1 was recognized to interact with the Igk 3’ enhancer cooperatively with IRF4 
(Mittrucker, 1997; Pongubala & Atchison, 1991). Transgenic studies implicated the PU.1 
binding site in the Igk 3’ enhancer in the regulation of the developmental stage specificity 
of V-J joining  (Hayashi et al., 1997).  In 1995, PU.1 was identified as an NF capable of 
interacting with pyrimidine-rich sequences in the Vk19 promoter (Schwarzenbach, 
Newell, & Matthias, 1995). PU.1 binding sites were predicted in numerous V region 
promoters of the Igk locus (Brekke & Garrard, 2004). Previous studies showed that PU.1 
interacts with numerous sites in the Igk locus in the B cell lineage. In mature splenic B 
cells, PU.1 was shown to interact with 45 sites in the 3-Mb Igk locus (Heinz et al., 2010). 
In Pro-B cells, PU.1 was shown to interact with 181 sites in the Igk locus (Schwickert et 
al., 2014). This study closely agrees with our result of 179 total PU.1 binding sites in the 
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Igk locus, and 74 of these sites were in common, with 35 of these sites in common in all 
three studies. Taken together, these studies correspond with our identification of PU.1 
binding sites in the Igk locus. 
The 3’ enhancer of the Igk locus is critical for the cell type and developmental 
stage specificity of V-J rearrangement (Gorman et al., 1996; Hayashi et al., 1997; Inlay 
et al., 2002; Mandal et al., 2011; Shaffer, Peng, & Schlissel, 1997). STAT5 binding 
induced by IL-7 signaling is a critically important repressor of Igk transcription to prevent 
accessibility and rearrangement during proliferation of Large Pre-B/Pre-BII cells 
(Mandal et al., 2011). PU.1 can compete with STAT5 for interaction with the Igk 3’ 
enhancer to regulate Igk transcription (Hodawadekar, Park, Farrar, & Atchison, 2012). 
Consistent with these studies, our results showed that PU.1 induced Igk transcription and 
rearrangement more efficiently when IL-7 concentration was reduced (Fig. 5). Our results 
are consistent with PU.1 being an important factor for inducing Igk transcription and 
accessibility when developing Pre-B cells migrate away from high IL-7 concentrations 
(Clark et al., 2014). Igk V region transcription is closely associated with accessibility of 
the recombinase apparatus and initiation of Igk V-J recombination (Schlissel & Stanhope-
Baker, 1997; Yancopoulos & Alt, 1985). The results presented in Fig. 6 demonstrate that 
Igk V region transcripts are not appropriately upregulated in the absence of PU.1 and Spi-
B. This suggest that PU.1 and Spi-B are important regulators of Igk V region 
transcription, accessibility, and rearrangement. The absence of IgM+ B cells in Mb1-
CreDPB mice suggests that Igl transcription may also be impaired in the absence of PU.1 
and Spi-B. Consistent with this idea, induction of PU.1 activated Igl1 transcription in 
i660BM cells (Fig. 5D). We previously demonstrated that Igl transcription was reduced 
in PU.1/Spi-B double-knockout Pro-B cell lines (Schweitzer & DeKoter, 2004). In 
summary, we expect that reduced Igk V region transcription in Fraction D Small Pre-B 
cells lacking PU.1 and Spi-B results in impaired Igk V region accessibility and impaired 
Igk recombination, which lead to a block in B cell development at the Small Pre- B cell 
stage. These studies reveal an important role for PU.1 in Igk transcription and 
rearrangement, as well as a requirement for PU.1 and Spi-B in B cell development. 
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2.4 Material and Methods 
2.4.1 Mice 
Mb1-Cre mice were described previously (20). Mb1-Cre mice were crossed with 
Spi1lox/lox Spib-/- to generate Mb1-CreDPB mice. Mb1+/Cre Spi1lox/lox Spib+/+ (Mb1-CreDP) 
and Mb1+/Cre Spi1+/+ Spib-/- or Mb1+/+ Spi1+/+ Spib-/- (DB) mice were used as experimental 
controls. C57BL/6 mice were purchased from Charles River Laboratories (Saint-
Constant, QC, Canada). All experiments were performed in compliance with the Western 
University Council on Animal Care guidelines. 
2.4.2 Flow Cytometry and Cell Sorting 
For spleen and BM analysis, cells were prepared from 6–10-wk-old Mb1-CreDPB, 
Mb1-CreDP, DB, and wild-type (WT) mice. RBCs were removed from single-cell 
suspensions using hypotonic lysis. Flow cytometric analyses were performed using an 
LSR II instrument (BD Immunocytometry Systems, San Jose, CA). Abs were purchased 
from eBioscience (San Diego, CA), BioLegend (San Diego, CA), or BD Biosciences 
(Mississauga, ON, Canada) and included PE–anti-CD19 (1D3), FITC–anti-BP-1 (6C3), 
allophycocyanin–anti-B220 (RA3-6B2), allophycocyanin–anti-IgM (II/ 41), PE–anti-Igk 
(187.1), FITC–anti-IL-7R (A7R34), BV421–anti- B220 (RA3-6B2), PE–anti-BP-1 
(6C3), FITC–anti-CD24 (M1/69), biotin– anti-CD43 (S7), and PE/Cy5 streptavidin. BM 
cell sorting was performed on a FACSAria with FACSDiva software (both from BD). 
Data were analyzed using FlowJo 9.7.4 software. 
2.4.3 Cell Culture 
The 660BM and i660BM cell lines used in this study were described previously 
(Christie et al., 2015). Cells were cultured in IMDM (Wisent, QC, Canada) containing 
5% IL-7–conditioned medium from the J558L–IL-7 cell line (21), 10% FBS (Wisent), 
penicillin/streptomycin/L-glutamine (Lonza, Shawinigan, QC, Canada), and 2-ME 
(Sigma-Aldrich, St. Louis, MO). i660BM cells were maintained in 0.5 mg/ml puromycin 
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(BioBasic, Markham, ON, Canada). Cell lines were maintained in 5% CO2 atmosphere 
at 37 ̊C. 
2.4.4 RNA-Seq Analysis 
i660BM cells were induced for 48 h with doxycycline (70 ng/ml) in the presence 
of 5% IL-7–conditioned medium described above, and RNA was extracted using an 
RNeasy Kit (QIAGEN, ON, Canada). Uninduced cells were used as a control. Paired-end 
(mRNA-sequencing stranded) libraries were prepared using Illumina TrueSeq Adapters. 
Libraries were sequenced using an Illumina HiSEquation 2000 sequencer in paired-end 
mode. Data analysis was performed as described previously (Batista, Li, Xu, Solomon, & 
DeKoter, 2017) using the tools available in Galaxy suite (Afgan et al., 2016). Standard 
Illumina sequencing adaptors (5’-AGATCGGAAGAGC-3’) and short reads were 
removed using Trim Galore! V0.2.8.1 in mate-paired mode with trim low quality: 20; 
maximum allowed error rate: 0.1; discard reads that became shorter than length: 20. 
Trimmed FASTQ files were aligned to the mouse genome (mm10) using TopHat2 v2.0.9 
in mate-paired mode, with mean inner distance between mate pairs: 140 and SD for 
distance between mate pairs: 30. Assembled transcript abundance and differential gene 
expression were determined using Cufflinks/Cuffdiff v2.1.1. Reference annotation files 
were down- loaded from UCSC RefSeq Genes (GRCm38/mm10) in gtf format. Cuff-diff 
output genes with a fold change < 0.5 or ³ 0.5 (log2) were classified as significantly 
upregulated or downregulated genes, respectively. Transcripts presenting PU.1 ChIP 
peaks within 15 kb upstream or downstream of the TSS and exhibiting significant fold 
change by RNA- seq were considered PU.1-regulated genes. Functional classification 
analysis was performed on predicted PU.1 target genes from the Data- base for 
Annotation, Visualization and Integrated Discovery (DAVID) using GOTERM_BP_FAT 
(Huang, Sherman, & Lempicki, 2009). Functional protein classification of PU.1-
regulated genes was determined using the PANTHER classification system (Huaiyu Mi, 
Muruganujan, Casagrande, & Thomas, 2013). 
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2.4.5 ChIP and ChIP-seq Analysis 
i660BM cells were induced for 24 h with doxycycline (70 ng/ml) in the presence 
of 5% IL-7–conditioned medium described above. Chromatin was cross-linked with 1% 
paraformaldehyde for 10 min, and crosslinking was terminated by the addition of glycine. 
Chromatin yielding 150–300 mg was immunoprecipitated using Dynabeads Protein G 
(Life Technologies) conjugated to 6 mg of rabbit polyclonal anti-PU.1 Ab (Santa Cruz 
Biotechnology, Santa Cruz, CA) or 6 mg of rabbit polyclonal anti-IgG Ab (Abcam, ON, 
Canada). Immunoprecipitated chromatin was de–cross- linked and DNA was purified 
using a QIAquick PCR Purification Kit (QIAGEN). PU.1 immunoprecipitation was 
validated by quantitative RT- PCR (RT-qPCR) using two sets of primers for the E2f1 
gene: a positive set targeting the PU.1 binding site on intron 1 of the E2f1 gene and a 
negative set targeting a region on intron 4 of the E2f1 gene. Illumina TruSeq DNA 
libraries were prepared from two biological replicates of PU.1- immunoprecipitated 
chromatin and one sample of input chromatin. Libraries were sequenced using an Illumina 
HiSEquation 2000 SR100 sequencer (Genome Quebec Innovation Centre, QC, Canada). 
ChIP-seq data analysis was conducted using Galaxy Suite (Afgan et al., 2016). Illumina 
sequencing adapters were removed using Trim Galore! Trimmed FASTQ files were 
aligned to the mouse reference genome GRCm38/mm10 with Bowtie, reporting only the 
best alignment for each fragment (–best) with a maximum number of two mismatches 
with an average quality score ³ 70 (Langmead, Trapnell, Pop, & Salzberg, 2009). 
Experimental replicate BAM aligned files were merged using merge BAM files in 
Galaxy. Peaks were called using MACS1.4.1 with a mappable genome size of 1.8 3 1010 
bp (mm10). Peaks were called with a tag size to 100, bandwidth of 300, and a p value 
cutoff for peak detection of 1e207. Sequences of regions with significant PU.1 binding 
were extracted using extract genomic DNA in Galaxy. Motif discovery was performed 
with MEME-ChIP version 4.11.1. Functional analysis of cis-regulatory regions bound by 
PU.1 were identified using CEAS (Shin, Liu, Manrai, & Liu, 2009). Heat maps of ChIP 
signals surrounding TSSs were generated using deepTools2 (Ramirez, Dundar, Diehl, 
Gruning, & Manke, 2014). 
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2.4.6 Igk Locus Analysis 
Transcription of Igk genes was evaluated from RNA-seq data using Cufflinks and 
the GENCODE mouse reference that contains a complete annotation for the Ig gene 
segments (Harrow et al., 2006). Average fold change expression of Igk genes was 
determined from three replicates for each group (-DOX and +DOX). Igk genes were 
classified as upregulated (fold change. 1.0) or downregulated (fold change, 21.0) as a 
ratio between induced and control condition. A heat map illustrating the upregulated and 
downregulated genes was generated using GENE-E (Broad Institute, Cambridge, MA). 
Regions of PU.1 binding were intersected with the reference vM9 GENCODE to correlate 
ChIP binding with transcripts using bedtools v2.22.1 (Quinlan & Hall, 2010). Regions 
overlapping by ³1 bp were reported as PU.1-bound transcripts and presented as Venn 
diagrams generated using InteractiVenn (Heberle, Meirelles, da Silva, Telles, & 
Minghim, 2015). RNA-seq and ChIP-seq genome tracks were visualized in the UCSC 
genome browser. 
2.4.7 PCR and Gene-Expression Analysis 
Genomic DNA was prepared from 660BM or i660BM cells after 48 h of PU.1 
induction with doxycycline (70 ng/ml) with low (0.1 ng/ml) or high (7.5 ng/ml) IL-7. 
RNA was prepared using TRIzol Reagent or an AllPrep DNA/RNA Mini Kit (QIAGEN) 
from 660BM or i660BM cells after 48 h of PU.1 induction with doxycycline (70 ng/ml) 
in 5% or 2.5% IL-7–conditioned medium. cDNA was synthesized from purified RNA 
using an iScript cDNA synthesis kit (Bio-Rad). cDNA was diluted to a concentration of 
30 ng/ml in RNase-free water for the RT-qPCR reactions. PCR reactions to detect 
Igk rearrangements were performed as previously described (Cobaleda, Jochum, et al., 
2007). RT-qPCR reactions were prepared with specific primers for the genes of interest 
using SensiFAST SYBR green (Bioline, London, U.K.), and amplification was performed 
on a Rotor Gene 6000 instrument (Corbett Life Sciences, Valencia, CA). Gene expression 
was normalized to B2m expression, and fold expression was calculated using the D 
threshold cycle method (Livak & Schmittgen, 2001). Primers sequences are shown on 
Table 1. 
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Table 1. Primer Sequences Used in The Study Described on Chapter 2. 
  
Genes Sequences
B2m F TGGCTCACACTGAATTCACCCCCA
R TCTCGATCCCAGTAGACGGTCTTGG
Bactin F CCTAAGGCCAACCGTGAAAAG
R TCTTCATGGTGCTAGGAGCCA
Hrpt F TCCTCCTCAGACCGCTTT
R TTTTCCAAATCCTCGGCATAATG
Igkv10-96 F GGTCTCCTGTTGCTCTGTTT
R CAACTGATGGTGACTCTGTCTC
Igkv12-98 F TATCAGCAGAAACCAGGGAAAT
R GATCCACTACCACTGAACCTTG
Igkv1-135 F CTCCAAAGCGCCTAATCTATCT
R GCCTCCACTCTGCTGATTT
Igkv4-57 F GTGCCAGCTCAAGTGTAAGT
R GCCAGGTTGGATGTGCTATAA
Igkv4-73 F GTGCCAGCTCAAGTGTAAGT
R CCAGAAGCCAGGTTGGATATG
Igkv12-44 F CAGGCTGTTGATCTTCAGAGAA
R CTCCTCAGCTCCTGGTCTATAA
Igkv6-13 F GGAGTCACAGATTCAGGTCTTT
R ACCCTGTCTCCTACTGATGT
Igkv3-5 F CTGCAGAGCCAGTGAAAGT
R CACGATAGATGAGGAGTTTGGG
Igkv12-98 F TATCAGCAGAAACCAGGGAAAT
R GATCCACTACCACTGAACCTTG
Glk-1 F GAGGGGGTTAAGCTTTCGCCTACCCAC
R GTTATGTCGTTCATACTTCGTCCTTGGT
Spi1 F ATTCGCCTGTACCAGTTCCTGC
R TGGACGAGAACTGGAAGGTACC
Btk F ACAGATTCCGAGGAGAGGTGAGG
R GGTCCTTCATATACAACCTGGAA
RT-qPCR
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Genes Sequences
Gapdh-ChIP F CGTTCACACCGACCTTCACCATTT
R GTCTGTTATATGGGCGTCGTGTCA
Hprt -ChIP F CGTTCACACCGACCTTCACCATTT
R GAAAGCAGTGAGGTAAGCCCAAC
E2f1  (positive)-ChIP (Intron 1) F AGAGATGGGGAAGTGCTTCACG 
R CGCACTCCCTAGCCATAGGTTC
E2f1  (negative)-ChIP (Intron 4) F GTTCCAGGACAGTCAGGGCTATACAG 
R CCATCTCTCCAGTCCTTGGCTTC
Genes Sequences
VHJ558 CGAGCTCTCCARCACAGCCTWCATGCARCTCARC 
JH4 TCTCAGCCGGCTCCCTCAGGG 
Vk GGCTGCAGSTTCAGTGGCAGTGGRTCWGGRAC 
Jk5 ATGCGACGTCAACTGATAATGAGCCCTCTCC 
Genes Sequences
Mb1/Cd79a F GAGAAGAAGGGACACCAGAATG 
R GCACTTGGGAGGCAGAAATA 
Mb1-Cre F ATCAGCCACACCAGACACAGAGATC 
R AGATGCCAGGACATCAGGAACCTG 
lox/lox 1 CTTCACTGCCCATTCATTGGCTCATCA
2 GCTGGGGACAAGGTTTGATAAGGGAA
Cd19 F GAGAGGCACGTGAAGGTCATTG
R CATGGCTCTGAGCTCCAGTATC
ChIP-primers
Rearrangement PCR
Genotyping
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2.4.8 Statistical Analysis 
All data are graphed as mean ± SEM. Statistical analysis was performed with 
Prism 5.0 (GraphPad, La Jolla, CA) using ANOVA or the Student t test, as appropriate. 
The p values £ 0.05 were considered significant. 
2.4.9 Availability of Data 
ChIP-seq and RNA-seq data have been submitted to the Gene Expression 
Omnibus (https://www.ncbi.nlm.nih.gov/geo/) under accession number GSE87316. 
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Chapter 3  
3 Deletion of Genes Encoding PU.1 And Spi-B Leads 
to B Cell Acute Lymphoblastic Leukemia Associated 
with Driver Mutations in Janus Kinases3 
Precursor B cell acute lymphoblastic leukemia (Pre-B-ALL) is associated with 
recurrent mutations that occur in cancer-initiating cells. There is a need to understand 
how these spontaneous driver mutations influence clonal evolution in leukemia. The ETS-
transcription factors PU.1 and Spi-B (encoded by Spi1 and Spib) execute a critical role in 
B cell development and serve as complementary tumour suppressors by opposing the 
proliferative events mediated by IL-7R signaling. Here, we used a mouse model to 
conditionally delete Spi1 and Spib genes in developing B cells. These mice developed B-
ALL with a median time to euthanasia of 18 weeks. We performed RNA and whole-
exome sequencing (WES) on leukemias isolated from the thymus of Mb1-CreΔPB mice 
and identified single-nucleotide variants (SNVs) in Jak1, Jak3 and Ikzf3 genes, resulting 
in amino acid changes and the gain of early stop-codons. JAK3 mutations resulted in 
amino acid substitutions located in the pseudo-kinase (R653H, V670A) and in the kinase 
(T844M) domains. Introduction of these mutations into wild-type Pro-B cells conferred 
survival and proliferation advantages. We conclude that mutations in Janus kinases 
represent secondary drivers of leukemogenesis in the absence of Spi-B and PU.1 
transcription factors. This mouse model represents a useful tool to study clonal evolution 
and tumour heterogeneity in B-ALL.  
                                                
3
  Text and figures within this section have been adapted from the manuscript under review on Blood 
Advances: 
Batista, C. R., Lim, M., Laramee, A.-S., Abu-Sardanah, F., Xu, L. S., Hossain, R., & DeKoter, R. P. (2018). 
Deletion of genes encoding PU.1 and Spi-B leads to B cell acute lymphoblastic leukemia associated 
with driver mutations in Janus Kinases. BioRxiv, 291054. http://doi.org/10.1101/291054 
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3.1 Introduction 
Acute lymphoblastic leukemia is the most common type of childhood cancer with 
approximately 6000 new cases diagnosed in the United States each year (R. Siegel, Ma, 
Zou, & Jemal, 2014). Most leukemias originate within the B cell rather than the T cell 
lineage (Hunger & Mullighan, 2015; Inaba, Greaves, & Mullighan, 2013). Precursor B 
cell acute lymphoblastic leukemia (Pre-B-ALL) is a disease revealed by the presence of 
transformed precursor B cells in the blood, bone marrow, and tissues; and is most 
prevalent in 1-5 year old patients (C. H. Pui, Robison, & Look, 2008). Most Pre-B-ALL 
cases are associated with genetic abnormalities that include chromosomal translocations 
or point mutations. In Pre-B-ALL, up to two thirds of genes with point mutations encode 
transcriptional regulators such as Pax-5, Ikaros, or EBF1 (Inaba et al., 2013). Pre-B-ALL 
cells are frequently arrested at an early stage of development, express interleukin-7 
receptor (IL7R), and have high levels of Janus Kinase (JAK)-STAT signaling to sustain 
survival and proliferation (Buchner, Swaminathan, Chen, & Muschen, 2015; Mangolini 
et al., 2013; Muschen, 2015). Activating mutations of the IL7R gene have been described 
in human Pre-B-ALL (Shochat et al., 2011). JAK and IL7R mutations are frequent in 
several subtypes of Pre-B-ALL including the recently described disease Ph-like leukemia 
(Jain et al., 2017; Roberts et al., 2017). In summary, mutations that activate cytokine 
signaling (IL-7R), or impair differentiation signals, function as driver mutations in Pre-
B-ALL. 
PU.1 (encoded by SPI1) and Spi-B (encoded SPIB in mice) are transcription 
factors of the E26-transformation-specific (ETS) family (Ray et al., 1992). These two 
proteins share a conserved DNA binding domain and interact with an overlapping set of 
DNA binding sites within the genome (Solomon et al., 2015). PU.1 and Spi-B 
complement each others function, and activate multiple genes involved in B cell receptor 
signaling (Christie et al., 2015; Garrett-Sinha et al., 1999; S. K. Li, Abbas, Solomon, 
Groux, & DeKoter, 2015; Solomon et al., 2015). Lack of these factors in developing B 
cells results in a block to B development at the Small Pre-B cell stage associated with 
impaired Ig light chain rearrangement (Batista et al., 2017; Christie et al., 2015). 
Importantly, conditional deletion of Spi-B and PU.1 in developing B cells leads to high 
incidence of B-ALL in mice, but the mechanisms of leukemogenesis in the absence of 
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these transcription factors remain undetermined (Sokalski et al., 2011). Thus, PU.1 and 
Spi-B are required for B cell development and function as complementary tumour 
suppressors in the B cell lineage. 
B cell neoplasms, like many cancers, are thought to be diseases in which there is 
clonal evolution from a common precursor, in which acquired gene mutations drive an 
evolutionary natural selection process (Greaves & Maley, 2012; Nowell, 1976). The 
mechanisms by which cancer-initiating cells respond to selection pressures during clonal 
evolution have been classified into a number of common hallmarks (Hanahan & 
Weinberg, 2011). In response to selection pressure, the genetic makeup of cancer-
initiating cells changes during the course of disease due to acquired mutation. Mutations 
can be broadly classified as drivers or passengers (Greaves & Maley, 2012; Vogelstein et 
al., 2013). Driver mutations are those that provide a growth advantage to a cancer clone, 
whereas passenger mutations do not provide a growth advantage. Pediatric B-ALL is less 
curable upon relapse due to clonal evolution of the leukemia, resulting in driver mutations 
inducing a more aggressive disease (Ferrando & Lopez-Otin, 2017). High levels of 
intratumoral heterogeneity of mutations is also a poor prognostic marker for leukemia 
(Hu, Sun, & Curtis, 2017). Whole-exome or whole-genome sequencing of Pre-B-ALL 
cases is expected to lead to a deeper understanding of the genetic causes of this disease, 
ultimately permitting targeted therapy for individual patients (Hunger & Mullighan, 
2015). 
In this study, we investigated the molecular features of leukemogenesis in a 
spontaneous model of B-ALL induced by deletion of genes encoding PU.1 and Spi-B. 
We generated Mb1+/CreSpi1lox/loxSpib-/- mice, called here Mb1-CreDPB mice (Batista et 
al., 2017). We previously found that Mb1-CreDPB mice developed Pre-B-ALL 
characterized by the high expression of IL-7R, with a median time to euthanasia of 18 
weeks. Using whole-exome sequencing (WES) and RNA-seq, we identified multiple 
single-nucleotide variants (SNVs), most of which were predicted to have a role in the 
control of cell proliferation, communication and metabolism. Strikingly, we identified 
recurrent SNVs in genes encoding Aiolos, Jak1, and Jak3 in mouse leukemias. Further 
analyses revealed that SNVs located in Jak3 resulted in three different types of amino 
acid substitutions within the pseudo-kinase domain (R653H, V670A) or kinase domain 
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(T844M). We confirmed the ability of these mutations to provide a survival and 
proliferation advantage to normal Pro-B cells. In summary, this study shows that Jak3 
mutations are secondary drivers of leukemogenesis in the absence of Spi-B and PU.1. 
This mouse model may be useful to determine the effects of molecular targeted therapies 
on intratumoral heterogeneity and clonal evolution in B-ALL. 
 
3.2 Results 
3.2.1 Deletion of Genes Encoding PU.1 And Spi-B Leads To B Cell Acute 
Lymphoblastic Leukemia 
We recently reported that deletion of the genes encoding both PU.1 and Spi-B in B 
cells under control of the Cd79a (Mb1) promoter (Mb1+/Cre Spi1lox/lox Spib-/- mice, 
abbreviated to Mb1-CreDPB) resulted in a severe impairment to B cell development at the 
Large Pre-B to Small Pre-B cell transition in the bone marrow of 6-10 week-old mice 
(Batista et al., 2017). Mb1-CreDPB mice expressing Cre recombinase and deleted for Spi-B 
but homozygous for the wild type Spi1 allele were fertile and healthy. However, Mb1-
CreDPB mice had a shortened life span, with median survival of 18 weeks, at which point 
they required euthanasia due to signs of illness, including lethargy and labored breathing 
(Fig. 3.1 A, B). Dissection of euthanized mice revealed enlargement of the spleen and 
thymus (Fig. 3.1 A, C, D). Histological analysis revealed that normal spleen and thymus 
organization was completely effaced in moribund Mb1-CreDPB mice compared to the 
control Mb-1Cre DB mice (Fig. 3.1 E).  
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Figure 3.1. Mb1-CreDPB Mice Develop B Cell Acute Lymphoblastic Leukemia (B-
ALL).  
 
(A) Mb1-CreDPB mice (DPB) mice developed B-ALL characterized by splenic and 
thymic enlargement (indicated by arrows). (B) Percentage survival of mice of the 
indicated genotypes by weeks elapsed: Mb1+/CreSpi1lox/lox Spib-/- (Mb1-CreDPB, n= 43); 
Mb1+/CreSpi1+/+ Spib-/- mice (Mb1-CreDB, n=36) and Mb1+/+Spi1lox/lox Spib-/- (Mb1-
CreDB, n=14). (C). Comparisons of enlarged spleens and thymuses extracted from Mb1-
CreDPB mice compared to control DB mice (Mb1+/+ Spi1lox/lox Spib-/-). (D) Spleen (left) 
and thymus (right) weight in grams (g) relative to the body weight in WT and Mb1-
CreDPB mice. WT, n=10 (spleen), 5 (thymus); Mb1-CreDPB, n=11 (spleen), 8 (thymus). 
p≤ 0.05 (*), mean ± SEM. (E). Histologic sections (HE) of spleen and thymus illustrating 
the lymphocytic infiltration and loss of normal organ structure in Mb1-CreDPB compared 
to controls Mb1DB (4x). 
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3.2.2 Characterization of Mb1-CreDPB Mice Leukemias Indicates Pro-B 
cell to the Pre-B Cell Origin 
Flow cytometry analysis was used to determine the stage in which leukemic cells 
begin to infiltrate the spleen and thymus of Pre-leukemic Mb1-CreDPB mice. We observed 
the presence of B220+CD19+ cells in the spleen and thymus of Mb1-CreDPB mice aged 11 
weeks, but not in either C57BL/6 or Mb1DB mice (Fig. 3.2 A, B). At the time of euthanasia 
of leukemic Mb1-CreDPB mice aged >15 weeks there were higher frequencies of 
B220+CD19+ cells in both organs (Fig. 3.2 A, B). Further analysis seeking to determine the 
phenotype of cells infiltrating the spleen and thymus showed that these organs contained 
high frequencies of B220+ and CD19+ cells that also expressed c-Kit, CD43, BP-1, and IL-
7Ra (Fig. 3.2 D). These analyses suggested that these cells were a Pre-B cell-like acute 
lymphoblastic leukemia similar to that previously reported in CD19-CreDPB mice (Sokalski 
et al., 2011) or mice deleted for genes encoding PU.1 and IRF4/8 (S. H. M. Pang et al., 
2016). 
 Next, leukemic cells obtained from the spleen or thymus of Mb1-CreDPB mice were 
characterized to determine expression of cell surface IgM and Igk. Analysis of leukemias 
from Mb1-CreDPB mice revealed that at least 74% of individual mouse leukemias did not 
express IgM or Igk at the cell surface (Fig. 3.2 E, bottom; F, left panel). Conversely, 26% 
of leukemias from Mb1-CreDPB mouse spleen or thymus had cell surface expression of both 
IgM and Igk (Fig. 3.2 E, top; F, left panel). In contrast, similar analysis performed on CD19-
CreDPB mice showed that 78% of leukemias had IgM and Igk on the cell surface (Fig. 3.2 
F, right panel). Most leukemias isolated from Mb1-CreDPB mice had IgH rearrangements, 
although fewer leukemias expressed IgM at the cell surface (Fig. 3.2 C). In summary, these 
results show that leukemia cells begin to appear in thymus and spleen of Mb1-CreDPB mice 
after 11 weeks of age. All leukemias in Mb1-CreDPB mice (11-26 weeks of age) expressed 
IL-7R, but most did not express Ig on their cell surface, suggesting that these cells resembled 
Pro-B or Large Pre-B cells.  
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Figure 3.2. Most Leukemias from Mb1-CreDPB Mice Resemble Pro-B cells and Do Not 
Express Either IgM Or Igk at the Cell Surface.  
 
(A) Representative flow cytometric analysis for the presence of CD19+ B220+ B cells in 
the spleen of C57BL/6 mice; 11 weeks old Mb1-CreDB mice and Mb1-CreDPB mice (left 
panels); and >15 weeks old Mb1-CreDPB mice (right panel). (B) Representative flow 
cytometric analysis for the presence of CD19+ B220+ B cells in the thymus of C57BL/6 
mice; 11 weeks old Mb1-CreDB mice and Mb1-CreDPB mice (left panels); and >15 
weeks old Mb1-CreDPB mice (right panel).  (C) PCR detection of heavy chain 
rearrangements (J558-JH4) in leukemia B cells extracted from the thymus of Mb1-
CreDPB mice (575-411). B cells extracted from WT mouse (C57BL/6) were used as 
control and presented the four types of rearrangements. Cd79 gene was used as control 
for DNA quality. (D) Representative flow cytometric analysis of leukemic cells from 
Mb1-CreDPB mice gated on CD19+ B220+ cells showed that leukemias expressed IL-7R 
on the cell surface (top and bottom). (E) Representative IL-7R+ leukemias expressing IgM 
and Igk, (top, Ig+) and those not expressing IgM and Igk (bottom, Ig-). (F) Percentage of 
leukemias expressing IgM and Igk (Ig+) or not expressing IgM and Igk (Ig-). Left panel, 
Mb1-CreDPB mice, n=14 (spleen) and n=8 (thymus). Right panel, CD19-CreDPB mice, 
n=9 (thymus).  
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3.2.3 Whole-Exome Sequencing (WES) Identified Somatic Nucleotide 
Variants in Leukemias Generated in the Lack of Spi-B and PU.1 
As described above, Mb1-CreDPB mice had a variable time to requirement of 
euthanasia as well as heterogeneity in Ig expression status of leukemias (Fig. 3.1 and 3.2). 
This variability suggested that secondary driver mutations were required to induce 
leukemia in addition to the initiating lesion of Spi1/Spib deletion. In order to discover 
potential driver mutations in Mb1-CreDPB mouse leukemias, we performed whole-
exome sequencing (WES) analyses of three mouse tumours, 853, 854, and 857, as well 
as on matched genomic tail DNA as a control. FACS analyses were performed in the 
leukemias submitted for sequencing and shows heterogeneity of leukemias (Fig. 3.3 A-
C). Single Nucleotide Variants (SNVs) for each of the samples were identified by 
comparing leukemia and control tail DNA exome sequences using the Strelka somatic 
variant caller (Saunders et al., 2012).  
 
The number of SNVs identified by Strelka differed for each of the tumours, where 
sample 854 showed the highest number of SNVs (3,887) (Fig. 4.1 A-C | Chapter 4). 
Samples 853 and 857 presented a very similar number of SNVs, totaling 2,558 and 2,465, 
respectively. Although the tumours had a variable number of SNVs, the distribution of 
the SNVs by chromosome followed a similar pattern in which chromosome 2 showed the 
highest frequency of SNVs, followed by chromosome 11, chromosome 1 and 
chromosome 7 (Fig. 4.1 A-C | Chapter 4).  
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Figure 3.3. Characterization of Mb1-CreDPB Leukemias After Whole-Exome 
Sequencing Analysis (WES). 
 
 (A) DNA and RNA were isolated from leukemic cells extracted from thymus of leukemic 
mice. Samples 853, 854 and 857 were submitted to WES and RNA sequencing, 
respectively. (B) Weeks of survival and weight of the organs extracted from leukemic 
Mb1-CreDPB mice. Samples 853 and 854 were used for sequencing experiments. (C) 
FACS characterization (IgM, x-axis; Igk, y-axis; Gated on CD19+ B220+ cells) of 
leukemic mice in which DNA and RNA were isolated for sequencing. C57BL/6, control; 
853, 854, 857, leukemic Mb1-CreDPB; FMO = fluorescence minus one.  
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3.2.4 Identification of the “High Confidence Somatic Nucleotide Variants 
(SNVs)” in Mb1-CreDPB mice Leukemias  
In order to increase confidence in the SNVs identified by Strelka and to reduce the 
number of SNVs without a potential biological function, somatic variants were called with 
a second variant discovery method, Mutect (Cibulskis et al., 2013). Mutect detected fewer 
SNVs than Strelka (Fig. 3.4A-C). The overlap of SNVs identified by both methods was used 
to identify high confidence SNVs. Using this strategy, we found that the number of SNVs 
was reduced, resulting in 183 SNVs for sample 853, 293 SNVs for sample 854, and 199 
SNVs for sample 857. High confidence SNVs were annotated using the mouse genome 
(mm10) using the SnpEff tool, which also enabled the prediction of the biological effect of 
the variants (Cingolani et al., 2012). We found that the majority of the high confidence SNVs 
were classified as having a MODIFIER or MODERATE deleterious impact while a few 
SNVs were classified as HIGH impact (Fig. 3.4D). 
 We looked at the effect of SNVs classified as MODERATE and HIGH, and found 
that most of the SNVs classified as MODERATE resulted in missense variants; while the 
few SNVs predicted as having HIGH impact caused the gain or loss of stop codons, or 
alterations in splice acceptor or donor sites, defined by two bases before exon start or end, 
respectively (Fig. 3.4E). We next investigated whether there were common SNVs among 
the three mouse tumours sequenced. Samples 854 and 857 showed common SNVs in the 
genes Sntg1, Brd8, Lrp5 and Slco1b2 (Fig. 3.4F). Samples 853 and 854 showed common 
SNVs in the genes Ryr2 and Skint6. Finally, samples 853 and 857 showed common SNVs 
in the genes Ikzf3 and Jak3 (Fig. 3.4F). Interestingly, sample 854 presented a unique SNV 
in the Jak1 gene. Sanger sequencing of samples 853, 854 and 857 confirmed the presence 
of SNVs identified by WES in the Jak3, Jak1 and Ikzf3 genes (Fig. 3.5) Interestingly, Ikzf3 
and Jak3 are well-characterized driver mutations in human Pre-B cell acute lymphoblastic 
leukemia (Iacobucci & Mullighan, 2017). The identification of common Ikzf3 and Jak3 
SNVs suggests that this approach is effective at identifying potential driver mutations. 
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Figure 3.4. Identification of the “High Confidence Somatic Nucleotide Variants (SNVs)” 
in Mb1-CreDPB Mice Leukemias.  
 
(A, B and C) SNVs identified by two different variant caller methods, Strelka and Mutect, 
were combined and overlapping SNVs were classified as “High confidence SNVs”. (D) 
Classification of “High confidence SNVs” for impact. Graph shows the number of SNVs 
classified according to impact. (E) Predicted biological effect of the “High confidence 
SNVs” classified as having MODERATE and HIGH impact. (F). Venn diagram showing 
the overlap among “High confidence SNVs” identified in the three-individual mouse 
leukemias. Genes containing common SNVs among the three mouse leukemias. 
Leukemias “853” and “857” presented common SNVs in the Jak3 and Ikzf3 genes. 
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Figure 3.5. Sanger Sequencing Confirmed the Presence of SNVs Identified by WES 
and Revealed Tumours Heterogeneity.  
 
PCR amplification of the region containing the SNVs were performed on cDNA 
synthesized from RNA extracted from mouse tumours. PCR product was sent to Sanger 
sequencing using specific primers targeting the region of interest. (A); Sanger sequencing 
of region containing Ikzf3 SNV identified in sample 857, transition C-T; (B) Ikzf3 SNV 
identified in sample 853, transition C-T; (C) Jak1 SNV identified in the sample 854; 
transition G-T; (D) Jak3 SNV identified in the sample 853; transition G-A. (E) Jak3 SNV 
identified in the sample 857; transition C-T. Chromatograms for individual samples are 
shown for each SNV investigated. Heterozygous SNVs present two peaks at one location 
(Fig. 3.6 D; sample 853), while homozygous variations presented a single peak (Fig. 3.6 
B, sample 853). 
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3.2.5 Mutations in Janus Kinase 1 And 3 (Jak1/Jak3) and Aiolos (Ikzf3) 
Genes are Potential Secondary Drivers of Leukemogenesis in 
Mb1-CreDPB Mice 
As cancer driver genes would be expected to contain mutations and be expressed 
(Vogelstein et al., 2013), we also performed RNA-sequencing analysis on leukemias 853, 
854, and 857 in order to assess gene expression levels. To filter data based on levels of gene 
expression, Fragments Per Kilobase of transcript per Million mapped reads (FPKM) was 
determined from RNA-seq data using Cufflinks. FPKM was plotted against variable allelic 
frequency (VAF) determined using Strelka (Saunders et al., 2012) for three mouse leukemias 
853, 854, and 857. In each of the three samples there were highly expressed genes that also 
had high VAF (Fig. 3.6 A-C). Importantly, sample 853 had high FPKM and VAF for variants 
in Jak3 and Ikzf3 (Fig. 3.6 A). Sample 854 had high FPKM and VAF for a variant in Jak1 
(Fig. 3.6 B). Finally, sample 857 had high FPKM and VAF for variants in Jak3 and Ikzf3 
(Fig. 3.6 C). The elevated expression levels added to the high VAF of Jak1, Jak3 and Ikzf3 
genes in Mb1-CreDPB mice leukemias supports the hypothesis that these variants represent 
secondary driver mutations.  
Next, we sought to define the biological processes in which mutated genes could be 
involved by performing gene ontology analysis in genes with VAF greater than 20%, using 
PANTHER Gene List Analysis (H Mi, Muruganujan, Casagrande, & Thomas, 2013). We 
observed a pattern for all three samples where most of the genes were categorized in two 
major biological processes, “Cellular Process” and “Metabolic Process”. Specifically, genes 
within “Cellular Process” were subcategorized in subprocesses such as cell communication, 
cell proliferation and cell cycle (Fig. 3.6 D-F). Genes as Cit, Cdk9 and Stag1 are related to 
the control of cell cycle by regulating cytokinesis, transcription and cohesion of sister 
chromatids after DNA replication, respectively. Importantly, Smarcb1 encodes a core 
subunit protein of the ATP-dependent SWI/SNF chromatin remodeling complex, and was 
previously identified as a tumor suppressor (Tokheim, Papadopoulos, Kinzler, Vogelstein, 
& Karchin, 2016). Nap1l4, encodes a member of the nucleosome assembly protein and has 
a role as a histone chaperone. Genes involved in cell communication and adhesion, as 
Cntnap5b, Fras1, Sdk1 and Magi, were also enriched in our pathway analysis. In summary, 
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Jak3 and Ikzf3 mutations were identified as potential drivers of leukemogenesis in Mb1-
CreDPB mice, based on the observation that these genes are mutated in two of three 
leukemias, have high VAF, and have high levels of expression.  
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Figure 3.6. Integration of RNA-Seq and Whole-Exome Sequencing (WES) Allows the 
Identification of Secondary Driver Mutations.  
(A, B and C). Scatter plot correlating the levels of gene expression in Fragments Per 
Kilobase of Transcript per Million of reads mapped (FPKM log10) and the Variant Allele 
Frequency (VAF) for genes in which FPKM was greater than zero. Leukemias 853, 854 
and 857 are shown, respectively. (D, E and F). Biological Pathway Analysis in genes with 
VAF equal or greater than 20% was performed using Panther – Gene List Analysis. 
Diagram shows the number of genes enriched according the biological process. 
Enrichment for genes related to “Cellular Process” and “Metabolic Process” was 
observed for the three samples analyzed. List shows that genes enriched within “Cellular 
Process” were mostly classified in sub processes as “Cell Cycle”, “Cell Communication” 
and “Cell Proliferation”. 
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3.2.6 Recurrent Mutations in Janus Kinase 3 (Jak3) and Janus Kinase 1 
(Jak1) in Leukemias from Mb1-CreDPb Mice 
Analysis of the impact of variants on protein expression showed that SNVs in 
leukemias 853 and 857 resulted in coding changes in Jak3 (R653H, V670A, and/or T844M) 
while the SNV in Jak1 in sample 854 resulted in a V657F substitution (Fig. 3.7 A, B). These 
genes encode for Jak1 and Jak3 that are critically required for signaling through cytokine 
receptors IL7R and CRLF2 (Babon, Lucet, Murphy, Nicola, & Varghese, 2014). 
Comparison of Jak3 and Jak1 protein sequences among six different vertebrates showed that 
amino acids that underwent substitution in consequence of a SNV were highly conserved 
between these species (Fig. 3.7 A, B).   
To determine whether these variants represent recurrent leukemia driver mutations, 
we performed Sanger sequencing on a total of 19 Mb1-CreDPB leukemias using primers 
flanking the regions containing the SNVs identified by WES. Interestingly, this examination 
revealed that Jak3 R653H mutation was detectable in 5/19 leukemias analyzed. Jak1 
mutations V657F or V655L showed even higher recurrence than Jak3 mutation, being 
detectable in 10/19 leukemias (Fig. 3.7 D). Ikzf3 mutations were detected only in samples 
853 and 857, confirming the exome sequencing (Fig. 3.7 D). In summary, these data show 
that leukemia in Mb1-CreDPB mice was accompanied by recurrent secondary driver 
mutations in Jak1 and Jak3.  
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Figure 3.7. Mutations Occur in Conserved Regions of Jak1 and Jak3 Genes. 
 (A, B and C; left) Schematic shows the protein domains of Jak3, Jak1 and Aiolos (Ikzf3). 
Amino acids substitutions caused by single nucleotide substitutions identified in the 
whole-exome sequencing in samples 853, 854 and 857 are also indicated.  
(A, B and C; right) Blast analysis comparing Human (Homo sapiens), Mouse (Mus 
musculus), Rat (Rattus norvergicus), African Elephant (Loxodonta africana), Giant 
Panda (Ailuropoda melanoleuca), Atlantic Salmon (Salmo salar), Zebrafish (Danio 
rerio), Tropical Frog (Xenopus tropicalis) protein sequences for Jak1, Jak3 and Aiolos 
shows that amino acids which undergo substitution in consequence of a single nucleotide 
variation are highly conserved between species. (D) Sanger sequencing screening for the 
presence of amino acids substitutions in Jak1 (V657F and V655L), Jak3 (T844M and 
R653H), and Aiolos (R137* and H195Tyr) in a panel of nineteen leukemias extracted 
from Mb1-CreDPB mice. Filled boxes indicate samples which mutations were identified 
by Sanger Sequencing. 
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3.2.7 R653H, V670A, and T844M Amino Acid Substitutions in Jak3 
Confers Survival and Proliferation Advantages 
We next tested whether R653H, V670A, and T844M amino acid substitutions in 
Jak3 were able to confer growth advantage to normal cells. Site-directed mutagenesis was 
used to introduce these mutations to the wild-type mouse Jak3 coding region in an 
MSCV-IRES-GFP vector (a kind gift from Dr. Kevin D. Bunting). Pseudovirus was 
generated to spin-infect wild-type Pro-B cells that grow in cultures containing IL-7 and 
ST2 stromal cells. Pro-B cells were also infected with MSCV-Jak3 and a MSCV- empty 
vectors as controls. Following infection, the cell lines were cultured at high (5% 
conditioned medium) or low IL-7 (0.5%). Flow cytometry was performed every two days 
for 14 days to determine the frequency of GFP+ cells. Pro-B cells infected with Jak3 
mutations R653H, V670A, or T844M outgrew uninfected or control infected Pro-B cells 
at both low and high IL-7 concentration (Fig. 3.8 A, B). Next, in order to verify whether 
Jak3 mutations resulted in greater proliferation, cells infected with mutant Jak3 were 
plated at the initial concentration of 1x105 cells/ml in conditions of low and high IL-7. 
Cell numbers and the percentage of viable GFP+ cells were determined after cells were 
kept in culture for the period of four days. At low IL-7 concentration, Pro-B cells infected 
with Jak3 R653H, V670A, and T844M mutations showed a significant increase in the 
number of GFP+ cells after four days in culture (Fig. 3.8 C, D). Therefore, we concluded 
that T844M, R653H and V670A amino acids substitutions increased the proliferation of 
Pro-B cells in conditions of low IL-7. Taken together, these data indicate that Jak3 
mutations identified in these analyses conferred survival and growth advantage to Pro-B 
cells, consistent with a role as driver mutations. 
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Figure 3.8. JAK3 Mutations Confer Growth Advantage and Increased Proliferative 
Potential in Pro-B cells.  
(A and B) Percentage of GFP+ cells over the course of 14 days after infection with MSCV-
empty, MSCV-JAK3, MSCV-T844M, MSCV-R653H, MSCV-V670A or MSCV-
V670A/T844M in conditions of low (0.5%) and high (5%) IL-7, respectively.  (C and D) 
Absolute number of viable GFP+ cells after four days in culture under conditions of low 
(0.5%) and high (5%) IL-7. Cells were previously infected with either MSCV-empty, 
MSCV-JAK3, MSCV-T844M, MSCV-R653H, MSCV-V670A or MSCV-
V670A/T844M. Data is presented as number of cells/ml; n=3. 
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3.3 Discussion 
In this study, we showed that Mb1-CreDPB mice develop precursor B-ALL that 
is detectable by 11 weeks of age and results in the requirement for euthanasia at a median 
of 18 weeks. The latency of 11-18 weeks, and variable frequency of leukemias expressing 
Ig, showed that there was clonal tumour heterogeneity, and suggested that secondary 
driver mutations were required for disease progression. By characterizing the mutation 
landscape of Mb1-CreDPB leukemias using whole exome sequencing coupled with RNA-
sequencing, we discovered that mutations in Jak1 and Jak3 represent recurrent secondary 
driver mutations. Introduction of mutant Jak3 into wild type cells was sufficient to 
promote growth in response to low IL-7 concentrations. Taken together, these results 
showed that deletion of genes encoding PU.1 and Spi-B result in leukemia with 
predisposition to additional de novo driver mutations in genes encoding Janus kinases. 
Dysregulation of PU.1 and/or Spi-B expression are known to be involved in 
human leukemia and have been previously established as tumor suppressors in mouse 
models (S. H. M. Pang et al., 2016; Sokalski et al., 2011). Minimal reductions in PU.1 
expression were sufficient to induce a preleukemic condition in hematopoietic stem cells 
(Will et al., 2015). Whole exome sequencing and whole genome sequencing studies have 
revealed that inactivating mutations in genes encoding PU.1 and Spi-B are detectable but 
infrequent in human leukemia (Mullighan et al., 2007, 2011). In contrast, PU.1 levels are 
repressed by frequently occurring chromosomal abnormalities such as FLT3 internal 
tandem duplication (FLT3-ITD) (Mizuki et al., 2003) and RUNX1-ETO fusion (Vangala 
et al., 2003). Spi-B levels are repressed by ETV6-RUNX1 chromosomal fusion (S. H. M. 
Pang et al., 2016). It is not known how reduced PU.1 and/or Spi-B might lead to 
acquisition of secondary driver mutations. However, PU.1 and Spi-B are involved in 
attenuating IL-7R signaling in developing pro- and Pre-B cells. Target genes of PU.1 and 
Spi-B involved in regulating IL-7-induced proliferation include Btk encoding the tumour 
suppressor Bruton tyrosine kinase (Christie et al., 2015), and Blnk encoding B Cell Linker 
Protein (L. S. Xu et al., 2012). Btk and Blnk work together to attenuate IL-7R signaling 
in developing B cells (Clark et al., 2014). We speculate that mutagenesis in Mb1-CreDPB 
is associated with genomic instability due to uncontrolled cell proliferation. Interestingly, 
a similar disease is induced by combined deletion of PU.1 and IRF4, suggesting a 
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common axis of gene regulation by PU.1/Spi-B and PU.1/IRF4 (S. H. M. Pang et al., 
2016). 
We identified a number of single nucleotide variants (SNVs) in our analysis, 
which suggest that several rounds of mutational events contributed to leukemogenesis. 
To select for potential leukemia initiator lesions, we focused our attention on genes that 
were highly expressed and had high variant allelic frequencies (VAF), reasoning that 
genes within this category are likely to have originated earlier in leukemia progression. 
Our analyses identified Aiolos (Ikzf3), Jak1 (Jak1) and Jak3 (Jak3) as potential secondary 
driver mutations. These genes are involved in signaling downstream of multiple cytokine 
receptors during B cell development. Cytokine receptor genes are commonly mutated in 
human B cell acute lymphoblastic leukemias (Ma et al., 2018), and mutations in Jak3 and 
Ikzf3 have recently emerged as novel mutated genes in high-risk B-ALL (J. Zhang et al., 
2011). In particular, our analysis focused on R653H, V670A, and T844M mutations in 
Jak3.  Jak3 R653H and V670A mutations were recently observed in B-ALL generated in 
activation-induced cytidine deaminase (AID) deficient mice (Auer et al., 2017). Human 
equivalents of Jak3 R653H and V670A have been described in human ALL (R657Q, 
V674F), and furthermore have been shown to function by activation of proliferation in 
response to interleukin-7 (Losdyck et al., 2015). Importantly, human JAK3 V674F is 
sufficient to induce T-cell acute lymphoblastic leukemia when retrovirally delivered to 
hematopoietic precursors (Losdyck et al., 2015). Jak1 missense mutations V655L or 
V657F were also detected in 10 of 19 leukemias in our analysis.  Jak1 V657F also 
corresponds to a human JAK1 mutation that is a frequent driver in human B-ALL (V658F) 
(Hornakova et al., 2009).  Interestingly JAK1 V658F mutation has been previously 
observed in T-cell acute lymphoblastic and acute myeloid leukemias (Kralovics et al., 
2005). V658F is also thought to be paralogous to the JAK2 V617F mutation that functions 
as a driver in more than 95% of cases of polycythemia vera (Bandaranayake et al., 2012). 
In summary, the mutations in Jak1 and Jak3 identified in this study are relevant to human 
leukemia. 
Taken together, this study confirms that leukemia in Mb1-CreDPB mice is 
accompanied by de novo recurrent secondary driver mutations in the Janus Kinase 
signaling pathway. Mutations in the JAK signaling pathway are recurrent in human 
leukemia including the recently discovered Ph-like classification that represents a high 
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priority for discovering new therapies (Jain et al., 2017; Roberts et al., 2017). In order to 
study the genetic clonal evolution that underlies diseases such as Ph-like leukemia, there 
is still a need for mouse models. In order to advance understanding, mouse models should 
have the following characteristics: 1) They should develop leukemias with high 
penetrance and reproducibility, 2) they should replicate the genetic and molecular 
heterogeneity of tumors and involve de novo mutations 3) they should occur in immune 
competent mice, and 4) they should mimic that clinical behaviour of human disease 
(Jacoby et al., 2014; Kohnken et al., 2017). The Mb1-CreDPB mouse model develops B-
ALL with 100% penetrance by 18 weeks of age that is driven by heterogeneous driver 
mutations. This mouse model may be useful to determine the effects of targeted molecular 
therapies on intratumoral heterogeneity and clonal evolution in B-ALL. 
3.4 Material and Methods 
3.4.1 Mice and Breeding 
 Mb1-Cre mice have been described previously (Hobeika et al., 2006). For this 
study, Mb1-Cre mice were crossed with Spi1lox/lox Spib-/- to generate Mb1+/Cre Spi1lox/lox 
Spib-/- mice (also referred to as Mb1-CreDPB mice). C57BL/6 mice were purchased from 
Charles River Laboratories (Saint-Constant, QC, Canada). Mb1+/CreSpi1lox/lox Spib+/+ 
(referred to as Mb1-CreDP) and Mb1+/CreSpi1+/+ Spib-/- or Mb1+/+Spi1+/+ Spib-/- (referred 
to as Mb1-CreDB) mice were used as experimental controls. Mice were fed with regular 
chow and tap water ad libitum and housed with a 12-h light–dark cycle. Mice showing 
signs of illness were euthanized and examined for spleen, thymus and lymph node 
enlargement and analyzed as described below. All experiments were performed in 
compliance with the Western University Council on Animal Care. 
3.4.2 Histology and Microscopic Analysis 
Mb1-CreDPB mice showing signs of disease were euthanized by CO2 and spleen 
and thymus were removed for histological analysis. Spleen and thymus removed from 
Mb1-CreDB mice were used as control. Organs were fixed in 10% buffered formalin. 
Tissues were paraffin embedded, sectioned, and stained with hematoxylin and eosin. 
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High-resolution micrographs were captured using a Q-Color3 digital camera (Olympus, 
Markham, ON, Canada). 
3.4.3 Flow Cytometry 
 Single cell suspensions were prepared from enlarged spleen and thymus from 
Mb1-CreDPB mice. Red blood cells were removed from single-cell suspensions using 
hypotonic lysis. Flow cytometric analyses were performed using a FACSCanto or LSRII 
instrument (BD Immunocytometry Systems, San Jose, CA). Antibodies were purchased 
from eBioscience (San Diego, CA), BioLegend (San Diego, CA), or BD Biosciences 
(Mississauga, ON, Canada) and included PE-anti-CD19 (1D3), FITC-anti-BP-1 (6C3), 
APC-anti-IgM (II/ 41), PE-anti-Igk (187.1), FITC-anti-IL-7Ra (A7R34), BV421–anti-
B220 (RA3-6B2), PE–anti-BP-1 (6C3). Data were analyzed using FlowJo 9.1 software 
(Tree Star, Ashland, OR).  
3.4.4 Whole-Exome Sequencing  
Three matched-tumour and tail mouse samples (853, 854 and 857) had genomic 
DNA isolated using Wizard Genomic DNA Purification Kit (Promega Corporation, 
Madison WI). Whole-Exome Sequencing was performed by McGill University and 
Génome Québec Innovation Centre (Montreal, Canada). The SureSelectXT Mouse All 
Exon kit (Agilent Technologies, Mississauga, Canada) was used to perform exome target 
capture. Paired-end DNA library preparation was performed using SureSelectXT Target 
Enrichment System. An Illumina HiSeq4000 instrument was used to perform the whole-
exome sequencing. BAM files were converted to Fastaq format on Galaxy suite  using 
“SAMtofastaq” (Afgan et al., 2016) tool. Fastaq reads had Illumina Adaptors were 
removed using Trim Galore!. Trimmed reads were aligned to the mouse reference genome 
(mm10) using Bowtie. BAM aligned files were used as input for single somatic variant 
callers. Somatic variants of three matched-tumour mouse samples were called by using 
two independent methods, Strelka and Mutect (Cibulskis et al., 2013; Saunders et al., 
2012). For both methods, variants were called using the standard settings recommend by 
the package documentation. VCF files containing the somatic nucleotide variants (SNVs) 
and Small insertions and deletions (INDELs) generated by Strelka and Mutect were 
further filtered following the criteria ‘passed’ or ‘keep’ for the Strelka and Mutect outputs, 
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respectively. Filtered VCF files outputted by Strelka and Mutect were intersected using 
VCFtools and annotated using the SnpEff (Cingolani et al., 2012) package using the 
mouse genomic annotation (mm10). Annotated variants were classified according the 
variant impact in HIGH, MODERATE, MODIFIER and LOW, and overlapping variants 
among the three samples were determined. Independently, outputs generated by Strelka 
and Mutect were also annotated using the SnpEff tool for further analysis. 
3.4.5 RNA Sequencing  
RNA was extracted from thymic tumours 853, 854 and 857 using RNeasy Kit 
(QIAGEN, ON, Canada). RNA-sequencing was performed by McGill University and 
Génome Québec Innovation Centre (Montreal, Canada). Paired-end (mRNA-sequencing 
stranded) libraries were prepared using Truseq stranded total RNA library prep kit. 
Libraries were sequenced using an Illumina HiSeq4000 PE100 instrument. Data analysis 
was performed as described previously (Batista et al., 2017). In summary, Standard   
Illumina   sequencing adaptors were removed using Trim Galore!. Trimmed Fastaq reads 
were aligned to the mouse reference genome version mm10 using TopHat2 (Trapnell et 
al., 2012) in mate-paired mode using Galaxy suite. Assembled transcript abundance was 
determined as previously using Cufflinks (Trapnell et al., 2012).  
3.4.6 Sanger Sequencing 
 RNA extracted from 20 thymic leukemias was reversed transcribed to 
complementary DNA using iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). Primers 
flanking the Ikzf3, Jak3 and Jak1 mutations identified by WES were designed using 
Primer-BLAST. cDNA was used as a template for PCR reactions using specific primers 
(Table 2). PCR reactions were run in a 1.5% agarose gel and the PCR products were 
excised and purified from the gel using QIAquick Gel Extraction Kit (QIAGEN, ON, 
Canada). Purified DNA was submitted for Sanger sequencing at London Regional 
Genomics Centre, Western University (London, ON, Canada). Sequencing 
chromatograms and DNA sequences were analyzed in the software 4Peaks (Mekentosj, 
Amsterdam).   
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Table 2. Primer Sequences Used in The Study Described in Chapter 3. 
  
SNVs/Consequences Reference Sequence Gene Sequences Product length 
SNV Position 101163673; Alteration C-A NC_000070.6 (JAK1 DNA) JAK1 F AAAGTCCTAGACCCCAGCCAC 401
R CGCTCTATGCACTCTTGCCTG
SNV Position 71685437; Alteration C-T NC_000074.6 (JAK3 DNA) JAK3 F CGAGTCCTCGAGATGAGCTGT 432
T844M (857) R GGTACTCCATGCCCTTGCAGAT
SNV Position 71684008; Alteration G-A NC_000074.6 (JAK3 DNA) JAK3 F GCATCATGGTGCAGGAATTTGT 549
R653H (853) R CGTTGAGGTCTCTGAGGATAGC 
SNV Position 98488858; Alteration G-A NC_000077.6 (IKZF3 DNA) IKZF3 F ACACGTGCCCTATGACAACA  503
SNV Position 98490344; Alteration G-A R GAGGCATCGAGCTTTTTCGC
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3.4.7 DNA Constructs and Site-Directed Mutagenesis 
 The mouse MSCV-IRES-GFP-JAK3 plasmid was kindly provided by Dr. Kevin 
D. Bunting. T844M, R653H, and V670A mutations were generated by site-directed 
mutagenesis using Q5® Site-Directed Mutagenesis Kit (New England BioLabs, Ipswich, 
MA). Site-directed mutagenesis primers for each one of the specific mutations were 
designed using NEBaseChanger tool. Mutations were confirmed by Sanger Sequencing 
before retroviral production and spinoculation.  
3.4.8 Retroviral Production and Infection 
 Retroviral supernatants for wild-type Jak3, and T844M, R653H, V670A mutants 
were generated Platinum-E retroviral packaging cells (Morita, Kojima, & Kitamura, 
2000) using PEIPro transfection reagent (PolyPlus, New York, NY). 10 µg of MSCV 
plasmid were cotransfected with 4 µg pECO plasmid (Clontech, Mountain View, CA). 
Plasmid DNA was mixed with polyethyleneimine (PEI) at a 2:1 PEI/DNA ratio and 
applied to 3 × 106 cells in a 10-cm plate. The medium was changed after overnight 
incubation, and virus-containing supernatant was collected 48 hours after medium 
change. Wild-type Pro-B cells were infected by spinoculation with 1 mL of viral 
supernatant containing 10ul of polybrene at the concentration of 10mg/ml. Cells were 
centrifuged at 3000 × g for 2 hours at 30°C and allowed to recover for 24 hours before 
medium change and infection was confirmed by flow cytometric analysis for GFP.  
3.4.9 Cell Culture 
 Wild-type and Jak3 mutant-infected Pro-B cell lines used in this study were 
cultured in IMDM (Wisent, QC, Canada) containing 10% FBS (Wisent), 1X 
penicillin/streptomycin/L-glutamine (Lonza, Shawinigan, QC, Canada), and 5 x 10-5 M 
b-mercaptoethanol (Sigma-Aldrich St. Louis, MO). Media also contained 5% or 0.5% 
conditioned medium from the IL-7 producing cell line J558-IL-7 (Winkler, Rolink, 
Melchers, & Karasuyama, 1995). Cell lines were maintained in 5% CO2 atmosphere at 
37˚C.  
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3.4.10 Availability of Data 
WES data is available from the Sequence Read Archive, accession SRP136503 
(https://www.ncbi.nlm.nih.gov/sra/SRP136503). RNA-seq data is available from the Gene 
Expression Omnibus, accession GSE112506. 
3.4.11 Statistical Analysis 
 All data reported in this study were graphed as mean ± SEM. Statistical analysis 
was performed using Prism 5.0 (Graphpad Software, La Jolla, CA) using ANOVA or 
Student’s t test. Values with p ≤ 0.05 were considered significant, where p ≤ 0.05 (*), p 
≤ 0.01 (**), p ≤ 0.001 (***), p≤ 0.0001 (****). 
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Chapter 4 
4 Deletion of Spi-B and PU.1 is Strongly Associated with C•G 
> A•T Genomic Transversions  
The absence of Spi-B and PU.1 in developing B cells causes a severe block in the 
development of B lymphocytes (Chapter 2) and generates B cell acute lymphoblastic 
leukemia associated with the presence of secondary driver mutations in the Janus Kinase 
proteins (Chapter 3). Another interesting observation from these studies, was the robust 
presence of C•G > A•T genomic transversions in leukemias initiated as a consequence of 
deletion of Spi-B and PU.1. In this Chapter, the etiology of leukemogenesis in the absence 
of these factors is further explored, extending the current knowledge regarding mutational 
signatures and their association with the genetic mechanisms contributing to 
leukemogenesis. 
4.1 Introduction 
Somatic mutations within cancer genomes arise as a result of many processes such 
as infidelity of the DNA replication machinery, enzymatic modifications of DNA, 
defective DNA repair and endogenous or exogenous exposures to mutagens (Greenman 
et al., 2007). Bulky somatic mutations can be associated with known cancer etiologies, 
such as tobacco smoking in lung cancers, UV light in skin cancers and DNA mismatch 
repair in some colorectal cancers (Alexandrov et al., 2013).  The somatic mutational 
pattern in cancers has been demonstrated to be an important tool to define the etiology of 
the mutational processes leading to carcinogenesis. The recent advances in next 
generation sequencing, allowed an extensive evaluation of thousands of somatic 
mutations within single cancers. Analysis of mutational catalogues of 7,042 primary 30 
different classes of cancers combined with normal DNA from the same individuals, has 
generated a repertoire of mutational signatures and their associated processes 
(Alexandrov et al., 2013). Twenty-one mutational signatures have been described by this 
analysis, however while the mechanistic basis of some signatures seems to be understood, 
for many other cancer types, their etiology remains unknown (Alexandrov et al., 2013). 
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The current understanding regarding the somatic signatures associated with 
leukemias and lymphomas is limited. According to Alexandrov et al., 2013, the signatures 
19, 6 and 9 have been enriched in leukemias and lymphomas. Signature 19 is associated 
with age related processes, while signature 6 is caused by over activity of members of the 
APOBEC family of cytidine deaminases, which convert cytidine to uracil, coupled with 
activity of the base excision repair and DNA replication machineries (Alexandrov et al., 
2013). Signature 9, which has been observed in chronic lymphocytic leukemia and B cell 
lymphomas, is mostly characterized by T>G transversions in association with cancers 
which have undergone somatic Ig hypermutation (Alexandrov et al., 2013). 
Therefore, we started exploring the mechanisms by which leukemogenesis arise, 
in the absence of the transcription factors Spi-B and PU.1. By investigating the mutational 
signature profile in SNVs generated through the WES analysis of three matched tumour- 
normal DNA leukemias, we gained insights on the basis of the mutagenic processes. 
Leukemias generated in the absence of Spi-B and PU.1 have a strong enrichment of C•G 
> A•T transversions which are commonly associated with 8-oxoguanine (8-oxo) DNA 
damage. This finding indicates the potential involvement of reactive oxygen species 
(ROS) in the generation of 8-oxo DNA damage, which consequently has the potential to 
lead to leukemogenic events. 
4.2 Results 
4.2.1 Deletion of Spi-B And PU.1 is Strongly Associated With C•G 
>A•T Genomic Transversions  
The majority of the nucleotide alterations in the three tumour samples analyzed 
(853, 854 and 857) were C•G > A•T transversions (Fig. 4.1). In order to gain further 
insight into the mutational processes associated with leukemogenesis in the Mb1-CreDPB 
mice, we determined the mutational signature of leukemias using DeconstructSigs 
(Rosenthal, McGranahan, Herrero, Taylor, & Swanton, 2016). This package compares 
the similarity of each tumour sample to a list of previous published signatures generated 
by the analysis of 40 distinct types of human cancer (Alexandrov et al., 2013). This 
analysis confirmed enrichment of C•G > A•T transversions in leukemias 853, 854 and 
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857 (Fig. 4.2 A, B and C). We also observed an enrichment of C>A transversions flanked 
5’base by either adenine (A), cytosine (C), guanine (G) or thymine (T) nucleotides. These 
transversions were consistently flanked at the 3’ base by an adenine (A) nucleotide (Fig. 
4.2 D). 
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Figure 4. 1. Characterization of the Nucleotide Somatic Nucleotide Variants (SNVs) 
Identified by Strelka Somatic Variant Caller in Three Mb1-CreDPB Mice Leukemias.  
 
(A, B and C) SNVs distribution according to chromosome in leukemias isolated from 
853, 854 and 857 mice, respectively. (D) Allelic frequency change for 853, 854 and 857 
leukemias showing an enrichment for G>T and C>A substitutions. 
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Figure 4. 2. Mutational Signature of Mb1-CreDPB Mouse Leukemias Shows Strong Bias 
to C•G -> A•T Transversions.  
(A-C) DeconstructSigs reconstruction analysis of mouse leukemias 853, 854 and 857. 
COSMIC mutation signatures were used to reconstruct the mutational profile of mouse 
leukemias and to predict similarity. (D) Heat map illustrating the mutational context of 
5’ and 3’ nucleotides surrounding the transitions identified in samples 853, 854 and 857. 
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Mutational signature analysis performed using DeconstructSigs indicated that the 
signatures in leukemias 853, 854, and 857 were most similar to COSMIC Signatures 18, 
24, 4, and 9. Signature 18, which showed the highest inferred weight for all leukemia 
samples analyzed, has been also commonly observed in human childhood cancers 
including B-ALL and neuroblastoma, but does not have a known mechanism (Alexandrov 
et al., 2013). Signatures 4, 24 and 29 despite being enriched in distinct cancer types, also 
exhibited a strong enrichment to C•G > A•T transversions. Interestingly, these signatures 
have a common proposed etiology, indicating the presence of guanine damage that is 
further repaired by transcription-coupled nucleotide-excision repair pathway (Table 3). 
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Table 3. COSMIC Signatures Showing an Enrichment of C•G > A•T Transversions.  
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4.2.2 Expression of DNA Glycosylases Mutyh, Neil3, Neil1 And Ogg1 
Is Enhanced in Leukemias Generated in The Absence of Spi-B And 
PU.1 
Due to the high abundance of C•G > A•T transversions present in leukemias 
extracted from thymic tumours of the Mb1-DPB mice, we asked whether the levels of 
expression of the genes encoding DNA glycosylases were enhanced in leukemias lacking 
Spi-B and PU.1. We took advantage of previous RNA-seq performed in six leukemias 
extracted from Mb1-DPB mice to determine the levels of expression (by FPKM) of 
Mutyh, Neil3, Neil1, Neil2 and Ogg1. For comparison, we reasoned that the levels of 
expression of these genes in Pro-B cells could be used as reference. Therefore, we plotted 
the levels of expression (FPKM) of non-leukemic Pro-B cells (i660BM) in which PU.1 
has been either induced or not induced. The i660BM Pro-B cell line has become a useful 
tool to study B cell development in the absence and in the presence of PU.1, as 
doxycycline treatment for a period of 48 hours restores PU.1 levels, recovering the normal 
developmental conditions of Pro-B cells. Therefore, PU.1 regulated genes such as Btk, 
Blnk and Il7r were strongly induced upon doxycycline treatment after a period of 48 
hours. As previously observed, Blnk, Btk and Spi1 were reduced in leukemias extracted 
from the thymus of Mb1-CreDPB mice (Fig. 4.3 A). Therefore, these findings support the 
use of i660BMPro-B cells as a reference control for normal gene expression during B cell 
development. 
The Mutyh gene was modestly increased in all leukemias compared to i660BM cells 
induced (DOX) or non-induced (-DOX) with doxycycline. Strikingly, Neil1 expression 
was enhanced ~6 fold in leukemias compared to Pro-B cells. Expression of Ogg1 and 
Neil2 genes did not vary in leukemias compared to i660BM Pro-B cells. Interestingly, 
although Neil3 expression was not changed in leukemias and Pro-B cells, the expression 
of Neil3 was upregulated after PU.1 induction after doxycycline treatment (Fig. 4.3 B). 
Overall the increase in Neil1 and Mutyh genes, point out to a possible involvement of 
nucleotide-excision repair pathway facilitating the repair of 8-oxoG lesions. 
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4.2.3 Generation of Reactive Oxygen Species (ROS) Leads to 8-
Oxoguanine Lesions Resulting in Leukemogenesis 
The current understanding is that 8-oxoG damage is caused mainly by reactive 
oxygen species (ROS) (David, O’Shea, & Kundu, 2007). ROS are produced as a 
consequence of normal cellular metabolism in processes such as aerobic respiration. The 
superoxide anion (O2 •-), is generated by enzymatic reactions of the mitochondrial 
electron transport chain, NAD(P)H oxidase, xanthine oxidase and nitric oxide synthase 
(NOS) among others (D’Autréaux & Toledano, 2007). In order to suppress the deleterious 
effects of ROS, cells have evolved intricate antioxidant mechanisms. Superoxide 
dismutase (SOD) enzymes are the first line of defense against ROS. Sod1 and Sod2 genes 
encoding superoxide dismutase 1 and 2 respectively, dismutate the O2 •- generating 
hydrogen peroxide (H2O2) as product (D’Autréaux & Toledano, 2007). However, H2O2 
is still mutagenic to cells, and can induce DNA single and double-strand breaks as well 
as to DNA lesions through oxidation of nucleotides (Driessens et al., 2009). Thus, a rapid 
antioxidative response, mostly mediated by enzymes such as catalase, peroxiredoxins 
(Prxs), and glutathione peroxidases (GPx) takes place mediating catalysis of H2O2 to H2O. 
Furthermore, the glutathione (GSH) system represents an essential defense mechanism 
against oxidative stress. GSH interacts directly with ROS or to act as a cofactor for 
glutathione peroxidases and GSH S-transferases. Oxidized GSH (GSHG) is converted 
back to a reduced state by glutathione reductase. With these pathways in mind, we raised 
the question of whether genes encoding superoxide dismutase (Sod1 and Sod2), as well 
as genes encoding members of the GSH system, (Gpx1, Gss and Gsr), were upregulated 
in Mb1-DPB mice leukemias compared to Pro-B cells. 
Interestingly, while the levels of Sod2 were not changed, upregulation of Sod1 
expression was observed in Mb1-DPB leukemias compared to Pro-B cells. Specifically, 
leukemias 853, 854 and 857 all showed 2-fold upregulation of Sod1 expression compared 
to expression in in Pro-B cells. Increased Sod1 levels has been observed in Down 
Syndrome (DS) children since Sod1 gene is located on chromosome 21 (Pallardó et al., 
2006; Turrens, 2001). Importantly, susceptibility of developing myeloid, lymphoid or 
megakaryocyte leukemia is increased significantly in DS children (Taub, 2001). 
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Surprisingly, the gene encoding glutathione peroxidase 1, Gpx1, which catalyzes the 
reaction that converts H2O2 to H2O also generating oxidized glutathione (GSHG), was 
reduced in leukemias in comparison to Pro-B cells. In line with that, Gsr gene which 
encodes glutathione reductase was also reduced in Mb1-DPB leukemias (Fig. 4.3 C). 
These preliminary findings indicate that potentially there is an accumulation of H2O2 
within leukemia cells, associated with impaired ability to neutralize antioxidant 
mechanisms mediating the conversion of H2O2 to H2O. 
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Figure 4.3. RNA-Seq Analysis of Six Thymic Leukemias Extracted from Mb1-CreDPB 
Mice. 
RNA-seq data from i660BM cells where PU.1 was induced (DOX+) or not induced 
(DOX-) using doxycycline administration. (A) Heat map showing gene expression levels 
(FPKM) of B cell related genes (left), graph shows FPKM levels of Spi1, Btk, Blnk and 
Il7r in DOX+, DOX- and Leuk samples (right). (B) Heat map showing gene expression 
levels (FPKM) of 8-oxoguanine glycosylases (left), graph shows FPKM levels of Ogg1, 
Neil1, Neil2, Neil3, Mutyh in DOX+, DOX- and Leuk samples (right). (C) Heat map 
showing gene expression levels (FPKM) of ROS responsive genes (left), graph shows 
FPKM levels of Sod1, Sod2, Gss, Gsr, Gxp1 in DOX+, DOX- and Leuk samples (right). 
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4.3 Discussion 
We observed that leukemias originating in mice that lack of Spi-B and PU.1 
present a high mutational spectrum, each tumour having over two thousand SNVs. These 
data led us to explore the possible mechanisms by which this high mutational load is 
generated. The mutational signature profile of these leukemias revealed an enrichment of 
C•G > A•T transversions, pointing towards the possible involvement of ROS in the 
generation of 8-oxoG DNA damage in the absence of the ETS transcription factors Spi-
B and PU.1. These findings raise the question of which cellular processes are altered in 
the absence of Spi-B and PU.1 that could lead to DNA damage in consequence of ROS 
production.  
The link between ROS generation and human leukemias has been previously 
addressed in a few studies. In a recent study, tumours from human pediatric cancers, 
including 689 B-ALLs, showed that 12% of B-ALL possessed a mutational profile 
containing the 8-oxoG damage signature, T-8 (ROS; COSMIC S-18) (Ma et al., 2018). 
Interestingly, 36% of neuroblastoma tumours, a disease which the mutational signature 
profile not yet associated with any known etiology, exhibited the 8-oxoG damage 
signature at the age of diagnosis (Ma et al., 2018). Analysis of the mutational spectrum 
of Down Syndrome AMkL leukemias with Gata1 mutations, also showed an elevated 
number of C•G > A•T mutation suggesting that early leukemogenic events could be 
related with oxidative stress (Cabelof et al., 2009).  
During development of B cells, ROS derived from metabolism is drastically 
increased at the Large Pre-B cell stage and decreases at the Small Pre-B cell stage (Stein 
et al., 2017). At the Large Pre-B cell, highly proliferative B cells execute the switch to a 
resting stage of Small Pre-B cell, by shutting down the IL-7R signaling via the signaling 
downstream of the Pre-BCR (Clark et al., 2014). We have shown, in Chapter 2, that 
developing B cells lacking Spi-B and PU.1 do not develop further than the Large Pre-B 
cell stage. In Chapter 3, we demonstrated that leukemias originated from Mb1-CreDPB 
mice are dependent in IL-7R signaling and are originated from Pro-B to Large Pre-B cell 
stages. Therefore, this led us to hypothesize that IL-7R signaling dependency in the lack 
of Spi-B and PU.1 leads to an extended period of ROS load, resulting in 8-oxoG damage 
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resulting on the C•G > A•T mutational signature. However, we still need to determine 1) 
whether the intracellular levels of ROS as well as the presence of 8-oxoG damage is 
increased in developing B cells lacking Spi-B and PU.1 compared to normal cells and 2) 
whether this damage is a consequence of the developmental block in a IL-7 signaling 
dependent stage. 
4.4 Material and Methods 
4.4.1 Mice and Breeding 
 Mb1-Cre mice have been described previously (Hobeika et al., 2006). For this 
study, Mb1-Cre mice were crossed with Spi1lox/lox Spib-/- to generate Mb1+/Cre Spi1lox/lox 
Spib-/- mice (also referred to as Mb1-CreDPB mice). C57BL/6 mice were purchased from 
Charles River Laboratories (Saint-Constant, QC, Canada). Mb1+/CreSpi1lox/lox Spib+/+ 
(referred to as Mb1-CreDP) and Mb1+/CreSpi1+/+ Spib-/- or Mb1+/+Spi1+/+ Spib-/- (referred 
to as Mb1-CreDB) mice were used as experimental controls. Mice were fed with regular 
chow and tap water ad libitum and housed with a 12-h light–dark cycle. Mice showing 
signs of illness were euthanized and examined for spleen, thymus and lymph node 
enlargement and analyzed as described below. All experiments were performed in 
compliance with the Western University Council on Animal Care. 
4.4.2 Cell Culture 
The 660BM and i660BM cell lines used in this study were described previously. 
Cells were cultured in IMDM (Wisent, QC, Canada) containing 5% IL-7–conditioned 
medium from the J558L–IL-7 cell line, 10% FBS (Wisent), penicillin/streptomycin/L-
glutamine (Lonza, Shawinigan, QC, Canada), 2-ME (Sigma-Aldrich, St. Louis, MO). 
i660BM cells were maintained in 0.5 mg/ml puromycin (BioBasic, Markham, ON, 
Canada). Cell lines were maintained in 5% CO2 atmosphere at 37 ̊C. For the RNA-
sequencing experiments i660BM cells were induced for 48 h with doxycycline (70 ng/ml) 
in the presence of 5% IL-7–conditioned medium described above, and RNA was extracted 
using an RNeasy Kit (QIAGEN, ON, Canada). Uninduced cells were used as a control. 
Data analysis and processing has was performed as described previously (Batista et al., 
2017). 
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4.4.3 RNA Sequencing  
RNA was extracted from thymic tumours 853, 854 and 857 using RNeasy Kit 
(QIAGEN, ON, Canada). RNA-sequencing was performed by McGill University and 
Génome Québec Innovation Centre (Montreal, Canada). Paired-end (mRNA-sequencing 
stranded) libraries were prepared using Truseq stranded total RNA library prep kit. 
Libraries were sequenced using an Illumina HiSeq4000 PE100 instrument. Data analysis 
was performed as described previously (Batista et al., 2017). In summary, Standard 
Illumina sequencing adaptors were removed using Trim Galore!. Trimmed Fastaq reads 
were aligned to the mouse reference genome version mm10 using TopHat2 (Trapnell et 
al., 2012) in mate-paired mode using Galaxy suite. Assembled transcript abundance was 
determined as previously using Cufflinks (Trapnell et al., 2012).  
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Chapter 5 
5 Discussion and Future Directions 
The findings in this thesis address the mechanisms by which the transcription 
factors Spi-B and PU.1 contribute to early B cell development and lineage progression, 
and how the lack of Spi-B and PU.1 results in leukemogenic potential. We confirmed the 
hypothesis that these transcription factors control events associated with transition from 
high to low proliferation stages during the development of B cells, at the Pre-B cell stage 
transition. We also identified events associated with leukemogenesis in mice with B cells 
lacking Spi-B and PU.1. The data in Chapter 3 suggested that absence of these factors 
favors a state of high proliferation, increasing significantly the leukemogenic potential of 
developing B cells. 
The experiments described in Chapter 2 assessed the function of PU.1 binding to 
the Igk locus. PU.1 binding at this region has been observed before (Schwickert et al., 
2014; Whyte et al., 2013), but its function remained to be investigated. The levels of PU.1 
remained constant following CLP commitment to the B cell fate suggesting an important 
function during B cell development. Here we demonstrate that the binding to the Igk locus 
is crucial to induce a state of genomic accessibility necessary for RAG rearrangements 
and therefore progression to the Small Pre-B cell stage. Our pioneering observations that 
PU.1 binds in close proximity to RSSs within the Igk locus, indicates PU.1 plays a role 
in accessibility for RAG binding and therefore initiation of recombination events.  In 
summary, we established that the transcription factors Spi-B and PU.1 are required for 
IgL recombination and transition to the Small Pre-B cell stage, independent of the 
presence of the transcription factors IRF4 and IRF8. 
We also observed that PU.1 and Spi-B deletion blocks B cell development in a 
IL-7 dependent stage of Large Pre-B cells, and that this blockade can result in the 
generation of leukemia overtime (Christie et al., 2015; Sokalski et al., 2011). In 
experiments described in Chapter 3, we worked with the assumption that loss of PU.1 and 
Spi-B were the ‘first hit’ for the initiation of leukemogenic events. In fact, we observed a 
significant number of mutations in leukemias originated in the absence of these 
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transcription factors, including mutations in known driver genes in human leukemias, 
such as Jak3 and Ikzf3 genes. The mutational signature profile for these leukemias 
(Chapter 4), also suggested that 8-oxoguanine damage is another initiator of mutagenic 
events in the absence of Spi-B and PU.1.  
Overall, we propose a working model whereby PU.1 and Spi-B function during B 
cell development (Fig. 5.1). PU.1 and Spi-B were previously known to transcriptionally 
control the expression of downstream components of Pre-BCR and BCR signaling such 
as Btk, Blnk and Syk genes. Signaling through this pathway is required for the transition 
from Large Pre-B cells to Small Pre-B cells, since it antagonizes IL-7R signals, 
consequently enabling IgL recombination. We observed that PU.1 binds to the Igk 
variable regions, as well as to Igk and Igl enhancers inducing transcription, a read-out of 
accessibility for Ig recombination. We concluded that PU.1 binding is required to initiate 
events leading to IgL recombination and therefore the progression to the Small Pre-B cell 
stage.  
We believe that three major events occur in the absence of PU.1 and Spi-B: 1) 
Cells at the Pro-B cell/Large Pre-B cell stage are not able to terminate IL-7R signaling 
due impaired Pre-BCR signals, 2) Large Pre-B cells are not able to start the events leading 
to rearrangement of IgL genes, as a consequence of constant IL-7R signaling added to the 
inability of binding of PU.1 in the Igk locus, and 3) Proliferative stress caused by IL-7 
signaling dependency has the potential to cause 8-oxoguanine damage, alongside 
oxidative stress, leading to mutations in genes conferring growth and survival advantages. 
Therefore, PU.1 and Spi-B not only coordinate the B cell transition from high to low 
proliferative stages and coordinates IgL recombination. The experiments performed in 
Chapter 3, also revealed a role for PU.1 and Spi-B as tumour suppressors genes, 
safeguarding the developing B cells against leukemogenic initiator events.  
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Figure 5.1. Proposed Model of Spi-B and PU.1 Function Controlling B Cell 
Development and Leukemia Progression. 
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5.1 PU.1 and Spi-B Redundancy and Function in B Cell 
Development 
 
The ETS family members PU.1 and Spi-B have redundant actions in developing 
B cells due to two major observations: 1) the lack of only PU.1 or Spi-B does not cause 
drastic impairments in B cell maturation (Sokalski et al., 2011) and 2) chromatin 
immunoprecipitation analysis of PU.1 and Spi-B in B cells revealed a high degree of 
binding overlap for these factors in the purine rich motif 5’ GGAA 3’(Solomon et al., 
2015). These observations bring to focus the importance of Spi-B and PU.1 in the 
activation of a genetic program essential for B cell development.  
Transcription factor redundancy is an evolutionary event linked with genomic 
duplication events (Demuth & Hahn, 2009). If the transcription factor regulatory 
redundancy is not resolved by mutations in the DNA binding domain resulting in slightly 
different proteins regulating distinct set of genes, the redundancy is retained increasing 
the network robustness allowing the transcription network to respond to diverse cellular 
signals as well as to interact with other proteins (Gu et al., 2003). This seems to be the 
case for Spi-B and PU.1, since Spi-B unique peaks are associated with ETS-IRF motifs 
while PU.1 binding is associated with POU2F2 motifs (Solomon et al., 2015). Genes 
regulated by overlapping transcription factors also have been noted to have increased 
expression levels (Wu & Lai, 2015), leading us to speculate that overlapping transcription 
factors work to guarantee the expression of “a critical genetic program” coordinating a 
stage/context specific cell process. As the organism genetic complexity increases, there 
is enhanced transcription factor redundancy in binding, associated with an increase in 
fitness of individuals with redundancy (Rosanova, Colliva, Osella, & Caselle, 2017). 
 Despite their redundant functions, PU.1 and Spi-B expression levels have distinct 
patterns during B cell development. While PU.1 expression remains constant through the 
different stages of B cell development (Nutt et al., 2005), Spi-B levels are nearly 
undetectable at the Pro-B cell stage achieving high expression levels at the Pre-B cell 
stage, and increase significantly as B cells exit the BM (M. K. Anderson et al., 1999). 
Thus, Spi-B and PU.1 transcription factors are both expressed at the Pre-B cell stage, a 
stage in which we demonstrated that the lack of these factors results in a B cell 
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development blockade.  Hence, our data together with the previous findings allow us to 
conclude that Spi-B and PU.1 redundancy reinforces the genetic program required to the 
transition from Large Pre-B cells to Small Pre-B cells during B cell development. The 
constant expression of PU.1 during B cell development (Nutt et al., 2005) and PU.1 
binding to the Igk locus (Schwickert et al., 2014; Whyte et al., 2013) have been observed 
before by previous studies, although experimental data unrevealing the biological 
significance of these results were lacking. We demonstrated here that PU.1 binding to the 
Igk locus induces accessibility, a function previously attributed to the transcription factors 
E2A and IRF4/8 (Lazorchak, Schlissel, & Zhuang, 2006; Lin et al., 2010). We have 
shown that the absence of Spi-B and PU.1is sufficient to generate a developmental block. 
We also established that PU.1 and Spi-B cooperate with IRF4/8 and E2A transcription 
factors for Igk recombination at the Pre-B cell stage checkpoint. 
5.2 Involvement of PU.1 and Spi-B in Human Leukemias 
The absence of Spi-B and PU.1 transcription factors lead to Pre-B cell leukemia 
with 100% of incidence in mice (Chapter 3, Fig. 3.1), however mutations in these 
transcription factors are not a common event in human B-ALL. Mutations in SPI1 gene 
is not associated with erythroleukemia or T cell leukemia, but is associated with human 
AML. PU.1 expression is repressed by the protein product of the RUNX1-ETO 
translocation, one of the most frequent chromosomal abnormalities in AML (Vangala et 
al., 2003). Although, few studies have shown a correlation between the presence of 
ETV6-RUNX1 translocation and decreased levels of Spi-B, in B-ALL. Spi-B shows to 
be the top upregulated gene upon knockdown of endogenous ETV6-RUNX1 fusion gene 
in two leukemia cell lines by using specific short hairpin RNAs (shRNA) (Fuka, Kauer, 
Kofler, Haas, & Panzer-Grümayer, 2011). In a mouse model of ETV6-RUNX1 genes 
related to Pro-B to Pre-B cell transition were downregulated including Blk, Blnk, CD19, 
Ebf1, Foxo1, Irf4 and Spib (van der Weyden et al., 2011). The majority of the childhood 
acute lymphoblastic leukemia abnormalities are frequently initiated by a chromosome 
translocation event in utero (Malouf & Ottersbach, 2018). Taking into account that PU.1 
deletion is embryonic lethal (Scott et al. 1994), this lethality could be a potential 
explanation for the low frequency of Spi-B and PU.1 alterations in human leukemias. 
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5.3 Transcription Factors as Therapeutically Targets of 
Malignancies 
Transcription factors are commonly dysregulated in human pathogenesis such as 
obesity, inflammation, cardiovascular disease, nervous system disorders, diabetes and 
cancer (Papavassiliou & Papavassiliou, 2016). Tumour cells often have genes encoding 
transcription factors amplified, deleted or rearranged by chromosomal translocations, or 
genes that are subjected to point mutations resulting gain or loss of function (Bradner, 
Hnisz, & Young, 2017). Mutagenesis events in transcription factors account for about 
20% of oncogenes in cancer. Transcription factors often mutated in human leukemias 
include the tumour suppressor p53 gene, the c-myb gene, the activator protein 1 (AP-1) 
and the E26 transformation-specific transcription factors which mutations affect the status 
of growth factor receptors such as epidermal growth factor receptor (EGFR) (Bradner et 
al., 2017). Although gene-targeted treatment has emerged as a promising strategy for 
cancer, only very few have been successfully approached by coordinated efforts in drug 
discovery. A successful example, of modulation of an oncogenic transcription factor, is 
the development of all-trans retinoic acid (ATRA) as therapy for acute promyelocytic 
leukemia (APML). The first case of leukemia remission was reported in 1985, where a 5-
year-old girl with anthracycline-refractory APML was administered ATRA, and achieved 
a complete long-term remission in combination with ATRA and chemotherapy (Z.-Y. 
Wang & Chen, 2008).  The interaction of ATRA with PML-RARA t(15;17) translocation 
leads to a conformational change that  disrupted its association with histone deacetylase-
containing corepressors in favor of acetyltransferase coactivators. Consequently, one of 
the outcomes of ATRA binding to PML-RARA is its conversion from a repressor to an 
activator of transcription, through the elevation of local histone acetylation at sites 
occupied by PML-RARA (Bhagwat & Vakoc, 2015). One of the limitations of gene-
targeted therapy is that transcription factors are required in many cell types, thus targeting 
this regulator has a risk-to-benefit ration of unspecific actions (Bhagwat & Vakoc, 2015). 
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5.4 A Potential Parallel of Developmental Malignancies  
Among childhood cancers, leukemia is the most frequently diagnosed, accounting 
for 30% of all childhood cancers. Neuroblastomas, accounts for 6% of all childhood 
cancers, and is the fourth most common cancer within this group (R. L. Siegel, Miller, & 
Jemal, 2016). Neuroblastoma is a solid cancerous tumour that begins in the nerve cells. 
It most often begins in the adrenal glands, but it can also develop in other areas of the 
abdomen and in the chest, in the neck, and near the spine (Louis & Shohet, 2015). In 
recent decades, cure rates for childhood cancers have increased to 80%, but cancer 
remains the leading cause of death in children (C.-H. Pui, Gajjar, Kane, Qaddoumi, & 
Pappo, 2011). Furthermore, harsh treatment methods such as chemotherapy, radiotherapy 
and surgery can cause long-term adverse effects, mental disabilities, secondary cancers 
and organ toxicity. Therefore, the development of less damaging therapies to treat 
childhood cancers. Aiming to identify a distinct genetic repertoire in pediatric 
malignancies, a recent study analyzed the landscape of genomic alterations in a cohort of 
961 child tumours (Gröbner et al., 2018). Most of the tumours exhibited a mutation 
signature enriched in C > T transitions (≥30% of SNVs in two-thirds of cancer types). 
This pattern, mutational signature 1, is associated with reduced age. In addition, signature 
18, associated with oxidative DNA damage and enriched to C>A transversions was 
heterogeneously represented within several cancer types (Gröbner et al., 2018). Mutation 
signature 18, was observed in leukemia tumours extracted from Mb1-CreDPB mice as 
discussed in detail in Chapter 4. Altogether, these observations suggest the presence of a 
potential shared mechanism responsible to driving tumourgenesis in children. Further 
investigation of this topic is needed to clarify the events leading to development of these 
two developmental cancer types. 
 
5.5 Concluding Remarks and Future Directions  
The work described in this doctoral thesis addresses two major aspects of 
transcriptional regulation: 1) it emphasizes the importance of transcriptional regulation in 
the progression of developmental events leading to the generation of mature cell types, 
and 2) it highlights the potential generation of disease by transcriptional regulation 
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disturbances. Particularly, the experiments described in this thesis illustrate the functions 
of Spi-B and PU.1 transcription factors in the development of B cells and leukemogenesis.  
 Our findings bring into perspective the potential role of PU.1 and Spi-B in Igk 
variable regions usage, since only half of the Igk variable genes were upregulated 
transcriptionally upon PU.1 induction (Chapter 2). The selection of the Igk variable 
regions that undergo recombination is still understudied, but evidence suggests that CTCF 
zinc finger transcription factors also play a role mediating Igk contraction and appropriate 
Vk  usage (de Almeida et al., 2015). The preferential binding of PU.1 in certain Igk 
variable genes, brings attention to the genomic features responsible for preferential 
binding and its implications. Therefore, we hypothesize that PU.1 binding has the 
potential to favor the selection of certain variable regions. Another interesting observation 
was the close proximity of PU.1 binding with the presence of RSSs (Chapter 2, Fig 2. 5). 
Thus, data reanalysis of ChIP-seq datasets of RAG-1/2, PU.1 and Spi-B in Pro-B cells 
provides a useful method to further investigate the existence of a binding overlap among 
these factors in bigger genomic datasets. The correlation between the binding of these 
factors into genomic regions enriched for H3K4me3 would strongly indicate that PU.1 
and Spi-B function as pioneer transcription factors mediating accessibility of certain Igk 
variable genes. 
Our second major observation was that the generation of leukemia was associated 
with driver mutations in Janus Kinases genes. Although our data indicates that driver 
mutations in Jak3 gene are enough to generate leukemia in the absence of Spi-B and PU.1 
(Chapter 3), we cannot rule out the possibility that mutations in other genes could 
synergize leukemogenic events. In addition, it is possible that the presence of multiple 
drivers increases leukemia fitness conferring morphologic and metabolic changes acting 
in combination to the survival and proliferative advantages conferred by Jak3 mutations. 
Some aspects regarding the molecular mechanisms associated with leukemogenesis in the 
absence of Spi-B and PU.1, need to be further investigated. We hypothesized that ROS 
leads of 8-oxoG genomic damage, consequently leading to C•G > A•T transversions 
observed in high frequency in leukemias lacking Spi-B and PU.1 (Chapter 4). These 
studies need to be experimentally validated as discussed in Chapter 4. The advantage of 
generating a mouse model resembling aspects of human leukemia - such as leukemias 
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associated with Down Syndrome and Ph-like leukemia, brings the potential to study the 
events leading to leukemogenesis, in addition to testing of new chemotherapies.  
In summary, our studies shed light on several unknown aspects of PU.1 and Spi-
B biology, specifically at their stage-specific function in B cell development and the 
mechanisms by which dysregulation of these factors generates leukemia. Our work also 
brought into perspective the broad roles of PU.1 and Spi-B in B cell physiology. By 
controlling the expression of a distinct set of genes, Spi-B and PU.1 transcription factors 
are able to promote B cell maturation by executing transition from high proliferative to a 
quiescent stage in B cell development.  
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